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Production of recombinant FVIII, the protein that is missing or dysfunctional in 
haemophilia A patients, is highly inefficient compared to other recombinant clotting 
factors such as FIX. This is predominantly due to complex intracellular trafficking, 
short half-life and protein instability. This study aimed to increase the amount of 
functional FVIII produced in mammalian cells by co-expression with anti-FVIII 
Camelid antibody fragments (VHH). Three VHH ligands were supplied by BAC BV 
(as DNA constructs), two of which when expressed in yeast are known to bind 
recombinant FVIII (ligands 2 and 7) and are used commercially as FVIII purification 
tools. From these three constructs, nine new VHH plasmids constructs were designed 
and transiently expressed in a stable BHK-human FVIII-expressing cell line.   
Of the nine VHH fragments that were co-expressed in the BHK FVIII cell line, four 
of these had a statistically significant impact on the ‘clotting time’ of the cell media 
as demonstrated by the activated partial thromboplastin time assay (aPTT). Two 
ligand 2 constructs (L2C1 and L2C2) prolonged the coagulation time by 4 seconds 
(P-value 0.0001, 95% confidence intervals 38.5-43.5), and 3.4 seconds (P-value 
0.0072, 95% CI 36.5-40.3) respectively, indicating a decrease in functional FVIII 
activity versus media from the untransfected and null transfected BHK-FVIII cell 
line. Two ligand 7 constructs (L7C1 and L7C3) caused a decrease in coagulation 
time of 3.2 seconds (P=0.0057, 95% CI 30.5-33.3), and 4 seconds (P=0.0002, 95% 
CI 29.1-32.9) respectively, indicating an increase in functional FVIII activity versus 
media from the untransfected and null transfected BHK-FVIII cell line.  
Ligand 7 and ligand 2 both bind to the FVIII light chain, albeit in different regions 
and with different affinities (data confidential to BAC BV). BAC studies showed that 
ligand 7 competes with vWF on the FVIII light chain, which is known to increase 
stability of FVIII in vivo, whereas ligand 2 does not compete for this binding site. 
The opposing effects of ligand 7 and ligand 2 on FVIII clotting times seen in this 
study could be due to their differences in FVIII binding properties, since it is known 







Haemostasis is the tightly regulated response to vascular damage in the body which 
stops bleeding from smaller blood vessels. In a healthy human this mechanism is 
normally rapid and efficient and involves the blood vessel wall, platelets and blood 
coagulation factors (Tanaka, Key et al. 2009). It is a fine balance between 
procoagulant (formation of a fibrin clot) and anticoagulant (breakdown of fibrin) 
activity, and it is essential for survival.  
There are three main mechanisms involved in haemostasis: vascular spasm whereby 
smooth muscle in damaged arteries contracts in order to limit blood loss,  platelet 
plug formation at the site of injury, and blood clotting via the coagulation cascade 
(Tortora and Derrickson 2006).  
The formation of a platelet plug begins when platelets are activated by von 
Willebrand Factor (vWF) and the exposed collagen fibres of damaged connective 
tissue. Binding of platelets to collagen occurs via platelet receptors alpha 2 beta 1 
integrin and glycoprotein (GP)VI/Fc-receptor gamma-chain (FcR gamma) (Jackson, 
Ortar et al. 2013). The platelet release reaction whereby the platelets undergo 
dramatic changes in shape, interact with one another and release their contents via 
cytoskeletal reorganisation. This involves a multitude of proteins, many of which 
have only recently been characterised (Cerecedo 2013). The platelet cytoskeleton 
contains two actin filament-based components. Upon platelet activation one of these 
components undergoes a surge in polymerization. These polymerized actin filaments 
bind to myosin, and move from the periphery of the platelet towards the center of the 
platelet enabling it to contract (Fox, 1993). Activated platelets release ADP, 
thromboxane A2 and serotonin, and in combination with thrombin produced at the 
platelet surface, result in the formation of platelet aggregates and the growth and 
stabilisation of the haemostatic plug (Schattner and Rabinovich 2013). A platelet 
plug may be sufficient to stop blood loss resulting from minor vascular damage, 
however more severe damage requires strengthening of the plug with fibrin threads 




Damage to vascular endothelium and the release of tissue factor (also known as 
Factor III) is the starting point of a complex series of reactions that is known as the 
coagulation cascade. The cascade involves the activation of blood coagulation factors 
via proteolysis, with the aim of generating sufficient levels of thrombin to convert 
plasma fibrinogen into fibrin. Fibrin, in cooperation with platelets forms a 
strengthened haemostatic plug at the site of vascular injury. There are several known 
bleeding disorders which result from defects in the haemostatic system including 
vascular and platelet abnormalities and defective or deficient coagulation factors 
(Hoffbrand, Moss et al. 2006).  
The traditional model of the coagulation cascade is comprised of independent 
extrinsic and intrinsic pathways that later merge to a common pathway after the 
activation of factor X (FXa) - so called the ‘MacFarlane Cascade’ (MACFARLANE 
1964), see figure 1.1. In the MacFarlane model, the extrinsic pathway begins with the 
release of tissue factor from the surface of damaged endothelial cells, into the blood 
and causes the activation of factor VII to factor VIIa. Factor VIIa forms a complex 
with tissue factor (TF-FVIIa) to activate factor X (factor Xa). Factor Xa and 
activated factor V (FVa) form prothrombinase. The intrinsic pathway, also known as 
the contact activation pathway, is slower than the extrinsic pathway and is more 
complex (more reaction steps are involved). It is call the contact activation pathway 
since it is activated when blood comes into contact with collagen fibres in connective 
tissue around a damaged blood vessel wall. Blood contact with collagen fibres causes 
activation of factor XII to factor XIIa via spontaneous cleavage of its single peptide 
chain due to surface contact (so called contact activation system) (Cool et al, 1985). 
Factor XIIa then activates factor XI to factor XIa, subsequently converting factor IX 
to factor IXa. Factor IXa works together with activated factor VIII (factor VIIIa) in a 
so-called ‘tenase’ complex to convert factor X to factor Xa, which can then go on to 




Figure 1-1 Schematic representation based on the traditional ‘MacFarlane 
Cascade’ coagulation model and the role of FVIII in forming a fibrin clot in 
humans. 
However, a more contemporary view of a ‘new cascade’ has emerged and has 
recently been adopted internationally. The new cascade moves away from separate 
intrinsic and extrinsic pathways, and instead describes a common set of cell-surface 
based reactions with three overlapping phases of thrombin generation; initiation, 
amplification and propagation (Pérez-Gómez and Bover 2007).  
The new cascade model describes a coagulation reaction which begins on tissue 
factor-exposing cells, and continues on the surfaces of activated platelets. Initiation 
encompasses the TF/FVIIa complex activation of coagulation factors IX to IXa and 
X to Xa, in order to generate trace amounts of thrombin. This initial thrombin burst 
can activate platelets and stop small bleeds by adhering to the site of injury and 
 
TF = tissue factor   
Roman numerals = clotting factors 
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forming a platelet plug as described earlier.  Amplification of the initial burst of 
thrombin occurs via a positive feedback mechanism to stop larger bleeds, by 
activation of circulating FVIII and FV. Thrombin’s proteolytic activity at ARG740, 
ARG1689, and ARG372, releases FVIII from von Willebrand factor to generate 
activated FVIIIa (Nogami, Shima et al. 2000), (Eaton et al, 1986). FVa and FVIIIa 
bind to the platelet surface and act as cofactors for the propagation phase whereby 
large-scale thrombin generation occurs. Thrombin also activates FXI which is bound 
to the platelet surface and plays a role in the propagation phase. 
In the propagation phase, FVIIIa/FIXa ‘tenase’ complex and the FVa/FXa complex 
(prothrombinase) assemble to accelerate the generation of FXa and thrombin, 
respectively at the platelet surface. In addition, FXIa bound to the platelet surface 
activates FIX to allow the formation of additional ‘tenase’ complex. The resulting 
burst of thrombin allows the conversion of fibrinogen to soluble fibrin fibres, which 
polymerise to form fibrin protofibrils. Thrombin activated FXIIIa stabilises the 
protofibrils which stabilises the platelet plug to form a platelet/fibrin thrombus (De 
Caterina, Husted et al. 2013).  
Due to the important amplification role of the ‘tenase’ complex, the cycle continues 
in a prothrombotic state until down-regulation occurs via anticoagulant pathways 
(Pallister and Watson 2010). Conversely, a deficiency or dysfunction in essential 
clotting factors can lead to a reduced ability to perform haemostasis, for example in 
the collection of disorders known as haemophilia.  
1.1 Haemophilia types A, B and C 
 
Haemophilia is a rare disorder which affects the blood coagulation pathway due to a 
deficiency in specific coagulation factors (Dahlbäck 2005). There are three types of 
Haemophilia, type A (classic Haemophilia) which is characterised by a deficiency in 
Factor VIII (Antonarakis, Kazazian et al. 1995), type B (Christmas disease) which is 
characterised by a deficiency in Factor IX (Bolton-Maggs and Pasi 2003) and type C 
which is caused by a deficiency in Factor XI (Bolton-Maggs 2013). The most 
common type is haemophilia A which affects 1 in 5000 males in the United States 
(Miao, Sirachainan et al. 2004), while type B is less common and affects 1 in 30,000 
males (Bolton-Maggs and Pasi 2003). Haemophilia type C is reported to be found in 
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1 in 100,000 males in the United States, with a high incidence in Ashkenazi Jews 
(although it has been reported in all racial groups) (Bolton-Maggs 2013).  
There is a long history of haemophilia with the first descriptions of the disease going 
back to the 10
th
 century, and the first recorded case being treated by transfusion in 
London in 1840 (Farr 1981). Type C was first described in 1953 (Rosenthal, Dreskin 
et al. 1953), affects both genders and is the most mild of the inherited coagulation 
disorders (Gomez and Bolton-Maggs 2008).  
Median life expectancy for those with severe haemophilia (A or B) has been 
estimated at 63 years, while for those with mild to moderate haemophilia it is 75 
years, compared to the general population of males having a life expectancy of 78 
years (Darby, Kan et al. 2007). This was calculated from data gathered over a period 
of 20 years from the NHS and haemophilia centres in the UK. 
1.2 Acquired Haemophilia A (AHA) 
 
While all three types of Haemophilia are inheritable via gene mutations  (Peyvandi, 
Jayandharan et al. 2006), type A can also be acquired. Acquired hemophilia A 
(AHA) is associated with other diseases such as auto-immune disorders, cancers, 
reactions to medications or even as a severe complication of pregnancy. These AHA 
patients develop polyclonal auto-antibodies to FVIII via multiple mechanisms, 
resulting in an impaired intrinsic coagulation pathway (Franchini, Gandini et al. 
2005). The mechanisms by which these inhibitors are formed have only recently 
come to light, and is still a topic that is not completely understand in the literature. 
Two pathways that have been suggested to play a role in AHA; 1) an increased 
frequency of a single nucleotide polymorphism of the CTLA-4 gene (which is 
found on the surface of activated and regulatory T-cells, and closely associated with 
auto-immune disorders) and 2) the elevation of B-cell activating factor belonging to 
the tumor necrosis factor family (BAFF) whose role has yet to be fully explained in 
AHA patients (for review see: Sakurai et al, 2014). The link between pregnancy and 
AHA is not clear, however since most of these cases occur postpartum, it has been 
suggested that the mother may develop autoantibodies due to exposure to fetal FVIII. 
It can also occur in mothers who are haemophilia carriers, who normally have low 
FVIII levels, but which rise during pregnancy. The sudden drop of FVIII levels after 
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childbirth can lead to severe postpartum haemorrhage (Hashimoto et al 2011). AHA 
is extremely rare (reported 0.2 - 2 per million population per year), and can occur in 
both sexes, whereas the inherited type A only affects males due to a recessive gene 
mutation on the X chromosome (Hay 1998).  
1.3  Inherited Haemophilia A 
 
The severity of this disease is determined by the blood plasma levels of FVIII, and 
this is expressed as a percentage relative to normal human plasma or in International 
Units relative to an International Standard, the details of which are updated 
periodically (Raut, Daniels et al. 2012). One International Unit (IU) is equivalent to 
that quantity of FVIII found in 1ml of normal human plasma (EMEA 2000).  
The definitions of disease severity are as follows; severe (<1% of normal activity or  
< 0.01 IU/mL), moderate (1–5% of normal activity or 0.01-0.05 IU/mL) or mild (5–
40% of normal activity or  >0.05 to < 0.40 IU/mL) (Ljung 2009).  Studies have 
shown that the half life of plasma FVIII is similar in all haemophilia patients, and 
that it is in fact the production rate of FVIII that determines the severity of the 
disease (Ghosh 2007).  
Haemophilia A is currently treated by replacing the deficient coagulation factor by 
infusion of recombinant FVIII (Giangrande 2011). Although there is significant 
potential for a gene therapy treatment for haemophilia A, as of 2015 studies have not 
progressed beyond preclinical experiments in animals. Gene therapies for 
haemophilia B are however in phase 2 human clinical trials (review, Carr et al 2015) 









Table 5 Gene therapy approaches in haemophilia A and B  
  
Reproduced from Carr et al, 2015. 
 
1.3.1 The symptoms 
 
The most common symptom in inherited haemophilia A is bleeding into the joints 
(haemarthroses) (Rodriguez-Merchan 1996), and muscles, often causing the patient 
severe pain and rendering them incapacitated. Haemophiliacs can experience 
bleeding into a range of joints including the ankle, knee, elbows and shoulders, and 
this can occur recurrently into the same joint (target joint). Bleeding into the joints 
can affect their motion, muscle strength and appearance. Recurrent bleeding into a 
target joint can eventually lead to further complications such as osteoarthritis 
(Mulder and Llinás 2004). Haemophilic arthropathy (damaged joints) is the major 
cause of morbidity among haemophiliacs (Raffini and Manno 2007). Other types of 
bleeding such as intracranial haemorrhage can also be life-threatening (Ljung 2009).  
Patients with acquired haemophilia (AHA) tend to have a different bleeding pattern 
to those who have inherited the disorder. They do not commonly bleed into their 
joints but they do suffer with large spontaneous life-threatening bleeds including 
intramuscular, epistaxes (nose bleeds), intracranial and sometimes major 
gastrointestinal bleeding (Hay 1998). As mentioned previously AHA can also occur 
in relation to pregnancy and in this instance tends to resolve itself spontaneously 
(Franchini, Gandini et al. 2005). It is much more frequently found in the elderly than 
the young and can be difficult to diagnose due the absence of patient/family history 
of bleeding episodes (Franchini, Targher et al. 2008). 
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1.3.2 Treatment of Haemophilia A 
 
Since haemophilia A is caused by a deficiency in the coagulation protein Factor VIII 
(FVIII), the aim of the treatment for this disease is to replace this protein, so called 
‘replacement therapy’. Historically, haemophilia patients were treated with whole 
blood transfusions, the first reported case of this being in 1840 (Farr 1981). 
Replacement therapy evolved to the use of whole blood plasma up until the 1940s, 
and then more specifically concentrated from pooled human plasma in the 1950s. 
This was further improved in the 1960s when scientists were able to produce plasma 
enriched with FVIII and von Willebrand Factor (VWF) (Saenko, Ananyeva et al. 
2003).  However the concern for all of these types of replacement therapy was that 
they contributed to the transmission of viral diseases such as HIV and Hepatitis B 
and C (HBV and HCV) (Jankowski, Patel et al. 2007). Before the introduction of 
virus-inactivation procedures, most haemophiliac patients treated in the UK between 
1969 and 1985 with blood products also contracted the hepatitis-C virus which put 
them at increased risk of death from liver cancer and liver disease (Darby, Ewart et 
al. 1997). The development of modern purification technology such as 
solvent/detergent (S/D) method, removed some serious pathogenic viruses from 
plasma derived clotting factors with the exception of non-enveloped viruses such as 
hepatitis A (HAV). These remained a risk factor to haemophiliacs and meant 
vaccinations were necessary alongside treatment (Chudy, Budek et al. 1999). Some 
countries have a zero risk policy on the use of blood derived products potentially 
containing infectious agents. Strict plasma-screening procedures together with an 
increase in the use of clotting factors globally, led to shortages in the availability of 
plasma-derived clotting factors (Evatt, Farrugia et al. 2002). Over the last 20 years, 
the risk of viral infection from plasma derived clotting factors has been virtually 
eliminated, however there are still theoretical concerns over the emergence of new 
strains of parvoviruses and prions since these cannot be 100% eliminated by current 
purification technologies (Norja, Lassila et al. 2012).  The most significant 
improvement in the treatment of haemophilia came with the development of 
recombinant biotechnology and the cloning of the FVIII gene in 1984, which allowed 
the production of various recombinant FVIII (rFVIII) products in mammalian cells 
(Toole, Knopf et al. 1984). The sources of currently marketed FVIII products vary 
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from the plasma derived FVIII to recombinantly derived FVIII, and are 
manufactured by a variety of pharmaceutical companies globally. There are two 
types of recombinant products used today, produced using the full length FVIII (FL-
FVIII) gene or B-domain deleted derivatives of FVIII (BDD FVIII), which is 
produced using a truncated version of the gene (the differences are discussed in more 
detail in section 1.6).   
Historically, recombinant FVIII has been reportedly difficult and expensive to 
produce due to low protein expression, lengthy purification procedures and limited 
stability of the protein both in vivo and in vitro (Wang, Wang et al. 2003, Miao, 
Sirachainan et al. 2004). More recently there have been reports of much improved 
yields with Human-cl rhFVIII, a new-generation recombinant factor VIII protein 
which is the first to be produced from a human cell line (approved by the EMA in 
July 2014). The purification procedure of this product involves one cell removal step 
(centrifugation/filtration), two filtration and five chromatography column steps 
giving an overall yield of approximately 50% (Winge et al 2015). This yield of 50% 
compares favourably to the 15% yield reported 5 years previously for another rFVIII 
product produced CHO cells (Thim et al 2010). 
Another limiting factor of haemophilia treatment is the immune response of patients 
to infused FVIII. Approximately 25% of haemophilia patients develop antibodies 
that are inhibitory to FVIII in response to treatment and this remains one of the most 
serious complications today (Ehrenforth, Kreuz et al. 1992). The European 
Medicines Agency (EMEA) reported in 2005 that occurrence of inhibitors to FVIII 
had been reported for all approved and marketed recombinant FVIII products 
(EMEA 2005). The appearance of anti-FVIII antibodies  can also occur as a 
spontaneous event in people with normal levels of FVIII (acquired haemophilia) 
(Lubin, Healey et al. 1994). There is still an ongoing debate over the use of plasma-
derived FVIII versus recombinant FVIII, and which type is safer in terms of the risk 
of FVIII inhibitor development. An ongoing international clinical study (SIPPET) 
hopes to provide an answer to this (Mannucci 2012).  
It is widely recognised that prophylactic treatment in the form of regular infusions 
(as often as 2-3 times a week) of FVIII is superior to ‘on-demand’ treatment to treat a 
‘bleed event’, especially for those with the severe form of the disease as it can 
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prevent arthropathy (chronic joint damage). Studies have shown prophylactic 
treatment can reduce the average number of bleeding episodes per year from 37 to 13 
(Miners, Sabin et al. 2004). However prophylactic treatment is limited by the 
relatively high cost of FVIII (approximately $1700 per dose for a 150lb adult) and 
also the lack of universal agreement in the clinic of correct dosage and dose intervals 
(Ljung 2009). Haemophiliacs with the severe form of the disease have been treated 
prophylactically with the aim of keeping trough FVIII levels above 1 IU/dL
-1 
since 
this can prevent arthropathy. Studies have shown that prophylactic treatment reduces 
bleed events from approximately 23 bleeds per year to 14 per year, but at an 
additional cost of £547 per patient compared to on-demand treatment (Miners, Sabin 
et al. 1998). However, new recombinant FVIII products with an extended half-life 
are shortly due to be commercialised (around 15-18 hours half-life extension) 
(Spiller 2013). There are a number of different approaches to extending the half-life 
of FVIII including Fc fusion e.g. Eloctate (which has regulatory approval in US and 
Canada), addition of polyethylene glycol e.g. turoctocog alfa pegol [N8-GP], and a 
single-chain construct (CSL627) (for review of these technologies see: Tiede 2015). 
These new products will require less frequent dosing, potentially lowering the cost of 
treatment, improving patient adherence and creating more favourable conditions for 
prophylactic treatment (Oldenburg and Albert 2014).  
The difficulty and high cost of producing rFVIII is also reflected in the limited use of 
the treatment in countries with economic constraints such as India, although many 
haemophiliacs in these countries often go undiagnosed and most likely die from the 
disease (Bolton-Maggs and Pasi 2003). Two-thirds of the world’s haemophilia 
population still do not have access to treatment and it is predicted that countries such 
as China and India may go on to make biosimilar FVIII products in response to this 
demand (Mannucci 2012). Up until 2014, biosimilar clotting factors were not 
permissible for approval in the European Union. However this exclusion has recently 
been removed from the EMA biosimilar guidelines (Guideline on similar biological 
medicinal products, October 2014) so we could yet see a biosimilar FVIII approved 
in Europe.  
Clearly there are still significant improvements to be made in the production of 
rFVIII if we are to increase the availability of haemophilia treatment globally, and 
enhance the quality of life of patients. In order to improve on the current treatments 
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available, it is first important to understand the nature of human FVIII production 
and function in vivo, as well as what has already been done in terms of 
bioengineering rFVIII.  
1.4 Factor VIII and its function in the blood clotting cascade 
 
Platelet adhesion to the subendothelium of a damaged blood vessel is mediated by 
von Willebrand Factor (vWF), a large glycoprotein (Kanaji, Fahs et al. 2012). This 
leads to activation and aggregation of platelets, localisation of inactive coagulation 
factors on the activated platelet surface, and their subsequent proteolysis and 
conversion to their active forms. This results in a burst of thrombin generation and 
conversion of fibrinogen to fibrin (Kaufman and Pipe 1999).  
Generation of thrombin occurs in two stages. An initial short burst via the extrinsic 
pathway produces small amounts of thrombin. The second stage and amplification of 
the coagulation cascade via the intrinsic pathway produces larger amounts of 
thrombin (Hoffbrand, Moss et al. 2006). Initial generation of thrombin via the 
extrinsic pathway is activated by the release of tissue factor, which forms a complex 
with activated factor VII (FVIIa-TF complex). FVIIa-TF complex activates FIX to 
FIXa. FIXa cooperates with its cofactor, FVIIIa to activate FX to FXa. FXa acts with 
its co-factor FVa to convert prothrombin to thrombin. FXa and thrombin act via a 
positive feedback mechanism to activate more FVIII and FV in order to amplify the 
generation of thrombin (Kaufman and Pipe 1999).  
The role of FVIII upon activation is to significantly increase the efficiency of FIXa 
in converting FX to FXa (Fang, Wang et al. 2007). Prior to activation by thrombin or 
FXa, FVIII circulates in the blood in a stable complex with vWF.  vWF can exert 
both a regulatory and inhibitory effect on FVIII, as it prevents a number of activities 
including phospholipid binding which is essential for FXa mediated activation of 
FVIII and its binding to activated platelets. It also prevents inactivation of FVIII by 
activated protein C (Kaufman and Pipe 1999). VWF is also a co-factor in the 
thrombin-catalysed activation of FVIII (Hill-Eubanks and Lollar 1990). 
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Human FVIII is a large plasma glycoprotein that contains multiple glycosylation 
sites (25 N-linked glycans and 7 O-linked glycans), some of which are known to play 
a role in its intracellular trafficking and degradation (described in detail later). 
1.5 The expression of factor VIII 
 
FVIII expression at the molecular level 
 
The FVIII gene is 186 kb in size, contains 26 exons and is located on the X 
chromosome (Toole, Knopf et al. 1984), see Figure 1.2. Haemophilia is caused by a 
broad range of mutations in the FVIII gene and over 900 mutations have been 
discovered (Castaman, Giacomelli et al. 2010).   
 
 
Figure 1-2 The structure of the Factor VIII gene containing 26 exons and 
located on the X chromosome. Reproduced from (Bagg 2007). 
 
FVIII mRNA is predominantly expressed in the sinusoidal cells of the liver, although 
it is also found at lower levels in the kidney, lung, brain and heart (Hollestelle, 
Thinnes et al. 2001). The liver has been shown to be the primary site of FVIII protein 
synthesis, and in fact liver transplantation in a haemophiliac has been shown to 
restore FVIII levels (Gordon, Mistry et al. 1998). 
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Around 50% of patients with severe haemophilia A have a mutation in their FVIII 
mRNA. It was suggested that this is due to insertion or inversion of a gene fragment 
in intron 22 of the FVIII gene (Naylor, Brinke et al. 1993). Other possible mutations 
include point mutations in the FVIII gene and a small proportion of severe 
haemophilia A patients (5%) have an inversion in intron 1 of the FVIII gene (Bolton-
Maggs and Pasi 2003).  
Approaches to increasing FVIII mRNA levels in vitro with a view to increasing the 
levels of FVIII expression have been tried including removing introns in the FVIII 
gene that contains transcriptional silencers, and replacing them with introns from 
other coagulation factor genes such as FIX that are known to have a positive effect 
on their secretion. For example splicing of a truncated FIX intron 1 into the site of 
FVIII introns 1 and 13 led to 13-fold higher levels of FVIII protein secretion versus 
the parent gene sequence (Plantier, Rodriguez et al. 2001). 
The FVIII gene encodes for a single chain polypeptide of 2351 amino acids including 
a signal peptide of 19 amino acids (Wang, Wang et al. 2003). The signal peptide is 
cleaved from the protein upon translocation into the lumen of the Endoplasmic 
Reticulum (ER) (part of the secretory pathway) producing a single chain polypeptide 
containing 2332 amino acids (Kaufman and Pipe 1999), with a molecular weight of 
approximately 265 KDa, although this changes depending on the extent of 
glycosylation and/or sulfation of the protein, and has been detected up to 330 KDa in 
SDS-PAGE (Vehar, Keyt et al. 1984, Peake 1995). The single chain polypeptide 
consists of three domains, A, B and C of which there are three A, one B, and two C 
domains. These domains are connected by short acidic sequences a1, a2 and a3, see 
figure 1.3. This structure is abbreviated to NH2-A1-a1-A2-a2-B-a3-A3-C1-C2-
COOH (Vehar, Keyt et al. 1984, Wang, Wang et al. 2003). There is high homology 
among species for the majority of amino acids in FVIII except for the B domain 





Figure 1-3 Schematic of FVIII domain structure, with binding sites indicated 
for calcium ions, copper ions, clotting factors IX and X, vWF and phospholipid 
surfaces (adapted from (Cao, Krishnaswamy et al. 2008) and (Lenting et al. 
1998). 
The A and C domains both have responsibility for coagulant function of FVIII, 
including binding sites for FIXa, FX, vWF and phospholipid surfaces (see figure 
1.3). The role of the B domain is not as well studied as the A and C domain, although 
it is known to have roles throughout the life cycle of FVIII including the intracellular 
trafficking and secretion of the protein (Pipe 2009). Removal of the B domain in 
recombinant expression systems, so called B-domain deleted (BDD) rFVIII resulted 
in up to 20-fold higher expression of primary translation product (basic peptide not 
yet processed by ER/Golgi) versus the wild type, probably due to more efficient 
production of rFVIII mRNA (Saenko, Ananyeva et al. 2003). However, a 20-fold 
increase in primary translation product resulted in only a 30% increase in secreted 
FVIII, suggesting that there are other limiting factors in the production of FVIII 
protein, including the secretory pathway (Miao, Sirachainan et al. 2004).  
Both full length FVIII and BDD-FVIII are currently marketed products, a summary 
of which can be found in table 2. It is important to note that FVIII produced by 
BDD-rFVIII cell lines is no more (or less) immunogenic than that produced by full 
length rFVIII cell lines (Saenko, Ananyeva et al. 2003), however there are reports 
that BDD-FVIII is less efficacious clinically than the FL-FVIII (Gruppo, Brown et 
al. 2003). A 2003 meta-analysis looking at clinical data for BDD-FVIII versus FL-
FVIII in prophylactic treatment showed that in general higher doses of the BDD-
FVIII were needed, the half-life of BDD-FVIII was shorter than FL-FVIII and the 
incidence of bleeding episodes/year was increased in those patients receiving BDD-
FVIII (Gruppo, Brown et al. 2003). 






Table 6. FVIII products marketed commercially for the treatment of 
Haemophilia A. 
 
FVIII at the protein level 
 
Most of our knowledge regarding FVIII expression has come from recombinant 
mammalian cell lines due to the difficulties in finding a suitable native cell line to 
study (Kaufman and Pipe 1999). Only as recently as 2014 a liver study identified the 
exact cell type that manufactures FVIII as liver sinusoidal endothelial cells (LSECs), 
rather than liver hepatocytes in which FVIII could not be detected (Shahani T et al, 
2014). To date, no successful attempts to immortalize cultured liver sinusoidal 
endothelial cells have been published. It has been demonstrated that rFVIII is 
expressed at levels up to 2 to 3 orders of magnitude lower compared to other similar 
sized recombinant coagulation proteins such as FIX (Doering, Healey et al. 2002), 
and up to 10,000-fold lesser production than is achieved for some monoclonal 
antibodies (Trent spencer et al 2011). In order to understand the reasons why FVIII is 
Product Marketed by Type of FVIII Source 
Production 
system 
















Bayer Full length Recombinant BHK cells 
Recombinate
®


















such a difficult protein to express at high levels and to potentially improve the 
situation, it is important to explore and understand the pathways of secretory protein 
expression in mammalian cells.  
1.5.1.1  The early secretory pathway 
 
Since FVIII is a protein normally destined for secretion out of the cell, it is processed 
via the secretory pathway composed principally of the cell organelles the 
endoplasmic reticulum (ER) and the Golgi apparatus. Secretory proteins contain a 
leader sequence (also known as signal peptide), normally located on their N-
terminus, which is recognised by a Signal Recognition Particle (SRP) (Walter, 
Ibrahimi et al. 1981). Upon binding of the SRP to the leader sequence, the protein is 
targeted to the SRP receptor on the ER membrane, initiating translocation through 
the Sec61 translocon (Nilsson, Lara et al. 2014). Sec61 is a pore that acts in 
partnership with another protein complex in the ER membrane called Sec62/Sec63, 
as well as a chaperone in the lumen of the ER called BiP, a member of the heat shock 
family of proteins (for review see (Park and Rapoport 2012)).  
The ER is the first entry point for a protein into the secretory pathway. The ER is 
responsible for the correct folding and assembly of secreted proteins and also acts as 
a quality control check before the proteins go on to the Golgi apparatus for further 
processing. Almost a third of the open reading frames found in the human genome 
code for proteins that enter the ER. The ER is distinct from the cytosol of the cell and 
provides a compartment for proteins to be folded, assembled, modified or recycled 
(Braakman and Bulleid 2011). As the protein enters the ER lumen the signal 
recognition peptide is removed, and oligosaccharides are added on to specific 
asparagine residues of the polypeptide (consensus sequence Asn-X-Ser/Thr, where X 
is any amino acid except proline), an ER specific process known as N-glycosylation 
(Nilsson and Heijne 1993). These N-glycosylation sites provide recognition sites for 
chaperones that assist protein folding (Helenius and Aebi 2004).  
Once in the ER lumen, the polypeptide chain is folded into a quaternary structure. 
Protein folding in the ER is assisted by a number of chaperones that belong to several 
well-known chaperone families including the heat shock proteins (Hsp)40, 70 and 
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90, as well as unique chaperones and enzymes like calnexin, calreticulin and thiol-
disulphide reductases (Ellgaard and Helenius 2003). 
FVIII contains 25 N-linked asparagine glycosylation sites, 19 of which are located in 
the B domain (Vehar, Keyt et al. 1984), as well as several sulphated tyrosine residues 
(Kaufman and Pipe 1999). Generally speaking, N-glycosylation patterns are unique 
to each protein and important for their biological function, their stability, solubility 
and their susceptibility to proteolytic attack (Roth, Zuber et al. 2010). Addition and 
initial processing of N-linked oligosaccharides takes place in the ER, with final 
processing completed in the Golgi apparatus (Lodish et al, 2000). 
Within the ER there are many proteins and folding chaperones that FVIII has to 
interact with before the correctly folded protein can be released from the ER (Pipe, 
Morris et al. 1998). One such protein that interacts with FVII is GRP78, which upon 
overexpression in CHO cells was shown to reduce FVIII secretion (Dorner, Bole 
1992). Interaction of FVIII with chaperones such as BiP in the ER has been shown to 
be a rate-limiting step in the production of FVIII in CHO cells (Dorner, Bole 1987). 
BiP (immunoglobulin heavy chain binding protein) is a major protein folding 
chaperone (Haas and Wable 1983), that can form a stable complex with FVIII via its 
B-domain. This interaction has been shown to limit the efficiency of secretion of 
FVIII as this stable complex with BiP is often retained in the cell, rendering the 
protein secretion – incompetent (Dorner, Bole et al. 1987). Stable complex formation 
with BiP can be dependent upon ATP hydrolysis (depending on the protein), which 
is regulated by ERdj1-5 proteins. Other regulatory proteins such as BAP allow the 
release of proteins from the BiP chaperone (Aridor 2007). 
The interaction with BiP is increased in cases where FVIII is incorrectly folded due 
to incorrect glycosylation. Consequently the FVIII protein is targeted for degradation 
and exported from the ER to the proteasomal machinery, rather than continuing its 
journey on to the Golgi apparatus (Soukharev, Hammond et al. 2002). Deletion of a 
portion of the FVIII B-domain which contains the majority of the N-linked 
glycosylation sites resulted in a transient association with BiP and a higher amount of 
secreted FVIII (Toole, Pittman et al. 1986). Deletion of the putative FVIII BiP 
binding site by site-directed mutagenesis also resulted in enhanced secretion of FVIII 
(Saenko, Ananyeva et al. 2003). A BDD-FVIII CHO cell line containing a BiP 
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mutant which could not perform ATP hydrolysis resulted in inhibition of secretion of 
the BDD-FVIII hinting that the release of FVIII from BiP may be dependent on the 
conversion of ATP to ADP. This appeared to be specific to the FVIII protein as the 
secretion of another protein that interacted with BiP (M-CSF) was not affected by the 
loss of ATP hydrolysis (Morris, Dorner et al. 1997). 
Two other protein chaperones calnexin (CNX) and calreticulin (CRT) which are 
endogenous lectin molecules found in the ER also interact with FVIII B domain. 
These two chaperones preferentially bind glycoproteins that contain N-linked 
oligosaccharides, and play a role in protein trafficking via degradative and/or 
secretory pathways (Pipe et al 1998). It has been suggested that CNX plays a positive 
role in promoting the release of FVIII from BiP and requires ATP. It is interesting to 
note that the secretion of another clotting factor, recombinant factor V, also involves 
interaction with CNX, CRT and BiP but this process is not dependant on ATP 
hydrolysis (Pipe, Morris et al. 1998). In mammalian cell lines that produce high 
amounts of recombinant proteins, these chaperones can become overloaded and this 
can lead to an accumulation of misfolded proteins and/or aggregated proteins 
(Jenkins, Murphy et al. 2008).  
Aggregation of non-glycosylated proteins, in the ER can occur as a result of a 
disrupted N-glycosylation process. Subsequently these aggregated, disulphide 
bonded proteins cannot exit the ER, and are degraded over time (Kim, Bole et al. 
1992). This has been demonstrated by multiple researchers on a variety of soluble 
and membrane bound proteins including Semliki Forest virus spike glycoproteins El 
and p62 and influenza hemagglutinin (Marquardt et al 1992). Aggregated proteins 
present in the ER can be transient and are sometimes simply folding intermediates 
(Pfeffer and Rothman 1987). It has been shown that FVIII can also form high 
molecular weight aggregates in the ER immediately after its synthesis, and that this 
is a rate limiting step for its secretion. These FVIII aggregates do not form disulphide 
bonds, and the process is reversible but requires ATP (Tagliavacca, Wang et al. 
2000). Where the process cannot be reversed, misfolded FVIII is destined for 
degradation via proteasomal and lysosomal pathways (Plantier, Guillet et al. 2005). 
Other chaperones exist that recognise misfolded or unassembled protein subunits 
which are then targeted for retrotranslocation out of the ER and back to the 
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cytoplasm of the cell. There are two pathways associated with this process called 
ER-associated degradation (ERAD), which occurs when proteins are terminally 
misfolded, and the unfolded protein response (UPR) which is associated with a stress 
response (Vasquez-Martinez, Diaz-Ruiz et al. 2012). Misfolded proteins can 
accumulate in the ER and aggregate causing the ER to dilate and activation of the 
UPR (Schroeder and Kaufman 2005). Proteins that are targeted for the ERAD 
pathway are ubiquitinated by Hrd1p. Another factor involved in this process is 
Yos9p, a lectin-like ERAD factor. Yos9p forms complexes with Hsp70, BiP and 
Hrd3p. Yos9p and Hrd1p together mediate the retention of proteins in the ER (Izawa, 
Nagai et al. 2012).  
As well as molecular chaperones such as BiP, calnexin and calreticulin, there are also 
‘chemical chaperones’ in the cell such as osmolytes that can inhibit aggregation and 
restore trafficking of misfolded proteins (Leandro and Gomes 2008). The chemical 
chaperone betaine (amino acid derivative) has been shown to restore intracellular 
trafficking of a trafficking-defective FVIII mutant both in vivo in murine models of 
haemophilia A and B and in vitro in cell based models (Roth, Schüttrumpf et al. 
2012). In this study, betaine increased FVIII solubility, facilitated movement of 
FVIII from ER to the Golgi and increased FVIII plasma levels in gene-corrected 
FVIII knockout mice. This demonstrates the importance and also the therapeutic 
potential for chaperones to improve FVIII secretion.  
A critical step for a correctly folded protein to exit the ER and be transported to the 
Golgi, is packaging into vesicles called coat protomer type II (COPII) in response to 
an ER export signal. The ER has specific exit points (tER sites) which are 
characterised by the presence of these vesicles (Barlowe 2003). The COPII coat is 
comprised of five proteins Sar1, Sec23/24 and Sec13/31. These are recruited to the 
ER and induce the ER membrane to curve and capture newly synthesised proteins 
that are to be exported (Gillon, Latham et al. 2012). Misfolded proteins mostly fail to 
enter the COPII vesicles although some proteins may make it out of the ER and into 
the Golgi before being retrieved into the ERAD pathway (Pagant, Kung et al. 2007). 
COPII vesicles bud away from the ER, lose their coat and fuse with pre-Golgi 
intermediates where they release their protein cargo (Dancourt and Barlowe 2010). 
Fusion of the vesicles is mediated by SNARE proteins (v-SNAREs) and target-
SNAREs (t-SNAREs) (Brandizzi, Barlowe 2013). These intermediates then move 
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along microtubules towards the Golgi apparatus where the proteins are delivered 
(Lippincott-Schwartz, Roberts et al. 2000).    
 
1.5.1.2  FVIII and the Golgi apparatus 
 
The Golgi apparatus is a dynamic organelle comprised of multiple cisternal 
membranes and an array of different enzymes, chaperones, lectins and transporters. 
The main roles of the Golgi consists of sorting proteins, providing a gateway for 
secretory proteins to move from the ER to the extracellular environment (Palade 
1975), O-glycosylation and final processing of N-linked glycans (Lodish et al, 2000). 
Besides mature glycosylation, sulfation and phosphorylation by Golgi enzymes, 
proteins also undergo post-translational modifications such as oligomerization and 
lipidation to aid protein transport to the cell membrane (Reynders, Foulquier et al. 
2011). Proteins such as FVIII can undergo proteolytic action in the Golgi, to convert 
them from inactive proproteins to biologically active mature proteins (Lodish, Berk 
et al. 2000).  Proteins destined for secretion from the cell move from the Golgi 
towards the cell membrane packed inside secretory granules, with both microtubules 
and actin filaments playing a role in moving these granules (Vasquez-Martinez, 
Diaz-Ruiz et al. 2012). With regard to FVIII, N-glycans are modified in the Golgi 
apparatus; O-glycosylation and sulfation of tyrosine residues occurs in the trans-
Golgi. FVIII has six locations of tyrosine sulfation at positions 346, 718, 719, 723, 
1664, and 1680 respectively, and these surround the sites where FVIII is cleaved by 
thrombin (Orlova et al 2013). 
With regard to the FVIII protein, provided it has folded correctly in the ER, the 
protein then moves to the Golgi apparatus via a facilitated transport mechanism 
involving a molecular chaperone, ERGIC-53 (also described as mannose-binding 
lectin LMAN1), which is a type 1 transmembrane protein found in the ER-Golgi 
intermediate compartment. ERGIC-53 also plays a role in retrograde transport, 
movement of proteins back to the ER as a recycling mechanism. It has been shown 
that a mutation in the gene encoding ERGIC-53 can cause a combined deficiency of 
both FVIII and FV (Nichols, Seligsohn et al. 1998). Binding FVIII to ERGIC-53 
occurs via the FVIII B domain, is dependent on the calcium concentration in the ER. 
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ERGIC-53 forms a complex with another protein called MCFD2 (LMAN1-MCFD2 
complex) which recruits FVIII to sites of transport vesicle budding within the ER 
lumen (Zhang et al, 2005). Miao et al developed a recombinant BDD-FVIII cell line 
which contained a short B-domain spacer with the oligosaccharides essential for 
ERGIC-53 mediated transport. This resulted in a cell line with 15-25 fold increased 
FVIII protein expression levels versus a full length wild type FVIII (Miao, 
Sirachainan et al. 2004). Kolind et al also investigated BDD-FVIII expression by 
varying the B-domain length and found that expression levels of recombinant FVIII 
decreased with increasing B-domain length (Kolind, Norby et al. 2010).  
Transport of proteins through the Golgi relies on vesicle carriers called COPI. The 
COPI coat is comprised of seven subunits which assemble on the Golgi membrane 
and form COP-I coated vesicles (Kondylis, Pizette et al. 2009). Besides the COPI 
coat proteins, there are many other proteins involved in regulating protein 
biosynthesis at the Golgi including Rabs, tethers, SM proteins and SNAREs (for 
review see (Cottam and Ungar 2012)). Sorting of proteins into COPI coated vesicles 
for movement around the Golgi occurs with all proteins regardless of whether they 
are Golgi resident proteins that move to different cisternae, proteins destined for 
secretion or proteins destined to return to the ER. Most proteins move in an 
anterograde (forward) fashion, but some move retrograde between the Golgi 
cisternae, and also back to the ER, thus ensuring a strict quality control system for all 
proteins (Lippincott-Schwartz, Roberts et al. 2000).  
An additional quality control mechanism exists for resident ER proteins that make it 
to the Golgi. ER-resident proteins contain a KDEL-like motif at their C-terminus 
which normally prevents them being secreted. There are KDEL receptors in the ER-
Golgi intermediate compartment and also in the Golgi itself, and binding of proteins 
to these receptors triggers retrieval of a protein back to the ER via COPI coated 
vesicles (Raykhel, Alanen et al. 2007). This is a highly selective and efficient process 
demonstrated by the fact that the receptor is capable of retaining a tenfold molar 
excess of KDEL-tagged protein. This is the case even when the protein is a KDEL-
tagged secretory protein normally destined to leave the ER (Pelham 1996). The 
KDEL motif has been used in genetic engineering to enhance the accumulation of 
proteins intracellularly. Schouten et al added a C-terminal KDEL sequence to an 
ScFv construct containing a secretory signal sequence, which caused an increase in 
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expression levels in tobacco plant cells compared to a construct without a KDEL 
sequence, probably due to an increase in ScFv protein stability (Schouten, Roosien et 
al. 1996).    
1.4.2.3 FVIII secretion from the cell as an inactive heterodimer 
 
FVIII is secreted from the cell as an inactive heterodimer following cleavage in the 
Golgi between the B and A3 domains, as well as several cleavages within the B 
domain (after residues 1313 and 1648) (Marder et al. 2013). The heterodimer 
consists of a 90-200KDa heavy chain (A1-A2-B) and an 80kDa light chain (A3-C1-
C2) associated by a metal ion (Yonemura, Sugawara et al. 1993). The metal ion 
linking the two chains has been identified as copper, and is released upon 
dissociation of the dimer. It has been shown that addition of copper is able to 
reconstitute FVIII activity from dissociated FVIII chains (Wang, Wang et al. 2003).  
In some recombinant cell lines it has been noted that the intracellular cleavage of the 
FVIII polypeptide chain in the B domain to form a heterodimer (two polypeptide 
chains) either does not occur, or is incomplete. To overcome this issue, several 
groups have investigated the co-expression of heavy and light chains using separate 
constructs. Yonemura et al co-expressed heavy and light chains using two separate 
plasmids and co-transfected these into CHO cells. Each chain was produced linked to 
an amino acid sequence that resembled the FVIII precursor sequence (signal 
peptide), and the heavy chain contained Kozak consensus sequence 
((G/A)NNATGG, plays a major role in the initiation of the translation process) 
flanking the translation initiation codon. These conditions resulted in a mammalian 
cell line expressing functional FVIII at levels of 15 IU/day/10
6
 cells, which is around 
10-fold higher than other full length FVIII expression systems (Yonemura, Sugawara 
et al. 1993).  
In vivo, FVIII heterodimer circulates in the blood complexed with a chaperone 
protein, von Willebrand factor (vWF), which acts as a stabiliser by preventing its 
proteolytic degradation and promoting the association of heavy and light chains 
(Wang, Wang et al. 2003). vWF is a large glycoprotein containing 2813 amino acids 
arranged into four homologous domains (A-D), of which the ‘D’ domain is 
responsible for non-covalent interactions with FVIII. It is produced as a pro-
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polypeptide in megakaryocytes and vascular endothelial cells, and is converted to a 
mature form by proteolysis (Wagner 1990). vWF is only activated during high blood 
flow conditions and shear stress (Siediecki, Lestini et al. 1996). FVIII contains 
several binding sites for vWF which can be found in the C2 domain and the A3 
domain of the FVIII protein and the D’D3 region of vWF (Saenko and Scandella 
1997).While it is well understood that FVIII and vWF are synthesised in different 
cell types and assemble in plasma after secretion, recent evidence suggests that 
additional cell types exist in vivo where these two proteins are co-expressed (Van 
Den Biggelaar, Bierings et al. 2007). vWF is stored in elongated secretory organelles 
specific to endothelial cells called Weibel-Palade bodies (WPBs)  (Weibel and 
Palade, 1964). WPBs contain a variety of other proteins that contribute to 
inflammation, angiogenesis, and tissue repair such as tissue-type plasminogen 
activator (tPA), P-selectin, interleukin-8 (IL-8), eotaxin-3, angiopoietin-2, 
osteoprotegerin, endothelin-1, endothelin-converting enzyme, and calcitonin gene-
related peptide (Valentijn et al, 2011). vWF is initially produced as multimers in the 
Golgi of endothelial cells. These multimers go on to fold into elongated tubular 
structures, the presence of which drives the formation of WPBs. Biogensis of WPBs 
is also dependent on Clathrin and the heterotetrameric adaptor protein (AP) complex 
AP1, which help to form vesicles that transport proteins between post-Golgi 
compartments (Metcalf et al 2007). It has been demonstrated that FVIII is also 
trafficked to the WPBs and that the FVIII:vWF complex can be stored here until 
required (van den Biggelaar, Meijer et al. 2009).  
In recombinant systems expressing FVIII, the absence of vWF in the cell culture 
media results in the secretion of dissociated heavy and light chains that are rapidly 
degraded. Research groups have overcome this issue by adding vWF to the culture 
medium (containing serum) or alternatively in serum-free systems, co-expressing 
vWF and FVIII together in CHO cells in order to increase the stability of the FVIII 
protein (Kaufman and Pipe 1999), (Kaufman, Wasley et al. 1989). Co-expression of 
vWF and FVIII in CHO cells also increased the total amount of FVIII secreted from 
the cell compared to the expression of FVIII alone. The secretion rate of FVIII was 
however much slower in the presence of vWF and this was thought to be due to an 
increase in BiP expression in the VWF/FVIII cell line which slowed the intracellular 
trafficking of the FVIII protein. Interestingly it was demonstrated that vWF had a 
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transient association with BiP and therefore its secretion rate was unaffected by the 
increase in BiP expression (Kaufman, Wasley et al. 1989). 
 
1.5 Activation and inactivation of FVIII  
 
Activation of the inactive protein FVIII to FVIIIa is induced by thrombin or FXa and 
results in an unstable heterotrimer that is susceptible to proteolytic degradation by 
activated protein C (APC), FIXa or FXa (Saenko, Ananyeva et al. 2003). The 
activation step cleaves the B domain from the heavy chain and releases vWF from 
the light chain, leaving FVIII free to exert its coagulant properties by interacting with 
FIXa (Kaufman and Pipe 1999). The heterotrimer consists of the A1 domain, A2 
domain and the A3-C1-C2 domain (Vehar, Keyt et al. 1984). The light chain (A3-
C1-C2)  and the A1 domain are linked by a stable divalent metal (copper) ion bond 
whereas the A2 subunit is weakly associated to the A1 domain via electrostatic 
interaction (Fang, Wang et al. 2007). Dissociation of the A2 domain occurs readily in 
wild type FVIIIa at physiological pH and results in loss of coagulant activity (Wang, 
Wang et al. 2003).  
Several attempts have been made by research groups at engineering parts of the A2 
domain in order to increase the stability and extend the half-life of the FVIII protein. 
Radtke et al produced a B-domain deleted cell line that contained an additional 
disulfide bond between the A2 domain and the A3 domain in order to prevent A2 
dissociation and prolong the half-life of activated FVIII. Compared to wild type 
FVIII, only 10% of the FVIII with an extra disulphide bond was required to produce 
the same clotting activity in whole blood bioassays (Radtke, Griffin et al. 2007). This 
approach of prolonging the half-life of FVIII seems promising when you consider the 
needs of haemophilia patients in terms of the frequency of FVIII infusions and the 
preference for prophylactic treatment with a longer half-life, meaning fewer doses 
would be required to elicit the same level of clotting activity. Pipe et al developed a 
cell line producing FVIII that was resistant to A2 domain dissociation, by deleting 
residues 794-1689 so that the A2 domain was covalently attached to the light chain, 
as well as introducing missense mutations at thrombin and activated protein C 
inactivation cleavage sites providing resistance to proteolysis. Both of these steps 
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resulted in increased protein stability demonstrated by FVIII activity remaining after 
4 hours in the mutated version, versus thrombin inactivation of FVIII within 10 
minutes in the wild type FVIII. (Pipe and Kaufman 1997).  
Aside from the dissociation of the A2 domain, there are other mechanisms of 
inactivating FVIII in vivo. Activated FIX, activated protein C (APC), activated FX 
and plasmin are all proteases capable of cleaving FVIII. The effect of APC can be 
enhanced by protein S and there is also evidence to suggest a role for FV in this 
process. 
A number of receptors are also involved in the clearance of FVIII including low 
density lipoprotein (LDL) receptor, the LDL receptor related protein-1 (LRP1), the 
asialoglycoprotein receptor (ASGPR) via the glycosylated regions of the B-domain, 
and the macrophage mannose receptor (CD206) (review, (Lenting, Christophe et al. 
2010)). In terms of the receptors involved in FVIII clearance, this appears to be a 
relatively recent area of research and the mechanisms of action need to be more fully 
understood before these receptors can be exploited with regard to extending the half-
life of FVIII. 
A high level summary of the steps that the FVIII protein goes through as it is 





Figure 1-4. A summary of the steps that FVIII goes through including secretion, 
activation and inactivation (image reproduced from Pipe et al, 2009). 
 
1.6 The formation of anti-factor VIII antibodies  
 
A serious complication of haemophilia treatment is the development of antibodies 
which are inhibitory to FVIII as a result of FVIII infusion (Hoffbrand, Moss et al. 
2006). The formation of these polyclonal alloantibodies occurs in around 25% of 
haemophilia A patients who receive repeated infusions of FVIII (Saenko, Ananyeva 
et al. 2003). Polyclonal autoantibodies to FVIII can also occur in people with normal 
FVIII levels (acquired haemophilia, AHA) (Lubin, Healey et al. 1994). Both allo- 
and autoantibodies bind to the A2 (454–509), A3 (1804–1819), or C2 domains 
(2181–2243) of the FVIII protein with varying modes of action. The anti-C2 
antibodies interfere with the binding of FVIII to phospholipids and VWF, A2 and A3 
inhibitors block the binding of FVIII to factor X (FX) and FIXa, respectively, 
2. The unactivated FVIII heterodimer circulates in blood 
plasma with its carrier protein, von Willebrand factor 
(VWF), to form a tight non-covalent complex.
1. Partial cleavage of the FVIII polypeptide in the B 
domain by an intracellular protease in the Golgi 
results in secretion of an inactive heterodimer 
consisting of an 80 kDa light chain composed of 
the A3-C1-C2 domains and a heterogeneous 90–
210 kDa heavy chain of the A1-A2-B domains.
3. Thrombin activates FVIII by proteolysis at three residues: Arg372, 
Arg740 and Arg1689. Arg372 and Arg1689 are known to be 
essential sites for FVIII activation (Fig. 1) [34]. Cleavage at Arg372 
bisects the A1 and A2 domains and at Arg1689 the acidic a3 
region from the light chain to create the FVIIIa heterodimer (A1-
a1/ A2-a2/ A3-C1-C2)
3. FVIII activity is rapidly lost either through spontaneous 
dissociation of the A2 subunit from the rest of the molecule 
or through proteolytic degradation by a number of enzymes, 
such as thrombin, FIXa, FXa and activated protein C (aPC). 
The main physiological inactivator of FVIIIa, aPC , cleaves 
FVIIIa in the A1 (Arg336) and A2 domains (Arg562). 
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obstructing the formation of the Xase complex (Sakurai, 2014). Alloantibodies occur 
in response to infusion of FVIII into the patient whereas autoantibodies form 
spontaneously against the patient’s own plasma FVIII. Interestingly it has been 
shown in several studies that alloantibodies against FVIII can demonstrate 
proteolytic activity although the clinical relevance of this has not yet been elucidated. 
In one such study, plasma purified from 13 of 24 FVIII inhibitor-positive patients 
contained IgG alloantibodies that demonstrated significant proteolytic activity, when 
incubated with biotinylated factor VIII, whereas FVIII that had been incubated with 
normal human IgG had no detectable proteolytic activity (Lacroix-Desmazes et al, 
2002).  
It is apparent that there is a link between the type of FVIII gene mutation a patient 
has and the likelihood of developing inhibitors. For those patients with mutations that 
prevent the production of FVIII e.g. intron 22 inversion, the likelihood of developing 
inhibitors is around 35% versus 5% for those patients who are able to produce small 
amounts of FVIII (Bolton-Maggs and Pasi 2003).   
The incidence of inhibitor formation in congenital haemophilia appears to be linked 
to the type of treatment given, either prophylactic or on-demand. There is evidence to 
suggest that patients who are given FVIII on demand are more likely to develop 
these inhibitors than those receiving prophylactic treatment prior to a bleeding event 
(Ljung 2009). There are also differences in the type of inhibitors formed in response 
to different commercial FVIII products. There is an ongoing debate over the 
immunogenicity of plasma derived versus recombinant FVIII products and which is 
safer in terms of inhibitor development. The European Medicines Agency published 
a report in 2007 on FVIII products and inhibitor development and stressed the need 
for clinical data comparisons between the two product types (EMEA 2007). Infusion 
of vWF along with FVIII in plasma derived FVIII products may be preferable to 
infusing FVIII alone since vWF appears to regulate immune recognition by 
concealing antibody binding epitopes (Terraube, O'Donnell et al. 2010).  
For recombinant FVIII products, even a small change to the manufacturing process 
can affect their immunogenicity profile. This has been seen with manufacturing 
changes to KOGENATE® and its successor, Kogenate® FS/Bayer (Bayer) that were 
made in order to improve pathogen safety. These included removal of albumin, 
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addition of an S/D viral inactivation step (to inactivate enveloped viruses) and a 
shortening of the protein residence time in the fermenter which lowers the 
probability of immunogenic FVIII degradation products forming. Improvements in 
the successor product have led to potentially improved immunogenicity profile in 
previously untreated or minimally treated patients with severe haemophilia A 
(Lusher and Scharrer 2009). An assessment by the EMA concluded that the product 
did not appear to be different from other FVIII products in terms of efficacy and 
safety in the treatment of PUPs (previously untreated patients) and MTPs (minimally 
treated patients), had sufficient viral safety due to the various viral 
removal/inactivation steps, and the sourcing of bovine products from countries 
without any reported cases of BSE (EMEA 2004). 
Other groups have looked at inducing immune tolerance to specific inhibitory 
epitopes. Rawle et al demonstrated this concept in a mouse model of haemophilia A 
by exposing the mice to purified FVIIII C2 domain via their mucosa. When dosed 
with whole FVIII, lower levels of antibodies to FVIII C2 domain were seen in the 
pre-exposed mice compared to those mice who had not been previously exposed 
(Rawle, Pratt et al. 2006).  
 
1.7 Porcine FVIII versus human FVIII 
 
One approach to overcome the problem of anti-FVIII antibodies takes advantage of 
the fact that these inhibitors of human FVIII have limited cross-reactivity (often 
negligible) with porcine FVIII (Kernoff 1991). Early attempts at treating 
haemophiliacs with porcine FVIII were abandoned due to allergic reactions and the 
presence of platelet aggregating factor which caused thrombocytopenia. However, a 
highly purified version of plasma-derived porcine FVIII (Hyate, Speywood) was 
used successfully to achieve hemostatic FVIII levels in patients in whom human 
FVIII was ineffective (Mayne, M et al. 1981), but possible residual viral 
contamination and immunogenicity prevented its routine use. More recently, OBI-1, 
a B-domain deleted recombinant porcine FVIII (manufactured by Ipsen and 
Inspiration Biopharmaceuticals Inc), showed promise in both animal and human 
haemophilia subjects. In a murine model of haemophilia A, OBI-1 demonstrated less 
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immunogenicity than plasma derived FVIII, and in cynomolgus monkeys, OBI-1 did 
not generate detectable inhibitors. In a human trial (phase II, open-label), patients 
with hemophilia A and inhibitors against porcine FVIII showed OBI-1 was well 
tolerated, without drug-related serious adverse events and showed promise for further 
studies (Toschi 2010). A phase 2/3 study also demonstrated that OBI-1 is safe and 
effective in treating bleeding episodes in patients with acquired haemophilia A 
(Kruse-Jarres, R. et al 2015). A Biologics License Application (BLA) was submitted 
in 2013 to the U.S. Food and Drug Administration (FDA) for the approval of OBI-1, 
as a treatment for patients with acquired hemophilia A (Baxter 2013), and received 
FDA approval in 2014. 
Although porcine and human FVIII have the same domain structure (A1-A2-B-A3-
C1-C2), human FVIII has weaker coagulant activity than porcine FVIII due to faster 
dissociation of the A2 subunit (Lollar, Parker et al. 1992). Porcine FVIII has limited 
cross-reactivity with human FVIII inhibitory antibodies, therefore, purified porcine 
FVIII has been used in the treatment of haemophilia patients who have developed 
inhibitors to human FVIII since 1980 (Kernoff 1991). Hyate:C, a plasma-derived 
porcine FVIII, was used in humans for approximately 20 years until it was 
discontinued due to suspected viral contamination of the porcine blood supply 
(Healey, Parker et al. 2009). Treatment with porcine FVIII results in cessation of 
bleeding in haemophiliacs with inhibitors to human FVIII, and can even be used 
when the patient has porcine FVIII inhibitors, as demonstrated in a case study 
(Gribble and Garvey 2000).  
Recombinant versions of porcine FVIII have also been investigated since it was 
noted that porcine FVIII exhibits high-level expression due to enhanced transit 
through the secretory pathway (Dooriss, Denning et al. 2009).  
Lubin et al developed a B-domain deleted human/porcine FVIII hybrid by 
eliminating the human FVIII A2 inhibitor epitope and replacing this with the 
homologous porcine sequence. The coagulant properties of the protein in a functional 
assay were unchanged but anti-A2 inhibitor binding was reduced (Lubin, Healey et 
al. 1994). The approach of deleting inhibitor epitopes on FVIII could be promising in 
terms of personalised medicine and tailoring treatment to the individual patient 
depending on the inhibitor type present. 
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In 2002, Doering et al looked at a recombinant B-domain deleted (BDD) porcine 
FVIII producing cell line in comparison with a recombinant BDD human FVIII cell 
line and saw expression levels 14-fold greater in the porcine system (Doering, 
Healey et al. 2002). The same group later went on to investigate the regions of 
porcine FVIII gene that are responsible for these increased expression levels. They 
developed a human/porcine BDD FVIII hybrid containing the porcine A1 and a3-A3 
domains and were able to achieve protein expression levels comparable to that of the 
native BDD porcine FVIII system. Human FVIII contains two potential 
glycosylation sites that are not present in porcine FVIII, at Asn-42 within A1 domain 
and at Asn-1685 within a3-A3 domain. Also, porcine FVIII contains a potential 
glycosylation site at Asn-213 in the A1 domain that is not conserved in human FVIII. 
It was hypothesised that due to the differences in the glycosylation patterns between 
the porcine and human molecules in the A1 and a3-A3 domains, and the fact that 
these sites normally affect the passage of FVIII through the endoplasmic 
reticulum/Golgi apparatus, the hybrid porcine/human protein had more efficient 
folding and passage through the ER-Golgi secretory pathway (Doering, Healey et al. 
2004). This is known to be a rate-limiting step for the production of human FVIII 
due to interactions with the BiP molecular chaperone as described earlier.  
 
1.8 Purification of FVIII 
 
Due to previous safety concerns about the pathogenicity of blood derivatives, the 
regulatory approval process for recombinant FVIII products requires that all human 
and animal protein additives have to be removed and of course this includes vWF. In 
a manufacturing setting, a complicated series of purification steps have to be taken to 
separate FVIII from a large volume of cell media before it can be infused into 
patients. In order to remove all medium components, host cell residues, and potential 
pathogens such as viruses, many techniques are employed. These vary depending on 
the manufacturer in question but can include crude physical restriction on the basis of 
protein size, immunoaffinity (using an anti-FVIII antibody), ion-exchange 
chromatography (based on charged side chains), pasteurization (heat treatment to 
remove viruses), solvent-detergent (to remove viruses) (Pipe 2008), and nano-
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filtration with more recent products (remove prions and viruses) (Lee, Berntorp et al. 
2010).  
Purification processes for FVIII vary according to the source of the protein and the 
manufacturer (for high level summary see table 7). The FVIII products listed in the 
table below can be classified into three groups ranging from the intermediate purity 
products obtained through precipitation/adsorption, concentrates purified through ion 
exchange chromatography and concentrates purified through the use of monoclonal 
antibodies. The recombinant FVIII products are all obtained using immunoaffinity 
chromatography (see review, Franchini, 2013).  
Table 7 Examples of commercialised FVIII products and their manufacturing 
processes (reproduced from Franchini 2013). 
Product Manufacturer Production characteristics 
  Purification Viral inactivation 
Plasma-derived FVIII concentrates 
Alphanate Grifols Heparin ligand 
chromatography 
S/D, dry heat 
Beriate CSL Behring Ion exchange 
chromatography 
Pasteurisation 
Emoclot D.I. Kedrion Ion exchange 
chromatography 
S/D, dry heat 
Fanhdi Grifols Heparin ligand 
chromatography 
S/D, dry heat 
Haemate P CSL Behring Multiple precipitation Pasteurisation 
Haemoctin Biotest Ion exchange 
chromatography 
S/D, dry heat 









Recombinant FVIII concentrates 
Advate Baxter Immunoaffinity 
chromatography 
S/D 
























Legend: S/D =  solvent/detergent. 
 
Purification of FVIII using immunoaffinity chromatography is an expensive 
procedure involving many steps, and is complicated by the use of antibody ligands 
which can elute along with FVIII and contaminate the product (Burnouf and 
Radosevich 2001). The antibody ligands also present other problems as they need to 
be virus-inactivated to minimise risk of contamination and are expensive to produce. 
Nord et al looked at an alternative to using antibodies by using phage display to 
produce FVIII specific-affibodies which are much smaller than antibodies and have 
an improved affinity to FVIII (Nord, Nord et al. 2001).  Knör et al also looked at 
alternatives to using antibodies by developing a small synthetic peptide ligand with 
high affinity to FVIII. This ligand offered several advantages over the use of 
antibodies as it was stable, non-toxic, cheap to produce and enabled the elution of 
FVIII under mild conditions (Knör, Khrenov et al. 2008).  
1.8.1 Antibody fragments as tools in the purification of proteins 
 
Another approach to the purification of large proteins such as FVIII is the use of 
small antibody fragments instead of whole antibodies. These include ‘Fab’ which is 
the antigen binding fragment composed of one constant and one variable domain 
from each heavy and light chain of the antibody or ‘Fv’, containing just the variable 
domain from the heavy and light chain (VH and VL) (Janeway, Travers et al. 2005). 
These fragments have been successfully expressed in bacteria, yeast and fungi and 
offer advantages over the use of whole antibodies such as improved stability. 
However these fragments are difficult to produce on an industrial scale as their heavy 
and light chains have a tendency to dissociate upon dilution. To overcome this issue, 
three strategies were tried including linking the two chains with glutaraldehyde, 
disulphide bonds or a peptide linker (Glockshuber et al 1990). However, the option 
of synthetically linking the chains to form a single chain fragment, so-called ScFv, 
lowered their affinity for their antigen compared to their parent antibody 
47 
 
(Muyldermans 2001). Also, the synthetic link used to form the ScFv caused the 
fragments to aggregate in the ER of the cell, resulting in ineffective secretion 
(Thomassen, Meijer et al. 2002). Ward et al also tried producing single chain VH 
antibody fragments in a mouse (Ward and Gussow 1989) however these are less 
soluble and have a lower antigen binding affinity than ScFv (Muyldermans 2001). 
1.8.2 Camelid antibodies 
 
An exciting new development in this field came with the discovery that Camelids 
(camels, dromedaries, llamas, alpacas, guanacos and vicunas) have a unique ability 
to produce not only conventional antibodies but also antibodies that are devoid of 
light chains and CH1 domains (constant heavy chain domain 1) (Omidfar, Rasaee et 
al. 2007), see figure 1.5. Despite the absence of the light chain and CH1 domain, 
these heavy chain only antibodies are able to bind to antigens as efficiently as 
conventional antibodies (Maass, Sepulveda et al. 2007). The antigen binding domain 
of these heavy chain only antibodies is denoted VHH (variable domain of the heavy 
chain of a heavy-chain only antibody), and at approximately 12-15 kDa is the 
smallest fragment known to derive from a functional antibody (Muyldermans 2001).  
The VHH and the VH region of a conventional antibody contain domains that are 
comparable in their basic structure, containing four conserved framework regions, 
and three hypervariable regions, the complementarity determining regions (CDR) 
(Muyldermans 2009). Although these VHH have adapted to compensate for the lack 
of a light chain, the VHH demonstrate a high degree of homology in their amino acid 
sequences with VH in conventional antibodies, particularly those amino acids that 
determine the typical immunoglobulin folding (Muyldermans, Cambillau et al. 
2001). The VHH also show a close homology to human VH domains which could be 
particularly useful for in vivo applications of antibody fragments when considering 
immunogenicity issues (Omidfar, Rasaee et al. 2007). 
Although close homology exists between VH and VHH, there are four specific 
amino acids that are normally present in VH that are constitutively replaced in VHH 
(residues Val37Phe (or Tyr), Gly44Glu (or Gln), Leu45Arg (or Cys) and Trp47Gly 
(or Ser, Leu, Phe)) and this makes it easier to distinguish between the two 
(Muyldermans, Cambillau et al. 2001). These amino acid substitutions are in regions 
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normally that normally bind to VL, renders this part of VHH more hydrophilic and 
less likely to bind to VL (Muyldermans 2001). The hydrophilic nature of VHH 
contributes to the increased solubility of these fragments compared to VH.  
In addition, the VHH CDR3 region is longer (17 amino acids), than in human VH (9 
amino acids) (Vu et al 1997). It is thought that the enlarged hypervariable regions of 
VHH results in a larger antigen binding site and compensates for the absence of the 
VL domain which in an Fv fragment would provide additional antigen contact sites. 
The enlarged hypervariable regions are responsible for many structural differences 
between VH and VHH, primarily the presence of loop structures in the CDRs of their 
antigen binding sites. The structural diversity and small size of VHH allows 
additional freedom with regard to the epitopes they recognise and can bind to 
(Muyldermans 2001).   
VHH fragments offer many advantages over other antibody fragments such as Fab, 
Fv or scFv due to their increased stability, solubility and antigen binding properties. 
This has led to interest in these VHH for research and commercial purposes (Maass, 
Sepulveda et al. 2007). Originally heavy chain antibodies were sourced from 
immunised Camelid, from which the VHH domain could be separated via proteolysis 
(Muyldermans 2001). More recently, research groups have looked into the 
production of Camelid derived ligands on a large scale using recombinant systems to 
express the VHH domains. Thomassen et al were able to produce VHH fragments on 
a large scale using a yeast expression system (Saccharomyces cerevisiae) and a 





Figure 1-5 The structure of a conventional antibody compared with a Camelid 
heavy chain only antibody. 
The Camelid immunoglobulin is devoid of the light chain and the CH1 region of the 
heavy chain that are both present on the conventional immunoglobulin G. The 
antigen binding region of the heavy chain of the Camelid antibody is referred to as 
VHH (variable region of the heavy chain of a heavy chain only antibody). 
 
 
1.8.2.1 Anti-FVIII specific VHH 
 
BAC BV in the Netherlands use a yeast expression system, free of animal derived 
components to produce recombinant VHH fragments (CaptureSelect
®
 ligands). 
These ligands have been developed specifically as tools in the purification of 
recombinant proteins. More specifically, BAC has developed several ligands that 
Constant regions, heavy chain (CH1, CH2, CH3)
Constant region, light chain (CL)
Variable region, light chain (VL)
Variable region, heavy chain (VH) 

















bind specifically to FVIII. Currently, these ligands are commercially available as 
tools for the purification of recombinant FVIII (FVIIISelect, GE Healthcare).  
Previous experiments (unpublished) were conducted at the University of Kent by Dr 
Kerry Tappenden and Dr Wynne Jones, who used these camelid ligands in a 2-stage 
purification of FVIII from cell culture media at pH7 and showed that they are robust 
and highly selective. In the first stage of the method, FVIII (Advate) was purified 
from AIM-V cell culture media using Mustang® Q (Pall Corporation) anion 
exchange chromatography. FVIII was then eluted from the Mustang® Q coin and the 
sample loaded directly on to a FVIII Select™ affinity chromatography column (GE 
Healthcare). FVIII Select™ contains anti-FVIII camelid antibody linked to a porous 
membrane. Given the current complex multi-step procedure of purifying FVIII in an 
industrial manufacturing setting, these camelid ligands provide some hope in 
simplifying the process. Also, harsh elution conditions can often prove harmful to the 
final protein product so the elution at neutral pH also offers advantages (McCue, 
Selvitelli et al. 2009). BAC has also demonstrated (confidential/unpublished) that 
these anti-FVIII VHH have high affinity binding to FVIII, which has contributed to 
their commercial value as simple purification tools.  
Based on the unpublished data generated by BAC and the University of Kent, it is 
possible that these ligands not only bind FVIII, but also increase the stability of the 
protein. This project will explore a targeted approach of co-expression of these anti-
FVIII VHH ligands with FVIII to investigate the possibility that these ligands do 
increase the stability of the FVIII protein upon binding, and subsequently impact the 
levels of functional FVIII protein secreted into the cell culture media of mammalian 
cells.  
Targeting of VHH ligands to specific proteins (membrane, secretory, intracellular, 
cell surface and others) has been reported in many studies in the literature 
(Wesolowski, Alzogaray et al. 2009). An example includes an anti-vWF VHH in 
development for detection of vWF in serum samples for the diagnosis of von 
Willebrand’s disease (Hulstein, Groot et al. 2005). Also, a VHH specific for hepatitis 
B particles has been targeted intracellularly (also known as an intrabody) by the 
addition of KDEL which led to the intracellular accumulation of hepatitis B particles 
in mice (Serruys, Houtte et al. 2009). The strategy of co-expressing VHH with a 
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target protein in the same cellular compartment has also been tried with Bax, a 
member of the Bcl-2 family. Bax-specific VHH were developed and used to inhibit 
Bax induced permeabilisation of mitochondria and resulted in cell lines that were 
resistant to oxidative stress (Gueorguieva, Li et al. 2006).  
In the present study, three Camelid-derived VHH ligands, named ligand 2, ligand 6 
and ligand 7 respectively have been supplied by BAC BV, Netherlands. Two of these 
ligands are reported by BAC to have anti-FVIII activity (ligands 2 and 7). The third 
ligand, (ligand 6) binds to FII and will therefore be used as a negative control. Both 
ligand 2 and ligand 7 bind to the light chain of FVIII (exact binding locations 
confidential to BAC), with ligand 7 demonstrating the best binding affinity (low nM) 
to FVIII.  Previous competition ELISA experiments (conducted by BAC) indicated 
that anti-FVIII ligand 7 competes with vWF for the same epitope on the FVIII 
protein (personal communication from BAC). It is possible ligand 7 may have 
similar properties to vWF such as stabilising the FVIII protein and/or protecting it 
from proteolysis since it binds the same epitope on the FVIII protein. Since vWF 
stabilises FVIII when the two proteins are co-expressed in vivo, it is hypothesised 
that co-expression of FVIII with ligand 7 could provide a route to producing 
increased levels of stable recombinant FVIII. Conversely, ligand 2 has a binding 
epitope on FVIII that does not compete with that of vWF so the present will also 
compare the effect of co-expression with FVIII between ligand 2 and ligand 7. In the 
present study, ligand 2, ligand 6 and ligand 7 will be co-expressed with FVIII, and 
the resultant effect on FVIII expression will be assessed using a gold standard 
coagulation assay. 
It is important to note here that an increase in total FVIII protein expression does not 
necessarily translate to an increase in the amount of functional FVIII i.e. that which 
is correctly folded and fully functional in terms of procoagulant activity. Therefore 
any differences in the amount of functional FVIII must be tested using a functional 
coagulation assay, which is currently widely used in a clinical setting to diagnose 
bleeding abnormalities and monitor anticoagulant therapies (Bates and Weitz 2005). 
Conversely, an increase in the amount of functional FVIII does not necessarily 
equate to an increase in total protein so both must be assessed.  
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In summary, the literature surrounding FVIII and haemophilia research is immense. 
It is clear that many different cell lines, expression systems and engineered versions 
of FVIII have been investigated, all with the aim of improving on current treatments 
for haemophilia. Since those products which are currently in clinical use are 
manufactured under confidentiality (at least the full chemistry, manufacturing and 
controls data is not normally published by regulatory agencies), it is difficult to say 
which of these areas of research have made the most impact. What is clear however 
is that there is still significant room for improvement to be made with FVIII 
expression, given the fact that it is expressed at much lower levels than other 
recombinant clotting factors, and the subsequent effect this is having on availability 
and cost of treatment for haemophiliacs worldwide. Any future FVIII products need 
to have a fine balance between safety, clinical efficacy and cost effectiveness if they 
are to have any impact on the current situation.  
This project aims to add to and complement this vast area of research with an 
alternative means of increasing the amount of functional FVIII that is expressed in a 
BDD-FVIII BHK cell line by using Camelid antibody fragments as molecular 
chaperones, an approach that has not previously been investigated in the production 




Aims of the project 
 
The overall aim of this project is to co-express three different Camelid antibody 
ligands (VHH ligands 2, 6 and 7) with FVIII. Two of these ligands are anti-FVIII and 
the third ligand is anti-FII (negative control). Upon co-expression, FVIII production 
in mammalian cells will be tested using both quantitative and functional assays in 




1. Using a variety of molecular techniques nine plasmid constructs will be 
created and cloned into a pcDNA3.1 vector that is suitable for mammalian 
transfection and expression. Each plasmid construct has either an 
immunoglobulin leader sequence, a HIS tag, a KDEL sequence (endoplasmic 
reticulum retrieval motif) or a combination of these (see figure 2.1). Plasmid 
constructs to be created include: 
a. Ligand 2, constructs 1, 2 and 3 
b. Ligand 6, constructs 1, 2 and 3 
c. Ligand 7, constructs 1, 2 and 3  
2. Transiently transfect Camelid antibody constructs into mammalian cells and 
confirm expression using ELISA or western blotting 
3. Co-express Camelid antibody ligand and FVIII in mammalian cells 
4. Test the pro-coagulant activity of FVIII protein secreted into cell media using 
a gold standard coagulation assay before and after co-expression with VHH. 
It is hypothesised that VHH ligands produced from construct 1 containing a 
leader sequence will be secreted from the cell; VHH ligands produced from 
construct 2 (containing no leader sequence and a HIS tag) will possibly not be 
secreted from the cell and stay in the cytosol due to the absence of a leader 
sequence. For construct 3 which contains both a leader sequence and KDEL, the 
hypothesis is more complicated. The presence of the leader sequence will direct 
the protein via the ER/Golgi pathway to be secreted from the cell. However, 
since KDEL is an endoplasmic reticulum retrieval motif, it is possible that a high 
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proportion of this protein will bind to the KDEL receptor in the Golgi apparatus 
and be rendered secretion incompetent, despite the presence of the leader 
sequence. Interaction of the VHH ligand at the KDEL receptor may have 
important consequences when considering those constructs that have anti-FVIII 
activity. If the VHH ligand is bound to FVIII when it binds to the KDEL 
receptor, this may also prevent FVIII being secreted, and result in both proteins 
being recycled back to the ER. The impact of this could be a reduction in 
secreted FVIII protein since excess FVIII accumulates in the ER, potentially 
resulting in overloading the system, the formation of aggregates and the 




Chapter 2: Methods 
2.1 Overview  
 
In order to meet the aims of this project, multiple laboratory techniques and 
experimental approaches were employed. The first aim of this project was to produce 
plasmids containing the insert for Camelid antibody (VHH) ligands supplied by BAC 
BV (The Netherlands) that were suitable for transfection into mammalian cells. Once 
the plasmids were produced and the gene sequence confirmed, they were transfected 
into a selection of mammalian cell lines, and the expression of VHH protein 
confirmed. 
Co-expression of VHH and FVIII in mammalian cells was then carried out and both 
VHH and FVIII protein expression was investigated at length. Lastly, since the 
ultimate aim of this project, was to investigate the effect of co-expressing VHH and 
FVIII on the functional activity of FVIII, the two proteins were co-expressed in BHK 
cells. A gold standard clotting assay and statistical analysis were then used to 
investigate any changes in FVIII functional activity when FVIII was co-expressed 
with VHH.  
Overall, a series of molecular, microbiological, cell biology, analytical and assay 
development techniques were utilised in order to achieve these aims in a stepwise 
fashion and will be described in detail in this chapter. 
2.2 Plasmid production 
 
In the present study, three Camelid antibody VHH ligands were tested, ligand 2, 
ligand 6 and ligand 7 respectively. For each ligand, three unique constructs were 
designed, with a combination of features in their gene sequence such as an 
immunoglobulin leader sequence, a histidine tag and KDEL (Endoplasmic Reticulum 
retrieval motif) (see figure 2.1 and table 8). Each of these constructs was cloned into 






Figure 2.1. VHH construct design.  
Construct 1 (C1) contains an immunoglobulin leader sequence from the 
commercialised monoclonal antibody herceptin (LEADER)  and a histidine tag 
(HIS). Construct 2 (C2) contains a histidine tag (HIS). Construct 3 (C3) contains an 
immunoglobulin leader sequence from the commercialised monoclonal antibody 
herceptin (LEADER) and an endoplasmic reticulum retrieval motif (KDEL). 
 
Table 8 Design elements of VHH constructs 
 
For simplification, each ligand construct was given an abbreviated name, for 
example, ligand 2, construct 1 was abbreviated to L2C1, as shown in table 9.  
 
Construct number 1 2 3 
Leader sequence Yes No Yes 
HIS tag Yes Yes No 
KDEL No No Yes 
Secreted 
extracellularly? 
Yes No Maybe 
57 
 
Table 9. Naming of plasmids. 
 Ligand 2 Ligand 6 Ligand 7 
Construct 1 L2C1 L6C1 L7C1 
Construct 2 L2C2 L6C2 L7C2 
Construct 3 L2C3 L6C3 L7C3 
 
2.2.1 Primer design 
The Camelid antibody gene sequences and partial template DNA were provided by 
BAC to the University of Kent for use in this project under a confidentiality 
agreement, and consequently this thesis will not disclose these gene sequences.  
The template DNA that BAC supplied was in fact a digested fragment that had to be 
‘rebuilt’ in order to produce the gene encoding a fully functional VHH protein. BAC 
had digested the VHH template DNA from a plasmid vector using two restriction 
enzyme sites (PstI x BstEII). This meant that the first 15 nucleotides were missing 
from the full VHH gene sequence and therefore primers were designed in such a way 
to ‘rebuild’ the full gene sequence using PCR. Forward primers, incorporated an 
‘ATATA’ clamp, a restriction enzyme cutting site (BamH1), a translation initiation 
codon, a leader sequence (for constructs 1 and 3 only), the first 21 nucleotides of the 
template DNA sequence and the 15 ‘missing’ nucleotides that had been digested 
from the template provided by BAC. 
 
Reverse primers incorporated an ‘ATATA’ clamp, a restriction enzyme cleavage site 
(EcoR1), a translation termination codon, the last 36 nucleotides of the template 
DNA and either a HIS tag (constructs 1 and 2 only) or KDEL (construct 3 only). The 
reverse primer was ordered as the reverse complement of the desired PCR product.  
 
Forward and reverse primers were designed manually and supplied by Eurofins.  
Each Camelid VHH gene of interest was supplied by BAC BV, Netherlands and was 
cloned into the vector pcDNA3.1 (Invitrogen V790-20/V795-20). The following 





1. Kozak consensus sequence (G/A)NNATGG which is needed to increase the 
likelihood of successful translation initiation  
2. Translation termination codon TCTAGA 
3. +/- immunoglobulin leader sequence from the monoclonal antibody 
‘Herceptin’ 
4. +/- endoplasmic reticulum retrieval motif. 
5. Restriction enzymes sites were carefully selected so that they did not disrupt 
the gene of interest or any vital sections of the plasmid vector for gene 
expression. 
 
2.2.1.1 Ligand 2 primers 
 
Ligand 2, construct 1 (L2C1):  
Forward primer format: ATATA/BamH1/START/LEADER SEQ/VHH 
Sequence: ATATA GGA TCC ATG TCT GTC CCC ACC CAA GTC CTC GGA 
CTC CTG CTG CTG TGG CTT ACA GAT GCC AGA TGC CAA GTT CAA CTT 
CAA GAG AGT GGG GGA GGC TTG GTG 
 
Reverse primer format: VHH/H6 tag/STOP/EcoR1/ATATA 
Sequence: ATATA GAA TTC TTA GTG ATG GTG ATG GTG ATG AGA AGA 
AAC AGT AAC CTG GGT CCC CTG GCC CCA GTA 
 
Ligand 2, construct 2 (L2C2): 
Forward primer format: ATATA/BamH1/START/VHH 
Sequence: ATATA GGA TCC ATG CAA GTT CAA CTT CAA GAG AGT GGG 
GGA GGC TTG GTG 
 
Reverse primer format: VHH/H6 tag/STOP/EcoR1/ATATA 
Sequence: ATATA GAA TTC TTA GTG ATG GTG ATG GTG ATG AGA AGA 
AAC AGT AAC CTG GGT CCC CTG GCC CCA GTA 
 
Ligand 2, construct 3 (L2C3): 
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Forward primer format: ATATA/BamH1/START/LEADER SEQ/VHH 
Sequence: ATATA GGA TCC ATG TCT GTC CCC ACC CAA GTC CTC GGA 
CTC CTG CTG CTG TGG CTT ACA GAT GCC AGA TGC CAA GTT CAA CTT 
CAA GAG AGT GGG GGA GGC TTG GTG 
 
Reverse primer format: VHH/KDEL/STOP/EcoR1/ATATA 
Sequence: ATATA GAA TTC TTA AAG TTC ATC TTT AGA AGA AAC AGT 
AAC CTG GGT CCC CTG GCC CCA GTA 
 
2.2.1.2 Ligand 6 primers 
 
Ligand 6, construct 1 (L6C1): 
Forward primer format: ATATA/BamH1/START/LEADER SEQ/VHH 
Sequence: ATATA GGA TCC ATG TCT GTC CCC ACC CAA GTC CTC GGA 
CTC CTG CTG CTG TGG CTT ACA GAT GCC AGA TGC CAA GTT CAA CTT 
CAA GAG AGT GGG GGA GGA TTG GTG 
 
Reverse primer format: VHH/H6 tag/STOP/EcoR1/ATATA 
Sequence: ATATA GAA TTC TTA GTG ATG GTG ATG GTG ATG AGA AGA 
AAC AGT AAC CTG AGT CCC CTG GCC CCA GTA 
 
Ligand 6, construct 2 (L6C2): 
Forward primer format: ATATA/BamH1/START/VHH 
Sequence: ATATA GGA TCC ATG CAA GTT CAA CTT CAA GAG AGT GGG 
GGA GGA TTG GTG 
 
Reverse primer format: VHH/H6 tag/STOP/EcoR1/ATATA 
Sequence: ATATA GAA TTC TTA GTG ATG GTG ATG GTG ATG AGA AGA 
AAC AGT AAC CTG AGT CCC CTG GCC CCA GTA 
 
Ligand 6, construct 3 (L6C3): 
Forward primer format: ATATA/BamH1/START/LEADER SEQ/VHH 
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Sequence: ATATA GGA TCC ATG TCT GTC CCC ACC CAA GTC CTC GGA 
CTC CTG CTG CTG TGG CTT ACA GAT GCC AGA TGC CAA GTT CAA CTT 
CAA GAG AGT GGG GGA GGA TTG GTG 
 
Reverse primer format: VHH/KDEL/STOP/EcoR1/ATATA 
Sequence: ATATA GAA TTC TTA AAG TTC ATC TTT AGA AGA AAC AGT 
AAC CTG AGT CCC CTG GCC CCA GTA 
 
2.2.1.3 Ligand 7 primers 
 
Ligand 7, construct 1 (L7C1): 
Forward primer format: ATATA/BamH1/START/LEADER SEQ/VHH 
Sequence: ATATA GGA TCC ATG TCT GTC CCC ACC CAA GTC CTC GGA 
CTC CTG CTG CTG TGG CTT ACA GAT GCC AGA TGC CAA GTT CAA CTT 
CAA GAG TCT GGG GGA GGC TTG GTG 
 
Reverse primer format: VHH/H6 tag/STOP/EcoR1/ATATA 
Sequence: ATATA GAA TTC TTA GTG ATG GTG ATG GTG ATG AGA AGA 
AAC AGT AAC CTG GGT CCC CTG GCC CCA GGT 
 
Ligand 7, construct 2 (L7C2): 
Forward primer format: ATATA/BamH1/START/VHH 
Sequence: ATATA GGA TCC ATG CAA GTT CAA CTT CAA GAG TCT GGG 
GGA GGC TTG GTG 
 
Reverse primer format: VHH/H6 tag/STOP/EcoR1/ATATA 
Sequence: ATATA GAA TTC TTA GTG ATG GTG ATG GTG ATG AGA AGA 
AAC AGT AAC CTG GGT CCC CTG GCC CCA GGT 
 
Ligand 7, construct 3 (L7C3): 
Forward primer format: ATATA/BamH1/START/LEADER SEQ/VHH 
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Sequence: ATATA GGA TCC ATG TCT GTC CCC ACC CAA GTC CTC GGA 
CTC CTG CTG CTG TGG CTT ACA GAT GCC AGA TGC CAA GTT CAA CTT 
CAA GAG TCT GGG GGA GGC TTG GTG 
 
Reverse primer format: VHH/KDEL/STOP/EcoR1/ATATA 
Sequence: ATATA GAA TTC TTA AAG TTC ATC TTT AGA AGA AAC AGT 




In order to produce each VHH construct ready for cloning into a pcDNA3.1 vector, 
PCR experiments were carried out using the primers previously designed. 
 
2.2.2.1 PCR for ligand 2, constructs 1, 2 and 3. 
 
Each PCR experiment was set up as a 50 µL reaction. Initially Taq DNA polymerase 
was used according to manufacturer’s instruction (Roche). For specific reaction 
conditions see table 10. 
 






Vol. (µL) in 50 µL 
reaction 
Filtered MilliQ H20     30.05 
PCR reaction buffer  10 x 1 x 5 
dNTP mix 10 mM 0.2 mM 1 
Forward primer 2 µM 0.2 µM 5 
Reverse primer 2 µM 0.2 µM 5 
DNA (ligand 2) 2.9 ng/µL 10 ng 3.45 




A negative control was run alongside all PCR reactions with no DNA template 
present, and the volume of H2O increased to ensure a total reaction volume of 50 µL.  
 
Cycle conditions for Taq Polymerase: 
1. 94 °C for 2 minutes (denaturation) 
2. 25 cycles 
a. 94 °C for 30 seconds (denaturation) 
b. 60 °C for 60 seconds (annealing) 
c. 72 °C for 60 seconds (extension) 
3. Hold at 4 °C 
 
Each PCR product was purified using a PCR purification kit according to the 
manufacturer’s instructions (QIAGEN) and then run on a 1.5 % agarose gel. The gel 
showed smeared bands at 250 bp, 500 bp and 1000 bp indicating the presence of 
primer-dimers and other unspecific by-products (see figure 3.2, panel A) and 
therefore an alternative enzyme was sought in order to improve the quality of the 
PCR product.  
 
A proofreading enzyme, Platininum pfx DNA polymerase (Invitrogen) was tested as 
an alternative to Taq Polymerase. The reaction conditions used are shown in table 11. 
 
 
Also an additional reaction was run with an ‘enhancer’ which was suggested in the 
Invitrogen protocol to lower the melting temp of the primer which is good for long 
primers. In this instance, 5 µL of 10 x enhancer was used to give a final 
concentration of 1 x enhancer. In this instance the MilliQ H2O was reduced by 5 uL. 
 
Cycle conditions for Platinum® Pfx:  
1. 94 °C for 5 minutes (denaturation) 
2. 30 cycles 
a. 94 °C for 15 seconds (denaturation) 
b. 55 °C for 30 seconds (annealing) 
c. 68 °C for 30 seconds (extension) 
3. Hold at 4 °C 
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Vol. (µL) in 50 µL 
reaction 
Filtered MilliQ H20     23.65 
Pfx amplication 
buffer  
10 x 1 x 5 
dNTP mix 10 mM 0.3 mM 1.5 
MgSO4 50 mM 1 mM 1 
Forward primer 2 µM 0.3 µM 7.5 
Reverse primer 2 µM 0.3 µM 7.5 
DNA (ligand 2) 2.9 ng/µL 10 ng 3.45 
Platinum® Pfx 2.5 U/µL 1 U/reaction 0.4 
 
 
PCR products were purified using a PCR purification kit according to manufacturer’s 
instructions (QIAGEN) before running products on a 1.5 % agarose gel. Bands at the 
expected sizes were excised using a scalpel and a UV light box and the DNA purified 
using a gel purify kit (QIAGEN). The same conditions were used to successfully 
amplify each of L2C1, L2C2 and L2C3. 
 
2.2.2.2 PCR for ligand 6, constructs 1, 2 and 3. 
 
Platinum® Pfx was used to amplify each of the constructs 1, 2 and 3 for ligand 6 in 
the same way as ligand 2 constructs (see table 12 for reaction set up). The PCR cycle 












Vol. (µL) in 50 µL 
reaction 
Filtered MilliQ H20     24.5 
Pfx amplication 
buffer  
10 x 1 x 5 
dNTP mix 10 mM 0.3 mM 1.5 
MgSO4 50 mM 1 mM 1 
Forward primer 2 uM 0.3 uM 7.5 
Reverse primer 2 uM 0.3 uM 7.5 
DNA (ligand 6) 6.25 ng/µL 10 ng 1.6 
Platinum® Pfx 2.5 U/µL 1 U/reaction 0.4 
  
 
The PCR products were purified as described previously above. 
 
2.2.2.3 PCR for ligand 7, constructs 1, 2 and 3. 
Based on results for ligand 2 and 6, initial PCR reactions for ligand 7 were carried 
out using Platinum® Pfx, however this produced no PCR product. Several 
optimisation steps were carried out including varying the MgCl2 concentration, 
running the reaction with and without enhancer, changing primer concentrations, 
adjusting the annealing temperature, none of which proved successful. A new 
polymerase enzyme was tested, Phire Hot Start DNA Polymerase (Finnzymes, NEB) 
which is only activated once the PCR reaction begins to heat up. See table 13 for 














Vol. (µL) in a 50 µL 
reaction 
Milli Q H20     10.1 
PCR reaction 
buffer  
5 x 1 x 10 
dNTP mix 10 mM 0.2 mM 1 
Forward primer 2 µM 0.5 µM 12.5 
Reverse primer 2 µM 0.5 µM 12.5 
DNA (ligand 7) 6.9 ng/µL 20 ng 2.9 
Phire Hot Start    1 unit 1 
 
A negative control was run alongside each PCR experiment where no DNA was 
added and the Milli Q H2O was increased to 13 µL. 
 
Cycle conditions for Phire Hot Start DNA polymerase: 
1. 98 °C for 1 minute (denaturation) 
2. 30 cycles 
a. 98 °C for 5 seconds (denaturation) 
b. 70 °C for 5 seconds (annealing) 
c. 72 °C for 10 seconds (extension) 
3. 72 °C for 1 minute 
4. Hold at 4 °C 
 
The PCR products were purified as described previously above. 
 
2.2.3 Restriction digest of purified PCR products 
 
The PCR products were double digested using restriction enzymes BamH1 and 
EcoR1 according to manufacturers’ instructions (Promega) which included 3 
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incubation steps; 37 °C for 1 hour, 65 °C for 15 minutes and hold at 4 °C (see table 
14) .  
Table 14. Typical reaction set up for restriction digest of PCR products. 
Reagent Amount 
MilliQ H2O 15.23 µL 
Buffer E 2 µL 
Acetylated BSA 0.2 µL 
DNA (concentration 638 µg/mL) 1.57 µL (1 µg) 
BamH1 0.5 µL 
EcoR1 0.5 µL 
Total volume 20 µL 
 
These products were then separated using agarose gel electrophoresis and the DNA 
purified using a Gel Extraction Kit according to manufacturer’s instructions 
(QIAGEN). The plasmid vector pcDNA3.1 was also cut with the same enzymes 
(BamH1 and EcoR1) according to manufacturer’s instructions, run on an agaroser gel 
and then purified using a Gel Extraction Kit ready to be ligated with the digested and 
purified PCR products. 
 
2.2.4 Ligation of pcDNA3.1 and PCR products (VHH) 
 
For six out of the nine gene inserts (L2C2, L2C3, L6C1, L6C2, L6C3 or L7C1), an 
overnight ligation was carried out using ligase enzyme (Promega), the digested 
plasmid pcDNA3.1 and one of the respective gene inserts.  
An equation was used to calculate how much plasmid and gene insert should be used 
in each ligation reaction: 
 ng of vector x kb of insert   x molar ratio vector: insert = ng of insert 




The following is a typical reaction set up, in this instance for L6C1: 
100 ng vector  x 0.45 Kb gene  x  3:1  = 24.9 ng of insert 
      5.4 Kb vector 
If the concentration of the plasmid vector pcDNA3.1 =14 µg/ml, and the 
concentration of the gene insert L6C1 = 7.6 µg/ml, the reaction required: 
100 ng vector DNA = 7.14 µL 
24.99 ng L6C1 DNA = 3.3 µL 
 H2O = 7.56 µL 
Total reaction volume = 18 µl 
 
Once the reaction mixture was assembled, the reaction was heated to 45°C for 5 
minutes, and then cooled immediately on ice. Once cooled, 2 µL of buffer and 0.5 
µL ligase enzyme was added. The reaction was incubated at 4°C overnight. 
In order to inactivate the ligase enzyme, the reaction mixture was heated to 65 °C for 
10 minutes, and then the sample could be frozen at -20 °C until needed, or used 
immediately. 
 
2.2.5 TA cloning 
 
For three of the nine VHH constructs (L2C1, L7C2 and L7C3), the overnight ligation 
procedure described above resulted in unsuccessful transformations in E. coli, 
therefore a TA cloning® kit (Invitrogen) was used according to the manufacturer’s 
instructions. TA cloning® is a one-step cloning process which does not require the 
restriction digest of PCR products prior to ligation into a suitable vector. When 
carrying out a PCR reaction using Taq polymerase, PCR products would be produced 
that have a single adenosine at the 3'-end (overhangs). These can then be cloned into 
a linearized plasmid vector that possesses a 3'-T overhangs on both ends, resulting in 
complementarity between the PCR product 3'-A overhangs and vector 3'-T 
overhangs (Zhou and Gomez-Sanchez 2000). However in this case the PCR products 
were generated using Platinum® Pfx, resulting in blunt ends that are not suitable for 
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TA cloning. Instead, a single adenosine is added to each of the PCR products as 
‘overhangs’ and then a ligation reaction carried out with a plasmid vector that has ‘T’ 
overhangs. 
Each of the PCR products were treated with Taq polymerase in order to add a 3’-A 
overhang which would complement the 3’-T overhang of plasmid pCR2.1 used in 
TA cloning as per the Invitrogen protocol. Table 15 describes a typical reaction set 
up for a TA cloning ligation. 
 
Table 15. Typical TA cloning ligation reaction set up for L2C1.  
Reagent Amount (µl) 
Milli Q H20 5.24 
10 x Ligation buffer 1 
pCR2.1 vector (25 ng/µl) 2 
PCR product 0.76 
Ligase 1 
  
For TA cloning ligation the insert:vector molar ratio was recommended 1:1 for the 
best efficiency. The reaction was incubated at 14 °C  overnight as per the Invitrogen 
protocol. Ligated plasmids were transformed into DH5α competent E. coli cells 
(using method 2.2.6). Plasmids were then purified from these cells using a miniprep 
kit (method 2.2.7).  The insert was then digested out of the TA vector using BamH1 
and EcoR1 and ligated into pcDNA3.1 using the ligation procedure as detailed in 
section 2.2.4.  
 
2.2.6 pcDNA3.1 transformation into XL-1 blue competent cells 
 
Initially commercially available XL-1 blue competent cells (Stratagene) were used 
for transformation experiments. However, it proved difficult to purify high enough 
DNA levels from either a miniprep or a maxiprep kit (QIAGEN) for transfection into 
mammalian cells so an alternative strain was sought. A strain of DH5α competent 
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cells was obtained from Mark Smales lab (University of Kent) and these were used 
to generate a large batch of competent cells for all transformation experiments. In 
order to prepare a large batch of competent cells, E. coli was grown on antibiotic free 
LB agar plates at 37 °C overnight. A single colony was selected from the plate using 
sterile technique and grown as a starter culture in 2 ml LB media without antibiotics 
in a 15 ml Falcon tube at 37 °C overnight, with shaking at 200 rpm. Sterile cryotubes 
were chilled on ice in preparation for the cells. 40 ml of fresh LB media (no 
antibiotics) was inoculated with 0.5 ml of the starter culture and incubated at 37 °C 
with shaking at 200 rpm. The OD600 was measured in a 1 ml cuvette (Fisher 
Scientific) using LB media as a blank. The OD was expected to be between 0.3-0.5 
when ready and this took approximately 2-3 hours. Once the OD reached the desired 
value, the cells were centrifuged in a sterile 50 ml Falcon tube at 6000 g in a table-
top centriguge for 5 minutes at room temperature.  The supernatant was discarded 
before re-suspending the pellet in 20 ml of sterile 50 mM CaCl2 and storing on ice 
for at least 30 minutes. The cells were centrifuged again at 6000 g for 5 minutes and 
the supernatant discarded. The cells were re-suspended in 4 ml of ice cold 50 mM 
CaCl2 and stored on ice for at least 30 minutes. After this the cells were deemed to be 
competent and ready for transformation experiments. The cells were diluted in LB 
media containing 15 % glycerol for storage at -70 °C. All nine plasmids were 
transformed successfully and propagated in these DH5α cells. 
Prior to transformation, the DH5α cells were thawed on ice and gently mixed before 
aliquoting 100 μl of cells into pre-chilled 15 ml Eppendorf tubes. 25 ng of DNA was 
added (or no DNA for negative control) to the cells and the tubes swirled gently. The 
tubes were incubated on ice for 30 minutes before heat-pulsing the tubes in a 42 °C 
water bath for 45 seconds. The tubes were then incubated on ice for 2 minutes before 
adding 0.9 ml of preheated SOC medium and incubating at 37 °C for 1 hour with 
shaking at 200 rpm. The transformation mixture was spread on to LB agar plates 
using sterile glass beads and grown overnight at 37 °C. 
 
 The host vector pcDNA3.1 carries the gene for Ampicillin resistance so transformed 




2.2.7 Miniprep and restriction digest 
 
Single clones were picked from successfully transformed E.coli cells growing on LB 
agar plates using sterile swabs. Each colony was grown up in a 15 ml Eppendorf tube 
containing 5 ml LB media, for 12 hours at 37 ºC with shaking at 200 rpm. Plasmids 
were then purified using a QIAprep Spin Miniprep Kit according to manufacturer’s 
instructions (QIAGEN). The DNA was digested using BamH1 and EcoR1 (see table 
16 for reaction set up) and run on a 1.5 % agarose gel to check for the presence of the 
Camelid antibody insert. Samples that showed the appropriate band size for the 
Camelid insert when run on a gel (for example. 450 bp for construct 1), were sent off 
for sequencing at either CoGenics or GATC Biotech.  
Table 16. Restriction enzyme digest reaction set up (L2C3 construct). 
Reagent Volume (µl) 
H20 6.8 
Buffer E (see appendix 5.4) 2 
BSA (10 µg/µl) 0.2 
DNA  10 (1 µg) 
BamH1 (10 u/µl) 0.5 




L2C2, L2C3, L6C1-C3 and L7C1 plasmids were sequenced by CoGenics using 
universal primer pairs T7P and BGHR. L2C1, L7C3 and L7C2 plasmids were 
sequenced by GATC Biotech using a T7 primer only as their sequencing process 




All sequencing data was analysed using a website SDSC biology workbench 
http://workbench.sdsc.edu/. Primer pair data was aligned using BL2SEQ which 
compares nucleotides to each other using BLAST. The forward primer and the 
desired construct sequence were aligned using BL2SEQ. All sequence data was 




After confirmation of the correct plasmid sequence, E. coli containing the correct 
VHH plasmid was grown up in 100 ml LB media ready for purification using an 
Endofree Maxiprep kit according to manufacturer’s instructions (QIAGEN).The 
Endofree Maxiprep kit removes endotoxin, which is a component of bacterial cell 
walls, from plasmid DNA preparations. If not removed, these endotoxins can have a 
negative impact on transfection efficiency and cell viability in mammalian cells upon 
transfection of plasmid DNA (Butash, Natarajan et al. 2000).  
Purified DNA stocks were stored at -20 °C and 15 % glycerol stocks of the bacteria 
containing the plasmid with the correct VHH gene sequence were prepared and 
stored at -80 °C for future use. 
 
2.2.10 Plasmid linearization 
 
All VHH plasmids were linearised using restriction enzyme Sca1 according to 
manufacturer’s instructions (Fermentas) prior to transfection into mammalian cells 
(see table 17). It has been demonstrated that transfecting mammalian cells with a 
linearised plasmid as opposed to an intact plasmid can improve levels of protein 
expression (Stuchbury and Münch 2010). 
Sca1 cleaves DNA in the Ampicillin resistance site at nucleotide 4984 of the 
pcDNA3.1 vector which is not needed for mammalian transfection experiments, and 




Table 17. Typical reaction set up for linearising 8µg plasmid DNA: 
Reagent Volume (200 µl reaction) 
DNA 
16 µL (8 µg of L2C1 plasmid at 485 
µg/ml) 
Sca1 enzyme (10 U/µL) 0.8 µL (8 units) 
Buffer H (see appendix 5.4) 20 µL 
Milli Q H2O 163.2 µl 
 
Restriction digests using Sca1 enzyme were incubated at 37 °C for 1 hour.  
The DNA was then purified using a Fermentas PCR purification kit (up to 25 µg 
DNA can be loaded on to each column). To cut 50 µg of plasmid DNA the volumes 
were increased as follows: 10 µl enzyme, 100 µl buffer H and make up to 1 ml with 
H2O. This reaction was incubated for 1 hour at 37 °C (as advised by Fermentas 
technical support).  
 
2.2.11 Full length FVIII plasmid 
 
PcDNA3.1 plasmids containing the full length human FVIII gene were available in-
house from previous work that had been done in the Peter Nicholls lab (University of 
Kent). For this project, these plasmids were transformed into DH5α cells using the 
same method as described in section 2.2.6. The host vector pcDNA3.1 carries the 
gene for Ampicillin resistance so transformed cells were selected in the presence of 
Ampicillin at 100 µg/ml. Selected colonies were grown up in 100 ml LB media ready 
for purification using an Endofree Maxiprep kit according to manufacturer’s 
instructions (QIAGEN) and as described in section 2.2.9. Purified DNA stocks were 
stored at -20 °C and 15 % glycerol stocks of the bacteria containing the plasmid were 




2.3. Protein expression studies in mammalian cells 
 
Mammalian cells were used as a biological factory to express VHH and FVIII 
proteins, initially in separate cell lines. They were also used to co-express FVIII and 
VHH proteins in the same cell line, to assess the effect of co-expression on FVIII 
protein expression levels.  
2 approaches were adopted in order to test the effect of co-expressing VHH with 
FVIII on FVIII expression levels: 
1. Create a cell line stably expressing VHH and transiently transfect in the 
FVIII gene 
2. Use (or create) a cell line stably expressing FVIII and transiently transfect in 
the VHH gene 
A summary of experiments carried out can be seen in table 18. 
Table 18. Summary of mammalian cell lines and their application in the current 
study 
Cell line 
CHO-K1 cell line 
(ECACC) 
BHK BDD-FVIII 
cell line (Pete Lollar) 





Transient transactions to 
produce FL-FVIII (with the 
aim of producing a new stable 
cell line if the transient 
transfection worked) 
N/A 
Transient transfections to 
produce FL-FVIII (with the 
aim of producing a new stable 






Stable cell line 
available at the start 




Transient transfection and 
stable cell line development 
Transient transfection 
to co-express BDD-
FVIII and VHH 
Transient transfection (with 
the aim of producing a new 





Three cell lines were available in-house (University of Kent) for use in this project. 
One of which was a Baby Hamster Kidney cell line (BHK) which stably expressed 
B-domain deleted FVIII (BDD-FVIII) and was kindly provided by John S. (Pete) 
Lollar, III, M.D., Atlanta, USA. The other cell lines available included a Chinese 
Hamster Ovary cell line (CHO-K1) originally obtained from ECACC, and a Human 
Epithelial Kidney (HEK) cell line that was donated by Mike Geeves of the 
University of Kent (originally from ECACC). 
The BHK cell line was originally developed by the Pete Lollar laboratory in the USA 
to stably express B-Domain Deleted FVIII to investigate the effect of removing the B 
domain on the function and expression of the FVIII protein. In this project, this cell 
line was transiently transfected with VHH constructs, and the effect on FVIII protein 
expression analysed. 
The CHO-K1 cell line was used to test if the VHH constructs would be expressed as 
proteins and a number of transfection techniques were utilised in this process. The 
potential of these CHO-K1 cells to develop a stable cell line expressing VHH was 
also investigated, with the aim of using this cell line to transiently transfect FVIII and 
assess the effect of co-expression on FVIII production. The CHO-K1 cells were also 
used to transiently transfect a full length FVIII plasmid with the aim of producing a 
new stable cell line if the transient expression proved successful. A stable full length 
FVIII cell line could then be used to co-express VHH and assess the effect on FVIII 
expression levels. 
The HEK cell line was transiently transfected with a plasmid encoding the full length 
FVIII gene, with the aim of developing a stable full length FVIII cell line that could 
be transiently transfected with the VHH constructs, and then any effect on FVIII 
protein expression analysed. HEK cells were also transiently transfected with VHH 
plasmids since BAC had previously had some limited success with the expression of 
their VHH proteins in this cell line. 
A number of analytical techniques were utilised to investigate expression levels of 
FVIII and VHH in BHK, CHO-K1 and HEK cell lines respectively, at both the 
mRNA and protein level.  
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2.3.1 Cell culture  
2.3.1.1. Reagents and consumables 
Tables 19 and 20 give a summary of all cell culture reagents and consumables used 
in the mammalian cell biology experiments.  
Table 19. Reagents for cell culture 
Item Supplier Code Amount 
CHO-K1 cells ECACC 85051005 1 ml 
DMEM/F-12 Gibco 21331020 500 mls 
Hepes Sigma- Aldrich H3375 100 g 
L-Glutamic acid Sigma-Aldrich G8415 100 g 
Dialysed Foetal Bovine 
Serum 
Invitrogen 26400-044 500 mls 
Penicillin/Streptomycin Invitrogen 15140-122 100 mls 
AIM-V media Invitrogen 12055-083 1 L 
L-Asparagine Sigma-Aldrich A4159 25 g 
Adenosine Sigma-Aldrich A4036 5 g 
Guanosine Sigma-Aldrich G6264 1 g 
Cytidine Sigma-Aldrich C4654 1 g 
Uridine Sigma-Aldrich U3003 5 g 
Thymidine Sigma-Aldrich T1895 1 g 
Phosphate Buffered Saline OXOID BR0014G 100 tablets 
0.25 % Trypsin –EDTA Gibco 25200-056 100 ml 
Genetecin Invitrogen 10131-019 20 ml 
TurboFect™ transfection 
reagent 
Thermo scientific R0531 1 ml 
Lipofectamine® LTX Invitrogen 15338-100 1 ml 







Table 20. Materials and equipment for cell culture. 
Item Supplier 





 and T-175 cm
2
 vented 
tissue culture flasks 
Sarstedt 
Sterile serological pipettes 1 ml, 2 ml, 5 ml, 
10 ml, 25 ml, 50 ml 
Sarstedt 
Sterile pipette tips 1 ml, 200 µl, 20 µl Fisherbrand 
Eppendorf pipettes Sigma-Aldrich 
BioAir Aura 2000 M.A.C. Class II Safety 
Cabinet 
Bioair Instruments, Italy 
Cell culture incubator Panasonic 
Waterbath Thermoscientific 
Gene Pulser Xcell total system Bio-Rad Laboratories 
Gene Pulser cuvettes 0.2 cm gap (50) Bio-Rad Laboratories 
1.5 ml Eppendorf microcentrifuge tubes Sigma-Aldrich 




2.3.1.2 Cell culture growth media  
 
All cell culture media ingredients were combined using sterile pipettes in a Class II 
safety cabinet, then sterile filtered using a vacuum pump and a 0.22 µM Millipore 
express 500 ml funnel/receiver bottle. For composition details see appendix. 
 
2.3.1.3 Resuscitating cells 
 
Mammalian cells were resuscitated from a liquid nitrogen-filled cryostat and thawed 
quickly using a water bath at 37 °C. The thawed cells were diluted in 10 ml media 
warmed to 37 ºC and centrifuged at 150 g. The supernatant was removed in order to 
remove any residual DMSO. The cell pellet was then resuspended in 10 ml media 
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warmed to 37 °C. All cells were then placed into a T-25 flask in an incubator at 37 
°C with 5 % CO2. Cells were left to grow for 2-3 days until confluent and then sub-
cultured into a T-75 flask for future experiments. 
 
2.3.1.4 Sub-culture of mammalian cells 
 
Cells were sub-cultured approximately every 48 hours, once cells reached 
approximately 90 % confluency. The correct seeding cell density and timings for 
sub-culture of cells was defined for each cell line to ensure consistency across 
experiments. For each cell line, cells were seeded at a variety of densities to find the 
optimal growth conditions for future experiments. For example in table 21, a cell 
density experiment was conducted with BHK-FVIII cells. Cells seeded at 1.5 x 10
6
 in 
a T75 cell culture flask reached approximately 90 % confluency within 48 hours, at 
which point the media was changed from DMEM/F12 to serum free AIM-V. The 
concentration selected meant that each co-expression study could be conducted 
within the space of 3 days which is a practical amount of time for managing 
laboratory work that requires multiple repetitions. It also meant that cells were left 
too long in the same media as this may lead to nutrient depletion and a decrease iin 
viability of the cells. Cell media was sampled later for use in the coagulation 
experiments that measured FVIII activity. Although subjective, this approach of 
changing the cell media when the cells were at 90 % confluency ensured a consistent 
approach and approximately the same number of cells in the flask every time the 
AIM-V media was added. 
 
To sub-culture cells, all cell media was removed from the flask before washing cells 
with sterile PBS warmed to 37 °C. Sterile PBS was removed before addition of 2 ml 
of trypsin (room temperature). Cells were incubated for 2-3 minutes at 37 °C. 10 mls 
cell culture media was added to the cells in order to neutralise the trypsin. Using a 
sterile pipette, cells were resuspended in order to break up any cells that had clumped 
together. Between 0.5 ml to 1 ml of counted cells were transferred into a new T-75 
cell culture flask containing 20 mls of cell media and placed in an incubator at 37 °C 




Table 21. Cell density experiment (BHK-FVIII cells) 
Day 1 cell 
density: 
Confluency (%)  
at Day 2 (+ 24 
hrs) 
Confluency (%) 
at Day 3 (+ 48 
hrs) 
Confluency (%) 
at Day 4 (+ 72 
hrs) 
Confluency (%) 




 <10 % 20 % 30 % 60 % 
5x10
5
 10-20 % 50 % 90 % (switch 




 20-30 % 60 % 90 % (switch 




 60-70 % 90 % (switch to 
AIM-V) 




 70-80 % Not viable (cells 
clumped) 
Not viable (cells 
clumped) 




2.3.2 Transient transfections  
 
Transient transfection was used as a method of introducing either VHH or FVIII 
genes into a mammalian cell line.  
VHH: plasmids encoding the VHH constructs were initially carried out in CHO-K1 
cells to see if the VHH proteins would be expressed. Later on in the project, VHH 
constructs were transiently transfected into the BHK cell line that was stably 
expressing B domain deleted FVIII, and the effect on FVIII expression analysed. VH 
proteins were also transiently transfected into HEK cells. 
FVIII: The full length FVIII gene was transiently transfected into either CHO-K1 or 
HEK cells to see if the full length protein could be produced and function in a gold 
standard coagulation assay (described in 2.4) If the transient transfection worked 
then the aim was to produce a stable cell line which could then be transfected with 
VHH and the effect on FVIII expression levels analysed.  
Two different methods were tested and optimised for transfection experiments; either 
chemical transfection or electroporation.  
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For all transfection experiments, a mock transfection was carried out (cells plus 
transfection reagents, no DNA), as well as a control transfection (plasmid containing 
no gene of interest), to make sure that any effects on protein expression were due to 
the gene of interest and not the transfection reagents. 
2.3.2.1 Transfection using electroporation (CHO-K1 example) 
 
This procedure required a Gene Pulser Xcell main unit and CE Module. Firstly, 
electro-competent cells were prepared as follows for the CHO-K1 cells: 
Cells were seeded into a T-75 flask ready for transfection after 2 days (70 % 
confluent).  After 2 days the growth media was removed from the flask and cells 
were washed using 5 ml of phosphate buffered saline (PBS) pre-warmed to 37 ºC. 
The PBS was removed and 2 ml of trypsin was added before incubating the cells 2–3 
minutes at 37 °C. The flask was then tapped gently to detach the cells from the 
surface. The trypsin was neutralised by adding 10 ml of growth media. 
Cells were then counted manually using a haemocytometer, and resuspended in 
electroporation buffer (PBS).  The cells were transferred to a 50 ml sterile centrifuge 
tube and centrifuged at 400 x g for 5–7 minutes at room temperature. The 
supernatant was discarded and then the cell pellet resuspended in PBS at a density of  
5 x 10
6
 cells/ml. The cells were gently pipetted to obtain a single-cell suspension. 
The pulse conditions were predefined according to the cell line, by the manufacturer. 
For CHO-K1, (square wave protocol), Voltage 160, and Pulse length 15 ms were 
used.  
CHO-K1 cells and VHH plasmid DNA (4 µg plasmid DNA per cuvette) were pre-
mixed before adding to the cuvette and electroporating as per the Bio-Rad 
protocol. Each electroporation cuvette (0.2 cm gap) contained 5 x 10
6 
cells in 1 ml 
electroporation buffer (PBS). 
Once the cells had been electroporated, the cells were transferred to a 6 well plate 
using 0.5 ml of media and a plugged pasture pipette. Each cuvette full of cells was 
added to 1 well of 6 well plate containing 2 ml full growth media.  The plates were 
rocked gently to assure even distribution of the cells over the surface of the plate, and 
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then incubated at 37 °C and 5 % CO2. VHH gene expression was analysed 48 hrs 
following electroporation in at least one of the following ways: 
(i) cells were viewed on a Leica MZFL III microscope under GFP2 filter to detect 
fluorescence level (for GFP transfected cells) 
(ii) the cell media was collected for protein expression analysis in a dot blot or 
western blot  
(iii) the cells were lysed for further analysis in a dot blot or western blot  
 
2.3.2.2 Transfection using chemical methods (CHO-K1 example) 
 
Four different reagents were tested to assess the optimal method for transfecting 
mammalian cells; TurboFect™ (Fermentas), Lipofectamine® LTX (Invitrogen), 
FuGENE®  and PEI.  
 
Initial experiments were carried out using a plasmid encoding for green fluorescent 
protein to determine the optimal reagent for transfecting CHO-K1 cells. The two best 
performing reagents were TurboFect™ and Lipofectamine® LTX. TurboFect™ is a 
cationic polymer which forms a stable complex with DNA, protecting the DNA from 
degradation and facilitating gene delivery into eukaryotic cells by endocytosis. 
Lipofectamine® LTX is a cationic lipid-based plasmid transfection reagent that 
according to the manufacturer provides the highest level of transfection efficiency in 
primary cells of any lipid- or polymer-based reagent. In lipid based transfection, a 
positively charged liposome (phospholipid bilayer) forms a complex with negatively 
charged DNA, which then binds to the cell membrane. The mechanism by which the 
DNA enters the cell has been investigated extensively and has shown that the 
cationic/DNA complex enters the cell by endocytosis. This causes the endosomal 
membrane to destabilise and this in turn induces movement of anionic lipids from the 
cytoplasmic-facing monolayer into the complex forming a charge neutral ion pair 
with the cationic lipids, displacing the DNA from the complex and releasing it into 






Cells were seeded into a 6 well plate at a concentration of 2.4 x 10
5
 cells/well with 4 
mls growth media at 37 °C and 5 % CO2 to ensure 90-95 % confluency within 24 
hours. After 24 hours cells were transfected with the test DNA. 
Transfections were carried out in Optimem media which is a serum free media from 
Invitrogen. This was pre-warmed in a 37 °C water bath. 
Plasmid DNA-TurboFect™ complex solutions were prepared in sterile 2 ml 
Eppendorf tubes as follows: 
Per well of a 6 well plate: 4 µg DNA + 400 µL Optimem + 6 µL TurboFect™.  
Stock DNA concentration is 100 µg/ml, final concentration 10 µg/ml. 
The DNA/TurboFect™ complex was incubated for 20 minutes at room temperature. 
Meanwhile the cells previously plated in 6 well plates were washed with 2 mL PBS 
(pre-warmed to 37 °C) and then 4 mL of fresh growth media (without antibiotics) 
was added to each well, before adding the DNA/TurboFect™ complex dropwise and 
swirling the plates gently. The plates were incubated at 37 °C in 5 % CO2 for 48 
hours prior before detecting protein expression. 
 
(ii) Lipofectamine® LTX 
 
Cells were seeded into a 6-well plate at a concentration of 2 x 10
5 
cells/well in 2 ml 
complete cell media ready for plasmid transfection into the cells 24 hours later.  
Per well of a 6 well plate: 4 µg (40 µl) DNA was mixed with 210 µL fresh cell media 
in a sterile 2 ml Eppendorf tube. 10 µl Lipofectamine® was mixed with 240 µl fresh 
cell media in a separate sterile 2 ml Eppendorf tube. Both of these mixtures were 
incubated for 5 minutes at room temperature before combining the two together and 
mixing gently. This was incubated for a further 20 minutes at room temperature, and 
then added to cells drop wise followed by gently rocking the plate. The plate was 







(iii) FuGENE®  
 
Cells were seeded into a 6-well plate at a concentration of 2 x 10
5 
cells/well in 2 ml 
complete cell media  ready for plasmid transfection into the cells 24 hours later. Per 
well of a 6 well plate: FuGENE®  was mixed directly with plasmid DNA in various 
ratios according to manufacturer’s instructions (see table 16). The mixture was 
vortexed immediately before incubating at room temperature for 15 minutes. Again 
the mixture was vortexed briefly before adding the complex directly to the cells. The 
cells were then placed into a 37 ºC incubator, and then checked for GFP expression 
48 hours later by viewing on a MZRFL III microscope under GFP2 filter to detect 
fluorescence level. 
Table 22. Optimisation of transfection using FuGENE®  
Well number 1 2 3 4 5 6 
Ratio of FuGENE®  to 
DNA 
4:1 3.5:1 3:1 2.5:1 2:1 1.5:1 
Serum free media (µL) 155 155 155 157 158 160 
GFP plasmid DNA total 
3 µg (µL) 
33 33 33 33 33 33 
Volume of FuGENE®  
reagent (µL) 




Cells were seeded into a 6-well plate at a concentration of 2 x 10
5 
cells per well in 2 
ml complete cell media  ready for plasmid transfection into the cells 24 hours later. 
Per well of a 6 well plate:  2 Eppendorf tubes were made up, 1 containing 30 µl DNA 
(3 µg) and 70 µl NaCl (supplied with PEI kit), and the other tube containing 6 µl of 
PEI (PolyPlus) and 96 µl NaCl. The two solutions were then mixed, vortexed and 
centrifuged briefly, before incubating for 15-30 minutes at room temperature. The 
mixture was then added drop wise to cells before gently swirling the plate, then 
incubating at 37 ºC. GFP expression was checked 48 hours later by viewing cells on 




Transient transfections were also carried out in HEK cells with a plasmid encoding 
full length FVIII, with the aim of creating a stable full length FVIII cell line that 
could later be transiently transfected with VHH.  
Lipofectamine® LTX (Invitrogen) was used in these experiments as described 
below: 
Cells were seeded into a 6-well plate, at a concentration of 2 x 10
5 
cells/well in 2 ml 
complete cell media ready for transfection 24 hours later.  
 
Per well of a 6 well plate: 4 µg (40 µl) DNA was mixed with 210 µL fresh cell media 
in a sterile 2 ml Eppendorf tube. 10 µl Lipofectamine® was mixed with 240 µl fresh 
cell media in a separate sterile 2 ml Eppendorf tube. Both of these mixtures were 
incubated for 5 minutes at room temperature before combining the two together and 
mixing gently. This was incubated for a further 20 minutes at room temperature, and 
then added to cells drop wise followed by gently rocking the plate. The plate was 
incubated at 37 °C in 5 % CO2 and after 48 hours, the cell media was removed and 
tested in a coagulation assay (as described in section 2.4). 
 
2.3.3 Stable cell line development 
 
Since expression of VHH protein was seen in CHO-K1 cells (albeit at very low 
levels), this cell line seemed a good choice to go on and try to develop stable cell 
lines expressing each of the nine VHH plasmids. Although the literature 
predominantly reports VHH expression in microorganisms such as yeast and 
bacteria, there are limited examples of their expression in mammalian cell lines. 
However there are many examples of other antibodies produced in CHO cells so this 
seemed a logical choice.   
The aim was to produce a stable VHH cell line that could then be used for further 
experiments to: 
1. Transiently transfect a FVIII plasmid and then test the effect of co-expression 
of FVIII with VHH 
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2. Develop a cell line stably expressing both VHH and FVIII at optimal levels 
for maximising FVIII production which would have therapeutic and therefore 
commercial value 
 
CHO-K1 cells were transfected using Lipofectamine® as described in methods 
section 2.3.2. All plasmids were linearised prior to transfection experiments. 24 
hours after transfecting the cells, the cell media was changed to media containing 
400 µg/ml genetecin (G418) to select for those cells which had taken up the VHH 
plasmid which contained a neomycin resistance gene (see appendix 3 for plasmid 
diagram). Control cells (untransfected) were also treated with genetecin. A range of 
genetecin concentrations were tested (200 µg / ml to 800 µg / ml) in both transfected 
and untransfected cells to see if the concentration used (400 µg / ml) was cytotoxic. 
After 24 hours the media was changed to fresh media containing genetecin and after 
another 2 days the cells were reseeded into a new T-75 flask. This procedure of 
changing the media every 2 days and then reseeding the cells every 2 days was 
repeated until all of the control (un-transfected) cells were completely eliminated.  
Once all the control cells were eliminated, a single cell cloning/limited dilution 
protocol was followed. Sub-cultured transfected cells were then counted and the cell 
density adjusted to 1 x 10
4 
cells / ml by adding the appropriate volume of cell media. 
The cells were then diluted into three separate concentrations that contained an 
average of 0.5, 3 and 10 cells per 100 µL respectively. 96 well plates were then 
seeded with 100 µl cells per well. The plates were left for 1-2 hours before 
examining each well for those that had only a single cell per well (hence the term 
single cell cloning). Wells containing only a single cell were observed for several 
days to see if they started to proliferate. Those wells where colonies formed were 
sub-cultured and bulked into 24 well plates initially, and then when the cells were 
growing sufficiently, they were transferred to 6 well plates, then subsequently T25 






2.3.4. Co-expression of VHH and FVIII in BHK cells using Lipofectamine® 
LTX 
 
Conditions for transient transfection of VHH plasmids into BHK cells were firstly 
optimised using Lipofectamine® LTX and a plasmid coding for expression of green 
fluorescent protein (GFP). A 6 well plate was seeded with 2 x 10
5 
cells per well. 
After 24 hours growth, cells were transfected with a pcDNA3.1 plasmid containing 
the gene for green fluorescent protein (GFP) using Lipofectamine® LTX in 2.5ml of 
AIM-V (serum free) media. Varying concentrations of Lipofectamine® and PLUS 
reagent were investigated to determine the optimal concentration for the highest 
transfection efficiency, as shown in table 23. Transfection efficiency was determined 
by viewing the cells under a MZRFL III microscope using a GFP2 filter to detect 
fluorescence levels. The percentage of cells expressing GFP was assessed by eye and 
the cells showing the highest percentage of fluorescing cells were deemed to have 
been transfected with the optimal Lipofectamine® and PLUS reagent concentrations. 
These were subsequently the concentrations used in all further transient transfection 
experiments in BHK cells. 
 
Table 23. Optimisation of transfection conditions using Lipofectamine® LTX 
and GFP plasmid 
Well of 6 well plate DNA 
(µg) 
Lipofectamine® LTX (µl) PLUS reagent (µl) 
1 4 7.5 0.5 
2 4 10 2.5 
3 4 12.5 5 
4 4 15 7.5 
5 4 20 8 




For transfection of BHK cells using VHH plasmids, the media was changed to AIM-
V (serum free) prior to the transfection to remove serum proteins that may affect the 
outcome of the coagulation assay to be run later. For every experiment there was a 
‘control’ well which received no transfection reagents or DNA and was treated as the 
negative control for VHH expression and the baseline FVIII expression for 
coagulation assays. 
Each well of a 6 well plate was treated as an independent transfection i.e. one 
transfection mixture was prepared per well. Each well contained 2 mls AIM-V media 
prior to transfection. The transfection mix contained 500 µl AIM-V media, 4 µg 
DNA, 0.5 µl PLUS reagent and this was incubated at room temperature for 5 minutes 
before adding 7.5 µl LTX reagent. This was incubated for 20 minutes at room 
temperature before adding the whole mixture drop wise to cells. The plates were 
gently rocked before incubating at 37 °C and 5 % CO2 for 48 hours before analysis 
of protein expression and coagulation assays. 
2.3.5 mRNA analysis of VHH gene expression by Reverse Transcriptase-PCR 
(RT-PCR) 
 
BHK cells were analysed for the presence or absence of beta-actin mRNA (control 
housekeeping gene) and VHH mRNA after transfection with pcDNA3.1 plasmids 
containing the VHH gene. Cells were transfected as described in method section 
2.3.4. Cells from one well of a 6 well plate were harvested using trypsin either 24 or 
48 hours after transfection. Cells were centrifuged briefly to form a pellet before 
removing the supernantant and homogenising the cells using a QIAshredder 
(QIAGEN) and extracting the RNA using an RNeasy mini kit (QIAGEN). 
RNA was quantified using a spectrophotometer and the quality of the RNA checked 
using the ratio of the absorbance at 260 nm and 280 nm (A260/280). For pure RNA the 
A260/280 is around 2. The RNA sample was then treated for the removal of genomic 
DNA using a TURBO DNase kit (Invitrogen). DNase was then removed from the 
RNA sample using an RNeasy mini kit (QIAGEN). RNA was then reverse 
transcribed into cDNA using a First Strand cDNA synthesis kit (Novagen). 1 µL of 
cDNA for each original RNA sample was taken through to PCR experiments in order 
to amplify either the VHH or beta-actin gene. 
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PCR experiments were carried out as described in method section 2.2.2. PCR primers 
for detection of VHH genes were designed as described in method section 2.2.1. 
Primers for the detection of the hamster beta-actin housekeeping gene were 
reproduced from Ley  et al (Ley, Balmanno et al. 2003). 
Beta-actin forward primer: 5’ -CCGGATGCAGAAGGAGATCA-3’ 
Beta-actin Reverse primer: 5’ -GCCACCGATCCACACAGAGTA-3’ 
PCR products were run on a 1 % agarose / TAE gel to assess the size of the DNA 
band and that it corresponded with the expected sizes of the VHH gene constructs 
and the beta-actin gene fragment (approximately 100 bp).   
 
2.3.6 Protein expression analysis  
 
In order to determine that the VHH ligands were being expressed by the cells, dot 
blotting and western blotting experiments were carried out. FVIII protein expression 
was also investigated in a similar manner. 
2.3.6.1 Treatment of cells prior to western blotting/dot blotting 
 
48 hours after all transient transfections, both cell supernatant and lysed cells were 
assessed for VHH expression in western blotting. Cell supernatant was collected in 
50 ml Falcon tubes. Cells were harvested as described in methods section 2.3.4 and 
resuspended in serum free media (AIM-V). Cells were centrifuged for 5 minutes at 
400 g. The cell pellet was resuspended in 0.5 ml lysis buffer (see composition in 
table 24) and used straight away or the sample was frozen at -20 °C until western 
blot. 
Alternatively cells were lysed whilst still adhered to the plate by adding 200 µl cold 
lysis buffer (containing protease inhibitors) to each well. The plate was left on ice for 
1-2 minutes with occasional rocking before using a cell scraper to loosen all of the 
cells. These were then collected and samples frozen at -20 °C prior to western 




Table 24. Lysis buffer composition  
Reagent Amount (to make 50 ml) 
200 mM Hepes pH7.2 0.24 g 
100 mM NaCl 0.294 g 
1 % Triton X-100 500 µL 
EDTA-free Protease inhibitor tablet (add at time of 
use) 
1 tablet per 10 ml buffer 
 
The lysis buffer composition was taken from Smales et al. Biochem Biophys Res 
Com 306 (2003) 1050-1055. 
  
Prior to western blotting, samples were syringed through a 19 gauge needle to break 
up nucleic acids then centrifuged at 3000 x g for 10 minutes. The cell pellet was 
discarded and the supernatant used in the western blot. 
2.3.6.2 Western blotting protocol  
SDS-Polyacrylamide Gel electrophoresis (PAGE) 
 
Electrophoresis experiments were conducted under either denaturing or non-
denaturing (native) conditions. 
For denaturing electrophoresis, pre-cast NuPAGE® Bis-Tris Mini Gels (Life 
Technologies) were used according to manufacturer’s instructions. To prepare 500 
ml of 20X NuPAGE® MES SDS Running Buffer, reagents were dissolved in 
ultrapure water as shown in table 25. The buffer was stored at 4 °C to ensure its 
stability for 6 months. For use in electrophoresis experiments, the buffer was diluted 







Table 25. NuPAGE® MES SDS running buffer composition  
Reagent Concentration Amount (500 ml 20 x). 
MES 50 mM 97.6 g 
Tris base 50 mM 60.6 g 
SDS 0.1 % 10 g 
EDTA 1 mM 3 g 
Ultrapure water n/a Up to 500 ml 
 
20 µL samples were made containing 5 µl LDS loading buffer (NuPAGE) and 15 µl 
of lysed cell or cell supernatant (cell media). These samples were heated at 70 °C for 
10 minutes before loading on to a NuPAGE Bis-Tris gel (1 mm containing 10 wells). 
Lane 1 of each gel always contained a protein size marker such as BIORAD 
kaleidoscope marker and 10 µl of this was loaded. 
XCell SureLock™ Mini-Cells were used for the electrophoresis which required 200 
ml running buffer for the Upper (inner) Buffer Chamber and 600 ml running buffer 
for the Lower (outer) Buffer Chamber. Conditions for electrophoresis were 200 V for 
35 minutes.  
For non-denaturing (native) electrophoresis, pre-cast NuPAGE® Tris-Acetate 
Mini Gels (Life Technologies) were used according to manufacturer’s instructions. 
Native electrophoresis also required a different running buffer (Tris-Glycine Native 
running buffer) which was made up to a 10 x solution and diluted in water to 1 x for 








Table 26. NuPAGE® Tris-Glycine Native Running Buffer composition (pH 8.3) 
Reagent Concentration Amount (1 L 10 x). 
Tris base 25 mM 98 g 
Glycine 192 mM 144 g 
Ultrapure water n/a Up to 1 L 
 
20 µL samples were made containing 5 µl Tris-Glycine Native Sample Buffer 
(NuPAGE) and 15 µl of lysed cell or cell supernatant (cell media). These samples 
were NOT heated before loading on to a NuPAGE Tris-Acetate Mini Gel (1mm 
containing 10 wells). Lane 1 of each gel always contained a protein size marker such 
as BIORAD kaleidoscope marker and 10 µl of this was loaded. 
XCell SureLock™ Mini-Cells were used for the electrophoresis which required 200 
ml running buffer for the Upper (inner) Buffer Chamber and 600 ml running buffer 
for the Lower (outer) Buffer Chamber. Conditions for electrophoresis were 150 V for 
2 hours.  
 
Transfer of proteins to PVDF membrane 
 
After the electrophoresis was complete, proteins were transferred to PVDF 
membrane using a BIORAD Trans-blot SD Semi-Dry Electrophoretic Transfer Cell. 









Table 27. Towbin transfer buffer composition 
Reagent Concentration Amount (for 1 L) 
Tris 25 mM 3.03 g 
Glycine 192 mM 14.4 g 
Methanol 20 %* 200 ml 
Distilled water n/a Up to 1 L 
*For native proteins, methanol concentration in Towbin buffer was reduced to 10%. 
Following electrophoresis, gels were equilibrated for 30 minutes in transfer buffer. 
PVDF membrane (Invitrogen LC2002) and blotting paper (Bio-Rad 170-3969) was 
cut to the same dimensions of the gel and soaked in transfer buffer. The sandwich 
was assembled according to manufacturer’s (BIORAD) instructions for semi-dry 
transfer. Proteins were transferred for 20 minutes at 20 V.  
All gels were stained (post protein transfer) with Coomassie Blue, and the PVDF 
membranes stained with Ponceau S to detect if proteins had transferred from the gel. 
 
 Immunoprobing of Western Blotted proteins 
  
Once proteins had been transferred from the gel to the PVDF membrane, the PVDF 
membrane was placed in approximately 30 ml of blocking buffer (see appendix 6) 
for 1 hour at room temperature or overnight at 4 ˚C in order to minimize the amount 
of non-specific binding. 
The blocking buffer was removed from the PVDF membrane before the addition of a 
primary antibody diluted in 10 ml fresh blocking buffer. This was incubated at room 
temperature for 1 hour with gentle shaking.  
After 1 hour the primary antibody was removed and the PVDF membrane washed 3 
times, 10 minutes each time with approximately 30 ml wash buffer at room 
temperature with gentle shaking. 
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If a secondary antibody was not necessary, i.e. if a HRP conjugated primary antibody 
was used then the antigen detection method could be used immediately. In this 
instance, 5-10 ml Pierce Supersignal West Pico Chemiluminescent substrate 
(Thermo scientific 34080) was used to detect antigen according to manufacturer’s 
instructions.   
If a secondary antibody was used, the membrane was incubated with 10 ml of   
antibody diluted in blocking buffer. This was incubated for 1 hour at room 
temperature with gentle shaking.  
After 1 hour the secondary antibody was removed and the PVDF membrane washed 
3 times, 10 minutes each time with approximately 30 ml wash buffer at room 
temperature with gentle shaking, and followed by a brief wash with 10 ml PBS. After 
this the antigen was detected by covering the membrane with 5-10 ml Supersignal 
West Pico Chemiluminescent substrate for 5 minutes at room temperature (for HRP 
conjugated antibodies). 
Excess substrate solution was poured away and the membrane covered with cling 
film or a piece of plastic pocket and placed in a film cassette. Any excess solution 
was removed and air bubbles expelled by wiping over the cling film or plastic with a 
piece of tissue. In a dark room the membrane was exposed to ECL Hyperfilm and the 
image developed using a hyper-processor. Films were exposed for various times until 
a good image was obtained. 
All antibodies (and their sources) used for anti-VHH and anti-FVIII western blotting 
are shown in table 28. 
All antibodies were used at a dilution of 1:2000 and were diluted in 2 % BSA in 0.05 
% Tween-20 in PBS. 
Detection of AP conjugated antibodies was done using AP colour development 
reagents from BIORAD, BCIP and NBT (170-6539 BCIP (5-bromo-4-chloro-3-
indolyl phosphate and 170-6532 NBT (Nitroblue Tetrazolium)) and used according 




Table 28.  Antibodies used in western blotting, dot blotting and ELISA 
experiments 
Antibody Supplier Code 
Rabbit polyclonal anti-VHH antibody BAC 
Not available 
commercially 
Anti-rabbit IgG (Fc) AP conjugate Promega 5373B 
Goat anti-VHH (biotinylated) BAC 
Not available 
commercially 
Sheep polyclonal anti-human FVIII Abcam ab20946-1 











Goat anti-rabbit HRP (GARPO) Dako P044801-2 
Swine anti-rabbit peroxidise 
(SWARPO) 
Dako P0217 
Streptavidin HRP Dako P0397 










2.3.7 Immunoprecipation of VHH proteins 
 
Immunoprecipitation (IP) is the technique of precipitating a protein antigen out of 
solution using an antibody that specifically binds to that particular protein. The 






Figure 2.2. Immunoprecipitation using sepharose beads coated with protein A 
Immunoprecipitation was used to increase the concentration of VHH protein in the 
cell supernatant of cells transfected with VHH plasmid. This was carried out prior to 
western blotting, in order to increase the likelihood of detecting these proteins at low 
expression levels. One sample from each transfection of ligand 2, 6 and 7 constructs 
was tested, (a total of 9 samples) plus one sample from untransfected cells as a 
negative control. Two positive control samples were tested; VHH ligand 2 and VHH 
ligand 7, both diluted in 1 x PBS. 
For each sample to be tested the following mixture was made: 
 150 µl supernatant 
 450 µl buffer (0.1 % BSA, 0.05 % Tween-20 in 1 x PBS)  
 4 µl of rabbit anti-VHH antibody (BAC in–house reagent, not available 
commercially)  
Each sample was incubated overnight at 4 °C on a rotating wheel, which allowed any 
VHH protein present in the test samples to bind to the rabbit anti-VHH antibody.  
After the overnight incubation, Protein A Sepharose beads were used to capture all of 
the anti-VHH in the sample. Prior to use the sepharose beads were washed in 20 % 





Antibody (rabbit anti-VHH) 
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2.5 µg sepharose beads were diluted in 50 µl of 0.05 % Tween-20/1 x PBS. This was 
added to each sample before placing on a rotating wheel at 4 °C for 1 hour.  
After incubating for 1 hour, each sample was centrifuged at 500 x g for 1 minute. 
The supernatant was discarded and the pellet resuspended in 800 µl 0.05 % Tween-
20 in 1 x PBS in order to wash the beads. The centrifugation and washing step was 
repeated three times with the third wash step using 500 µl 1 x PBS. After washing 
the beads, each sample was centrifuged and the supernatant removed. The pellet was 
air-dried in a bench top heater in order to remove excess PBS. When the pellet was 
almost dry the pellet was resuspended in 45 µl SDS-PAGE sample buffer (50 nM, 
diluted in H2O). 10 µl of each sample was run on a Tris-glycine SDS-PAGE gel, 140 
V for 1 hour.  
3 SDS-PAGE gels were run in total, 1 to be used for anti-VHH western blot, 1 to be 
used for anti-FVIII western blot, and 1 for SYPRO® staining (section 2.5.5).  
Transfer of proteins to PVDF membrane was carried out at 35 V for 90 minutes. The 
PVDF membrane was blocked overnight in 4 % protifar (milk protein powder) in 1 x 
PBS at 4 °C before immunoprobing the membrane for either VHH or FVIII. 
 
2.3.8 Dot blotting 
 
Dot blotting was used as a crude experiment to check for protein expression in 
mammalian cells. 100 µl samples (either harvested and lysed cells, or spent cell 
media) were applied to methanol-activated PVDF membrane via a 96 well manifold. 
A vacuum pump was applied in order to allow the samples to enter the membrane. 
After this the PVDF membrane was left to air dry before Immunoprobing as 
described in 2.3.6.2 using anti-FVIII, anti-VHH or anti-His antibodies to check for 
VHH or FVIII expression in cell media after transient transfections and during the 





2.3.9 SYPRO® Ruby Protein PAGE Gel Stain 
 
SYPRO® Ruby Protein PAGE Gel stain (Molecular Probes, Invitrogen) is a 
sensitive fluorescent stain that can detect proteins separated by SDS-PAGE. It has 
the same low nanogram sensitivity as silver staining but detects more proteins over a 
broader size range, making it ideal for detection of proteins which are expressed at 
low levels (Lopez, Berggren et al. 2000). 
The basic protocol for SYPRO® staining involved 3 steps; fixing, staining and 
washing.  
Firstly the fixing and washing solutions were prepared as follows: 
Fix Solution:  50 % methanol, 7 % acetic acid. 200 mL fix solution was prepared per 
mini gel. 
Wash Solution:  10 % methanol, 7 % acetic acid. 100 mL wash solution was 
prepared per mini gel. 
 
After electrophoresis, the gel was placed into a clean container with 100 mL of fix 
solution and agitated on an orbital shaker for 30 minutes. This was repeated once 
more with fresh fix solution. After removing the fixing solution, 60 mL of SYPRO® 
Ruby gel stain was added. This was agitated on an orbital shaker overnight at room 
temperature and the gel covered with foil to exclude light. The next step was to wash 
the stain away. The gel was transferred to a clean container and washed in100 ml of 
wash solution for 30 minutes with gentle agitation at room temperature. 
The transfer of the gel to a clean container and the washing step helped to minimize 
background staining irregularities and stain speckles on the gel. Before imaging the 
gel, it was rinsed in ultrapure water a minimum of two times for 5 minutes to prevent 
possible corrosive damage to the imager. The gel was covered to exclude light in 
each of these steps. SYPRO® Ruby protein gel stain has two excitation maxima, one 
at ~280 nm and one at ~450 nm, and has an emission maximum near 610 nm. 
Proteins stained with the dye were visualized using a UV transilluminator and the 




2.3.10 Nickel column purification of histidine-tagged proteins 
 
Since some of the VHH constructs encoded a histidine tag in their gene sequence, it 
was deduced that these proteins could be purified using a nickel column in order to 
increase the protein concentration of samples and enhance the likelihood of detecting 
these proteins in dot blotting and/or western blotting.  
The GE Healthcare HisTrap HP system was used according to the manufacturers 
instructions (protocol 71-5027-68 AF, 1ml column). The HisTrap HP system is an 
immobilized metal affinity chromatography (IMAC) system, which in this case relies 
on the bonds formed between histidine amino acids and immobilised nickel ions. 
This technique is designed for one-step purification of histidine-tagged proteins 
using columns that are pre-packed with Ni Sepharose, which has high binding 
capacity, and does not biological activity of the target antigen.  Peptides containing 
sequences of consecutive histidine residues are efficiently retained on the Ni 
Sepharose column, and can be eluted by either adding imidazole to the column buffer 
or adjusting the pH of the column buffer (Porath, 1992). 
In the present study, several buffers were prepared (see appendix) including a 
binding buffer and elution buffer at a variety of imidazole concentrations. The 
binding buffer was used to equilibrate the column and the elution buffer was tested at 
a variety of concentrations to ensure that the VHH protein was eluted.  
Prior to loading the sample on to the column, samples were passed through a 0.45 
µM filter to remove large host cell proteins that may have contaminated the 
procedure.  
When eluting proteins a range of imidazole concentrations was tested in order to find 
the optimal concentration for eluting VHH. 10 mls of elution buffer was run through 
the column at each concentration, and 1ml samples were collected.  





2.3.11. Enzyme Linked Immuno‐Sorbent Assay (ELISA) 
 
Several ELISA formats were investigated for the detection of VHH or FVIII protein 
in the cell culture media of transfected or untransfected cells. The aims for each 
experiment were different depending on the protein being detected. Ultimately these 
were the main goals 
1. The FVIII ELISAs were developed in order to detect any increase or decrease 
in protein levels (quantitative) between cells transfected with VHH constructs 
and untransfected cells. 
2. The VHH ELISAs were developed in order to detect the presence or absence 
of protein (qualitative), to give an indication whether the proteins were being 
expressed or not in transfected cell lines. 
3. Detection of ‘VHH:FVIII complex’ in BHK FVIII cell line transfected with 
VHH (qualitative) to see if the VHH was bound to FVIII 
Typical assay format (per 96 well plate) as shown below: 
 1 2 3 4 5 6 7 8 9 10 11 12 
A BHK L2C1 L2C2 L2C3 L6C1 L6C2 L6C3 L7C1 L7C2 L7C3   
B BHK L2C1 L2C2 L2C3 L6C1 L6C2 L6C3 L7C1 L7C2 L7C3   
C BHK L2C1 L2C2 L2C3 L6C1 L6C2 L6C3 L7C1 L7C2 L7C3   
D BHK L2C1 L2C2 L2C3 L6C1 L6C2 L6C3 L7C1 L7C2 L7C3   
E BHK L2C1 L2C2 L2C3 L6C1 L6C2 L6C3 L7C1 L7C2 L7C3   
F BHK L2C1 L2C2 L2C3 L6C1 L6C2 L6C3 L7C1 L7C2 L7C3   
G Std Std Std Std Std Std Std Std Std    
H Std Std Std Std Std Std Std Std Std    
Std = Standard; BHK = Baby Hamster Kidney cell media (untransfected cells); 
L2C1, L2C2, L2C3, L6C1, L6C2, L6C3, L7C1, L7C2, L7C3 = Test samples (cell 
media or lysate from BHK cells transfected with VHH plasmid). 
 
The development of these assays was restricted by the limited selection and 
specificity of both anti-VHH and anti-FVIII antibodies currently available. At the 
time of the experiments, no antibodies (primary, conjugated) were available for the 
direct detection of either VHH or FVIII and therefore a direct ELISA was not 
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possible. Therefore all ELISAs investigated were designed for an indirect detection 
of protein.  
All antibodies used in the detection of either VHH or FVIII are listed in table 28 and 
all buffers used in ELISA are listed in appendix 8. 
2.3.11.1 ELISA protocol 
 
Most of the ELISA tested followed the protocol as described below. Some of the 
ELISA formats deviated from the standard protocol to accommodate different assay 
formats and this will be described later. 
The first step in the ELISA protocol is to coat a 96 well microtiter plate. 100 µl of 
antigen (antibody or cell supernatant) was added to each well and incubated for 1 
hour at room temperature with gentle shaking. The antigen was then washed from the 
plate 5 times using wash buffer. The plate was blocked by adding 200 µl of 2% 
blocking buffer and incubating for 1 hour at room temperature with gentle shaking. 
Samples and controls (or antibody depending on format of assay) were then added to 
the plate in the desired wells. 100 µl of sample or control in 1 % sample buffer was 
added to each well and incubated for 1 hour at room temperature with gentle shaking. 
The plate was then washed 5 times with wash buffer. Antibody was then added to the 
plate, 100 µl per well diluted in sample buffer and incubated for 1 hour at room 
temperature with gentle shaking. The plate was then washed 5 times with wash 
buffer. If necessary, a secondary antibody (conjugated to AP or HRP) was then 
added to the plate, 100 µl per well in sample buffer and incubated for 1 hour at room 
temperature with gentle shaking. The plate was then washed 5 times with wash 
buffer and then twice with demineralised water. In order to detect either the HRP or 
AP, 100 µl of enzyme substrate was added to each well. To stop the reaction from 
proceeding, 50 µl of 1 M H2SO4 was added to each well, causing a colour change 
from blue to yellow. The OD was measured at 450 nm using a plate reader and a 





2.3.11.2 Commercially available ELISA 
 
At the time of the project there was a commercially available anti-VHH ELISA, the 
CaptureSelect™ VIII Select Leakage ELISA. This was originally designed for the 
detection of less than 1 ng/mL Factor VIII ligand (VHH ligand 7) that may be 
present in FVIII product purified with GE‐Healthcare’s VIII Select. This ELISA kit 
was used to test cell media and lysed cell samples from cells transfected with VHH 
plasmid (these experiments were conducted in the BAC laboratory in the 
Netherlands). 
The CaptureSelect™ leakage assay enabled detection of the VHH in solutions with 
and without the presence of the target protein i.e. VHH alone or VHH bound to FVIII 
(see figure 2.3). This assay involved the following steps: 
• A microtiter plate was coated with either anti-VHH antibody (goat)  
• Samples containing the affinity ligand (VHH or VHH bound to FVIII) were 
incubated in the coated plate wells. 
• Bound affinity ligand (VHH or VHH bound to FVIII) was detected using a 
biotinylated affinity ligand (either anti-VHH or anti-FVIII). 
• Streptavidin horseradish peroxidase conjugate was added to bind to the 
biotinylated antibody in the sandwich complex. 
• Substrate reactive with horseradish peroxidise (tetramethylbenzidine‐hydrogen 
peroxide) was added. 
• The amount of hydrolyzed substrate was determined (directly proportional to the 




Figure 2.3. ELISA formats using CaptureSelect VIII Leakage ELISA coating 
antibody 
Assay 1: Original manufacturer specified assay format to detect VHH in the cell 
media or cell lysate of cells transfected with VHH plasmid;  
Assay 2: Modified manufacturer specified assay format to detect VHH:FVIII 
complex in cell media or cell lysate of BHK cells transfected with VHH plasmids 
using a mouse anti-FVIII antibody as a secondary antibody;  
Assay 3: Modified manufacturer specified assay format to detect VHH:FVIII 
complex in cell media or cell lysate of BHK cells transfected with VHH plasmids 
using a sheep anti-FVIII antibody as a secondary antibody. 
 
In addition, it is worth noting that there are commercially available ELISA kits for 
detection of FVIII; however these were prohibitively expensive and therefore were 
not able to be used for the purpose of this project. For example it costs approximately 
£1500 per FVIII ELISA kit from Affinity Biologicals, which is an FDA approved kit 
used to assess FVIII concentrates, as well as distinguishing patients with FVIII 
inhibitors. 
Purpose: To detect ‘VHH :FVIII complex’ in VHH 










Cell media or lysate
Mouse anti-FVIII mAb
Anti-mouse peroxidase
Purpose: To detect ‘VHH :FVIII complex’ in VHH 
transfected  BHK FVIII cells
Plate 
Goat anti-VHH (coat)
Cell media or lysate
Goat anti-VHH (biotinylated)
Streptavidin HRP




2.3.11.3 Bespoke ELISA 
 
The limited selection and prohibitive cost of the commercial ELISA kits for VHH 
and FVIII meant that a bespoke solution was sought. Several ELISA formats were 
designed and optimised in-house. Multiple formats were tested for both VHH and 
FVIII proteins and these are summarised in figure 2.4 
 
 
Figure 2.4. ELISA formats tested 
Assay 1: For the detection of VHH in cell media or cell lysate of cells 
transfected with VHH plasmid;  
Assay 2 and 3: For the detection of FVIII in BHK cell media or cell lysate 
  
Plate
Cell media or lysate (coat)
Rabbit anti-VHH
Swine anti-rabbit peroxidase (SWARPO)
Purpose: To detect VHH expression in transfected cells 21
Plate 
Sheep anti-FVIII pAB (coat)
Cell media or lysate
Mouse anti-FVIII mAb
Anti-mouse peroxidase





Cell media or lysate
Sheep anti-FVIII HRP




2.4. Detection of FVIII activity using Ceveron automated 
coagulation assay (One stage clotting assay) 
 
There are many methods available for testing the functional activity of clotting 
factors and more specifically the activity of FVIII including clot-based assays, 
chromogenic, and immunoassay methods. The most common method used for 
measuring FVIII activity is the 1-stage activity (clot-based) assay based on the 
activated partial thromboplastin time (aPTT), which is a highly sensitive and precise 
way of measuring FVIII activity, even at low levels (Chandler, Ferrell et al. 2003). 
Platelet poor plasma [PPP] is incubated at 37°C then phospholipid and a contact 
activator are added followed by calcium (also at 37°C). Addition of calcium initiates 
clotting, and the aPTT is the time taken from the addition of calcium to the formation 
of a fibrin clot. In the clinic, the aPTT time can be normal with very mild FVIII 
deficiency, and in general FVIII levels have to be less than 20-40% of a normal level 
before the aPTT is prolonged. A mild FVIII deficiency can be detected around 0.35-
0.4 IU/ml (Lee et al, 2010). 
Ceveron® alpha, a machine manufactured by Technoclone, is a sophisticated and 
fully automated blood coagulation analyzer (figure 2.3). The Ceveron® alpha 
consists of an analyzer, a personal computer and an optional printer. Ceveron® alpha 
operates on the photometric measurement principle. This measurement method finds 
the coagulation time by an optical detection of the change of turbidity caused by the 
formation of fibrin fibres during an in-vitro ‘clot’ formation.  
Alternative methods exist for testing FVIII activity. These include chromogenic 
methods which measure the change of absorbance after adding a chromogenic 
substrate after plasma and reagent incubation. Immunological methods measure the 
change of absorbance during the reaction of antigen and antibody complex 
formation.  
For this study, the machine was regularly calibrated as recommended by the 
manufacturer (Technoclone), using the coagulation reference plasma, to ensure 
reproducible and accurate data. All reagents and consumables required for the 




Table 29. Reagents and consumables for Ceveron coagulation assay (all 
supplied by Technoclone) 
Reagent, equipment and consumables 
Ceveron Alpha machine 
Dapttin aPTT reagent with sulfatides and silica as surface activators 
25 mM CaCl2 
Imidazole buffer 
FVIII deficient plasma 
Control plasma (normal/abnormal) 
Coagulation reference 
Ceveron Alpha cuvettes 
Ceveron Alpha sample cups (3 ml) 
 
Samples, controls and calibrators were loaded into the sample rotor of the analyzer. 
Samples, controls, calibrators and reagents could be identified by two independent 
bar code readers, one on the outside of the machine, and one built into the sample 
rotor, and allowing for quality control of ‘use-by’ dates and batch numbers. After 
loading all samples and reagents manually, the machine was fully automated 
according to a pre-defined assay protocol. 
 In order to avoid damaging the pipettor arms, the position of the cover (open or 
closed) was automatically checked during operation. These positions were indicated 
on the screen and on the LED display that indicates when an error has occurred, 
when it is busy (the cover is locked) and when it is ready to go (the cover is 
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unlocked). The measuring rotor is where the assay took place. There were two 
dilutors fitted with 500 μL syringes that performed all dilutions and dispensing of 
samples and reagents. Samples, controls and reagents were assembled into cuvettes 
by the pipettor arms, into the measuring rotor, and the wavelength measured. The 
temperature of the reagent pipettor was pre-set to 37 °C, which also had a liquid 
volume sensor. The computer attached automatically converted collected data 
including the number of seconds taken to form a ‘plasma clot’. Each sample or 
control was tested twice, and an average clotting time calculated (the 
system/software was pre-designed by the manufacturer to do this and it could not be 
changed by the user).  Acceptable values for control samples were provided in ranges 
by the manufacturer with each new batch. The barcodes on the control vials were 
scanned each time they were used so that the software could conduct quality control 
calculations each time they were used. If a control value fell outside the expected 
range then the whole experiment would be abandoned (this only happened once 
during the entire study and a new control batch was opened). 
 
 




Marketed FVIII products were tested in the coagulometer to compare their clotting 
times with the FVIII produced in the stable BHK cell line, and also in an attempt to 
correlate FVIII protein concentration or international units with clotting times. Media 
(cell supernatant) was taken from each of the nine VHH ligand plasmid transfections 
in the BHK cell line stably expressing FVIII, 48 hours after transfection, and used 
immediately in the Ceveron assay, which was carried out according to the 
manufacturer’s instructions. Media from transfected cell lines was compared with 
media from the untransfected cells (stable FVIIL cell line) to assess if there was a 
difference in coagulation time. 
 
In order to minimise variability in the assay, cells were counted prior to seeding and 
the exact same seeding density was used for every experiment. In addition, the cells 
were incubated for exactly the same time after every transfection, and after 48 hours 
the media was extracted and immediately tested in the coagulation assay as it was 
known that FVIII can be unstable in cell media. For every experiment, a null 
transfection (no DNA) was carried out and the media tested alongside those 
transfected with VHH. Coagulation assays were repeated at least 16 times (individual 
transfection experiments) for each of the transfected cell lines as well as the 
untransfected cells. This was following advice sought from a qualified statistician at 
the School of Maths, University of Kent on experimental design and statistical 
analysis methods to ensure that the data produced was of high quality.  
 
Controls were included in every experiment using a ‘normal’ and ‘abnormal’ 
reference plasma provided by Technoclone, which represented healthy human 
plasma and that of a human with an abnormal blood clotting time. Because the 
Technoclone system was programmed to compare all samples against the controls (% 
activity versus the ‘normal’ reference sample), those experiments where the control 
data did not fall into specified brackets (as specified by Technoclone) meant that 





Samples and reagents were loaded into the appropriate parts of the machine 
according to Ceveron instructions. Using the programme ‘FVIII Dapttin TC 
10ml_[V001]’ each sample was tested in duplicate and the time taken to form a ‘clot’  
measured in seconds. Each reagent had a lot number and expiry date that was entered 
into the Ceveron before each experiment to confirm that they were viable. For each 
new batch of reagents a calibration curve was generated to ensure that the expected 
clotting times of the control reagents were correct. 
 
The difference in clotting times between media from untransfected cells and 
transfected cell lines was statistically analysed using an unpaired t-test and a 
graphpad calculator website http://www.graphpad.com/quickcalcs/ttest1.cfm.  
An unpaired t-test compares the means of two data sets from independent sources 
(two batches of cells in this case) and indicates if they are statistically significantly 
different. It assumes that the data follows a Gaussian (normal) distribution. As well 
as a t-test the standard deviation, 95 % confidence intervals and the p-values were 
calculated in order to determine if the data were statistically significant. In addition, 
Analysis of Variance (ANOVA) (Cochran and G.M.Cox 1957) was carried out on 
the entire dataset of clotting times. The null hypothesis was that all media samples 
tested had the same amount of functional FVIII (clotting times used as an indirect 
measure). Statistical evaluation was conducted under the guidance of a qualified 




Chapter 3:  Production of plasmids containing VHH genes suitable 




In order to investigate the effect of co-expression of anti-FVIII VHH and FVIII on 
FVIII production, the VHH genes needed to be placed into a vector suitable for 
mammalian expression. Three anti-FVIII VHH ligands were used to make nine 
constructs with a variety of design elements including a leader sequence, a histidine 
tag and/or KDEL, an endoplasmic reticulum retrieval motif. All nine constructs were 
designed, cloned into a mammalian expression vector pcDNA3.1 and sequenced 
ready for transfection into mammalian cells. 
3.2 Aims 
 
The first aim of this project was to produce nine plasmids, each encoding the gene 
for one Camelid antibody (VHH) ligand 2, 6 or 7 respectively. The genes encoding 
each of these ligands were supplied by BAC BV in the Netherlands and these had to 
be manipulated to ensure expression and include various design elements.  
3.3 Plasmids and primer design 
 
For each of the 3 VHH ligands, 3 different constructs were designed (see methods 
2.2).  Each construct was cloned into a pcDNA3.1 vector (Invitrogen) ready for 
transfection into mammalian cells.  
 
3.4 PCR to generate VHH ligand constructs 
 
In order to generate the VHH constructs previously designed, PCR experiments 
needed to be carried out. Primers were designed in house as described in 2.2. The 
expected sizes of PCR products were as follows: 
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Construct 1 = 496 bp 
Construct 2 = 446 bp 
Construct 3 = 490 bp 
 
3.4.1 PCR for ligand 2 constructs 1, 2 and 3. 
 
Initially Taq DNA polymerase (Roche) was used to amplify L2C1. The PCR product 
was purified using a QIAquick PCR purification kit (QIAGEN) and then run on a 
1.5% agarose gel. The gel showed smeared bands at approximately 250bp, 500bp 
and 1000bp indicating the presence of primer-dimers and other nonspecific by-
products (see Figure 3.1, Panel A). Therefore, a proofreading DNA polymerase, 
Platinum® Pfx DNA polymerase (Invitrogen) was used as it is claimed to have a 
much higher fidelity rate (lower error rate) than Taq polymerase. This is important 
when the DNA sequence needs to be 100% correct after amplification, as it needed to 
be in this project. Also, an additional reaction was run using an 'enhancer' suggested 
in the Invitrogen protocol to lower the melting temperature of the primers. Lowering 
the melting temperature below 65 ºC generally reduces the potential for secondary 
annealing of primers to the DNA template. Also, since the primers being used in 
these experiments were relatively long, and the longer the primer the more inefficient 
the annealing step in PCR, lowering the melting temperature may have improved the 
annealing efficiency. 
The use of Platinum® Pfx gave improved results over the Taq DNA polymerase with 
distinct bands in the agarose gel (see Figure 3.1, Panel B) for L2C1 and was used to 
generate L2C2 and L2C3. The ‘enhancer’ did not appear to make a significant 
difference to the performance of the PCR and was not used in any future PCR 











Figure 3.1. PCR products for ligand 2, construct 1.  
1.5% agarose (Melford) gels.   
A. Taq polymerase results, lane 1 and 4 DNA ladder, lane 2 negative control, lane 3 
L2C1. Cycle conditions: 94 °C for 2 minutes followed by 25 cycles of 94 °C for 30 
seconds, 60 °C for 60 seconds, 72 °C for 60 seconds, hold at 4 °C.  
B. Platinum® Pfx results, lane 1 and 6 DNA ladder, lane 2 negative control, lane 3 
L2C1, lane 4 L2C1 + ‘enhancer’, lane 5 plasmid vector pcDNA3.1. Thermocycler 
conditions: 94 °C for 5 minutes followed by 30 cycles of 94 °C for 15 seconds, 55 °C 
for 30 seconds, 68 °C for 30 seconds, hold at 4 °C. Lane 3 and 4 show L2C1 
construct at approximately 500 bp.   
 
After purification, the PCR products were run on another agarose gel to check their 























































































































Figure 3.2 Purified PCR product Ligand 2, construct 2 
Purified PCR products (L2C2) run on 1.5 % agarose gel. Lane 1 DNA ladder, lane 2 
L2C2, lane 3 negative control (PCR). Lane 2 contains L2C2 construct at 
approximately 450 bp. 
 
3.4.2 PCR for ligand 6, constructs 1, 2 and 3. 
 
Platinum® Pfx was used to amplify each of the constructs for ligand 6 in the same 
way as ligand 2 constructs. The PCR products were purified using QIAquick PCR 








































Bands of the appropriate size (approximately 500 bp for L6C1 and L6C3, and 
approximately 450 bp for L6C2) were excised using a scalpel and UV light box and 
the DNA purified using QIAquick Gel Extraction Kit according to the 
manufacturer’s instructions (QIAGEN). After purification, the PCR products were 
run on another agarose gel to check their purity (data not shown). 
 
Figure 3.3. PCR products for ligand 6 constructs.  
Lane 1 DNA ladder, lane 2 L6C1, lane 3 negative control, lane 4 L6C2, lane 5 
negative control, lane 6 L6C3, lane 7 negative control. Cycle conditions: 94 °C for 5 
minutes followed by 30 cycles of 94 °C for 15 seconds, 55°C for 30 seconds, 68 °C 
for 30 seconds, hold at 4 °C. As expected L6C1 in lane 2 is approximately 500 bp, 


































































3.4.3. PCR for ligand 7, constructs 1, 2 and 3. 
 
Based on previous results for ligand 2 and 6, initial PCR reactions for ligand 7 were 
carried out using Platinum® Pfx, however this produced no PCR product. Several 
optimisation steps were carried out including varying the MgCl2 concentration, 
running the reaction with/without enhancer, changing primer concentrations, 
adjusting the annealing temperature, none of which proved successful.  
 
An alternative enzyme was used, Phire Hot Start DNA Polymerase (Finnzymes, 
NEB) which is only activated once the PCR reaction begins to heat up and this 
proved successful. All 3 ligand 7 constructs were produced using this enzyme. The 
PCR products were purified using QIAquick PCR Purification Kit according to the 
manufacturer’s instructions (QIAGEN) before running on a 1.5 % agarose gel (see 
Figure 3.4). Bands were excised using a scalpel and UV lightbox and the DNA 
purified using QIAquick Gel Extraction Kit (QIAGEN). After purification, the PCR 





Figure 3.4 PCR products for ligand 7 constructs.  
Lane 1 DNA ladder, lane 2 and 3 L7C1, lane 4 and 5 L7C2, lane 6 and 7 L7C3. 
Cycle conditions: 98 °C for 1 minute, 30 cycles of 98 °C for 5 seconds, 70 °C for 5 
seconds, 72 °C for 10 seconds, hold at 72 °C for 1 minute, hold at 4 °C. As expected 
L7C1 in lane 2 and 3 is approximately 500 bp, L7C2 in lane 4 and 5 is approximately 
450 bp and L7C3 in lane 6 and 7 is approximately 500 bp. 
 
3.5 Plasmid ligation 






















































All PCR products were digested using the restriction enzymes BamH1 and EcoR1 
ready for ligation into pcDNA3.1. These products were then run on a gel and the 
DNA re-purified using a Gel Extraction Kit (QIAGEN). The vector pcDNA3.1 was 
also digested with the same restriction enzymes and purified ready to be ligated with 
the digested PCR products (see Figure 3.5). 
 
Figure 3.5. Purified and restriction enzyme digested PCR products (L2C3). 
1.5% agarose gel. Lane 1 DNA ladder 100 bp, lane 2 negative control, lane 3 purified 
PCR product L2C3, lane 4 and 5 L2C3 digested with BamH1 and EcoR1 restriction 
enzymes, lane 6 and 7 pcDNA3.1 digested with BamH1 and EcoR1 restriction 















































































approximately 500 bp, and pcDNA3.1 bands in lanes 6 and 7 are approximately 5 
Kb. 
3.5.2 DNA ligation (pcDNA3.1 + VHH) 
 
A standard overnight ligation was carried out using ligase enzyme and pcDNA3.1 for 
inserts L2C2, L2C3, L6C1-3 and L7C1.  
For the other inserts L2C1, L7C2 and L7C3, standard ligation procedures resulted in 
unsuccessful transformations in E. coli, therefore a TA cloning kit (Invitrogen) was 
used (see 2.2.5). TA cloning resulted in successful ligations for all three of these 
constructs, confirmed by transformation into E. coli.  
Single E. coli colonies were picked and placed into an overnight starter culture (LB 
media). The plasmids were purified from the bacteria using QIAGEN miniprep kits 
and the DNA subsequently digested using BamH1 and EcoR1 restriction enzymes. 
An example of 2 positive colonies containing a ligated plasmid with the L2C1 gene 
insert can be seen in figure 3.6, lanes 3 and 5. 
After propagation of the TA plasmid in DH5α E. coli cells, the insert was then 
digested out of the TA vector using BamH1 and EcoR1 and successfully ligated into 







Figure 3.6. Plasmids digested with restriction enzymes (L2C1).  
1.5 % agarose gel.  Lane 1 DNA ladder, lanes 2-7 L2C1 miniprep DNA digested 
with EcoR1 and BamH1 restriction enzyme. Lanes 3 and 5 show the presence of 
L2C1 gene insert at approximately 500 bp. 
  
3.6 Transformation of VHH plasmids into bacterial cells 
 
All plasmids were transformed successfully into competent DH5α bacterial cells and 




























































DNA samples that showed the appropriate band size for the VHH gene insert when 
run on an agarose gel were sent off for sequencing at either CoGenics or GATC 
Biotech. Eight out of nine plasmids showed a 100% homology with the desired 
sequence at the first sequencing attempt.  L7C2 however had to be sequenced 3 times 
(3 individual clones were analysed) before a plasmid containing the correct sequence 
was found. 
The first L7C2 construct to be sequenced had a cytosine base missing in the 3’ end of 
the gene sequence which encoded the histidine tag. The second L7C2 construct to be 
sequenced contained a base change from a cytosine to a thymine residue, also at the 
3’ end of the gene sequence in the region encoding the histidine tag. The third 
attempt at sequencing resulted in a L7C2 construct that was 100% homologous with 




All nine VHH constructs were designed, built and inserted into the mammalian 
expression vector pcDNA3.1 ready for transfection into mammalian cells. Each 
plasmid encoded the gene for one Camelid antibody (VHH) ligand 2, 6 or 7 
respectively, with 3 different constructs designed per ligand giving a total of nine 
unique plasmids. Since the genes encoding each of these ligands were supplied by 
BAC BV in the Netherlands as an incomplete DNA template, several molecular 
techniques had to be employed in order to produce a plasmid containing the full 
length gene sequence as well as the various design features of each construct, such as 
the region encoding a histidine tag. Several important design features were included 
such as the Kozak sequence which is critical for initiation of the translation process 
(Kozak 1987). For successful initiation, the small ribosomal subunit must bind to the 
translational start site (Kozaks DNA consensus sequence in eukaryotes) and recruit 
the large ribosomal subunit to form a functional ribosome (Grzegorski et al, 
2014).  A translation termination codon was included so that translation would stop 
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at the end of the mRNA sequence, and no more amino acids added to the polypeptide 
chain. An immunoglobulin leader sequence was added to VHH constructs 1 and 3 in 
order to encourage secretion of the VHH into cell media. The leader sequence used 
was an exact copy of that used in the production of the antibody Herceptin (supplied 
by Peter Nicholls, University of Kent). An endoplasmic reticulum retrieval motif was 
added to construct 3 in order to influence the intracellular trafficking of the protein 
(binding to KDEL normally results in proteins being retained in the ER and 
subsequently degraded). Restriction enzymes sites were added to ensure that the 
VHH gene could be digested and ligated into the plasmid of interest. 
In order to make the constructs and produce enough DNA for ligating the genes into 
a plasmid, the genes were amplified by PCR. Initially Taq Polymerase was used; 
however the error rate appeared to be high with the formation of primer-dimers and 
smeared band sizes when running PCR products on an agarose gel. The constructs 
for ligand 2 and ligand 6 were amplified using, however a different enzyme had to be 
used for the ligand 7 constructs (Phire hotstart) despite several optimisation steps 
being taken and the manufacturer’s advice being followed. It was expected that all of 
the PCR experiments would be successful using the same enzyme as the gene 
sequences are all of a similar length (450-500 bp) and fairly homologous. The only 
difference between each of the three ligand gene sequences is in the antigen binding 
region where one or two base pairs are different (data not shown, confidential to 
BAC BV). It is still unexplained why ligand 7 constructs could not be amplified 
successfully using Platinum® Pfx.  
When it came to ligating the VHH gene constructs into pcDNA3.1, six of the nine 
VHH constructs were successfully ligated using a standard ligase enzyme reaction. 
However the remaining 3 VHH gene constructs (L2C1, L7C2 and L7C3) were not 
successfully ligated using a standard ligase enzyme reaction, and an alternative 
method had to be used, TA cloning. Again, there does not seem to be a logical 
explanation for this as the 3 constructs that required TA cloning are not from the 
same ligand family, for example, all ligand 7, nor are they all of the same construct 
design, for example all construct 1.  
Sequencing of the plasmids was relatively straight forward apart from L7C2, where 3 
individual colonies were analysed before the correct sequence was found. The first 
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two attempts at sequencing L7C2 showed a base change or a base deletion in the 
3’end of the gene which encoded the histidine tag. Interestingly this is where the 
reverse primer would bind at the 3’ end of the gene. A possible explanation for this is 
that there was some variation within the primer solution provided by the 
manufacturer. This could be due to an error in the manufacturing process and was 
therefore beyond the control of the experimenter.  
In summary, all nine VHH plasmids were confirmed to have 100 % homology with 
the expected gene sequence and were therefore deemed ready for transfection into 








In the previous chapter it was described how nine unique plasmids were made 
encoding VHH proteins, ready to be transfected into mammalian cells. This chapter 
describes the VHH expression studies that were conducted in mammalian cells, 
including co-expression in a FVIII expressing cell line. The expression of the VHH 
ligands was investigated at both the RNA and at the protein level, the results of 
which will be discussed in this chapter.  
Prior to investigating RNA and protein expression of the VHH ligands, both physical 
and chemical transfection techniques were investigated. A GFP expressing plasmid 
was used in order to ensure that transfection conditions were optimal to allow 
introduction of the plasmids into the cells and to ensure that the cells were not 
exposed to toxic levels of reagents. The transfection methods tested included 
electroporation, where an electrical field was applied to the mammalian cells in order 
to increase the permeability of the plasma cell membrane and allow the introduction 
of the plasmid into the cell. Several chemical-based transfection methods were also 
tested including liposomal and non-liposomal cationic reagents that form a positively 
charged complex with the plasmid which then binds to the negatively charged cell 
surface residues. The DNA is then displaced from the cationic complex and enters 
the cell by endocytosis (see 2.3.5). The chemical method, in particular the cationic 
lipid-based reagent Lipofectamine®, proved to be the optimal transfection method 
and this was then employed for all further VHH transfection experiments. 
Confirmation that the VHH were being expressed in mammalian cells was 
demonstrated by a series of experiments investigating both RNA and protein 
expression by PCR and western blotting respectively. Attempts at manufacturing 
stable cell lines expressing VHH were unsuccessful, so the majority of the VHH 
expression studies were carried out using transient transfections.  
Upon confirmation that the VHH were successfully expressed in mammalian cells, 
the VHH plasmids were then transfected into a stable BHK-FVIII expressing cell 
line. In this cell line both VHH and FVIII was expressed at levels too low to be 
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detected in a standard western blotting experiment. Therefore immunoprecipitation 
was used in order to concentrate the sample (cell media and cell lysate tested) prior 
to carrying out western blotting again, as well as SYPRO® protein staining (see 
methods 2.3.6 and 2.3.7) to detect both the VHH and FVIII proteins.  
Given the negligible or non-detectable levels of protein expression seen in the BHK-
FVIII/VHH co-expression studies, an alternative assay method was sought in order 
to detect both the VHH and FVIII proteins. Several different ELISA based formats 
(both commercially available and in-house versions) were tested but unfortunately 
these experiments either did not work or did not provide any statistically significant 
results.  
Studies investigating the function of FVIII and any effect co-expression with anti-
FVIII VHH ligands may have had on this were also carried out (see chapter 5). 
 
4.2 Experimental Aims 
 
One of the experimental aims in this project was to successfully transfect Camelid 
antibody (VHH) plasmid constructs into mammalian cells. This initial step was taken 
in CHO-K1 cells to confirm VHH expression prior to co-expressing the VHH with 
FVIII. This was investigated using several techniques including RT-PCR and 
western blotting. Once this was confirmed, the two proteins (VHH and FVIII) could 
be co-expressed in BHK cells. 
 
4.3 Optimisation of transfection conditions in CHO-K1 using a GFP plasmid  
 
Transfections conditions were optimised in CHO-K1 cells by using a plasmid 
encoding for the reporter gene, green fluorescent protein before proceeding to any 
work using VHH plasmids. CHO-K1 cells were either electroporated with a GFP 
plasmid or transfected using chemical methods as described in 2.3.2. These 
experiments were carried out in order to ensure that the conditions imposed on the 




4.3.1. Electroporation using a GFP plasmid in CHO-K1 cells 
 
Efforts to optimise GFP expression included varying the amounts DNA plasmid per 
electroporation and testing various buffers (see appendix for composition). A variety 
of buffer compositions were found in the literature so it was important to find the 
optimal conditions for CHO-K1 cells. The best electroporation conditions of those 
tested for expression of GFP was found to be 10 µg plasmid DNA in PBS (see figure 
4.1). To improve upon this further, a number of chemical transfection methods were 
tried to see if the amount of GFP-expressing cells could be further increased over and 
above what was seen in the electroporation experiments. 
 
Figure 4.1. CHO-K1 cells transfected with GFP plasmid. A comparison of 
electroporation buffers and their effect on GFP expression in CHO-K1 cells. 
A comparison of 6 different electroporation buffers on GFP expression in CHO-K1 
cells showed that PBS was the best buffer in terms of the number of fluorescing 





4.3.2. Chemical transfection of GFP plasmid in CHO-K1  
 
4 different commercially available chemical transfection reagents were tested as 
described in methods section 2.3.2.2, including cationic polymers (FuGENE® , 
TurboFect™ and PEI) and a cationic lipid-based product (Lipofectamine®).  
FuGENE® was tested at various ratios to DNA as recommended by the manufacturer 
with the 4:1 ratio giving the highest number of fluorescing cells. However, none of 
the concentrations tested gave a high level of fluorescing cells indicating low 
transfection efficiency. This was also the case with PEI which was also tested 
according to the manufacturers’ instructions (data not shown). 
Both TurboFect™ treated cells and Lipofectamine® treated cells showed a higher 
percentage of fluorescing cells when compared with the FuGENE®  and PEI treated 
cells (figure 4.2). Lipofectamine® appeared to be the best reagent out of all four 
chemical methods based on the highest proportion of fluorescing cells. 
Having tested both the electroporation and chemical methods in CHO-K1 cells, it 
was clear that the chemical method (Lipofectamine®) gave the greatest GFP 
expression and this was therefore the method of choice for all future transfection 
experiments. 
 
Figure 4.2. Comparison of TurboFect™ and Lipofectamine® transfection 
reagents of GFP expression in CHO-K1 cells. 
A comparison of TurboFect™ treated cells and Lipofectamine® treated cells shows a 
higher number of fluorescing cells indicating higher transfection efficiency in the 
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Lipofectamine® treated cells. 4 µg plasmid DNA was used for each experiment 
Magnification x 400. 
 
4.3.3. Chemical transfection of GFP plasmid in BHK cells  
 
The results of GFP plasmid transfection experiments in CHO-K1 cells indicated that 
Lipofectamine® was the best performing reagent of the four tested, however the  
manufacturer had made a change to the product with the introduction of 
Lipofectamine® LTX (and PLUS reagent). Therefore an additional optimisation 
experiment was carried out in order to determine the optimal ratio of 
Lipofectamine® LTX: PLUS reagent. This was carried out as described in methods 
section 2.3.2.2. The optimal concentrations were found to be 7.5 µl of 
Lipofectamine® LTX, 0.5 µl of PLUS reagent and 4 µg plasmid DNA (see figure 4.3 
and table 30) 
 
Figure 4.3. Optimisation of Lipofectamine® LTX transfection in BHK cells 
BHK cells expressing GFP
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Panels 1 to 6 represent wells 1 to 6 of a 6 well plate (each well was seeded at 2 x 10
5
 
cells/well). Panels 1 and 2 show the greatest GFP signal when compared to all other 
panels. Panel 1 was transfected with 7.5 µl of Lipofectamine® LTX and 0.5 µl of 
PLUS reagent. Wells 2 to 6 contain increasing amounts of both Lipofectamine® 
LTX and PLUS reagent as shown in table 30. Magnification x 400. 
 
Table 30: Lipofectamine® LTX: PLUS regent ratios used for optimisation of 
transfection conditions 







1 4 7.5 0.5 
2 4 10 2.5 
3 4 12.5 5 
4 4 15 7.5 
5 4 20 8 
6 4 25 10 
 
4.4 mRNA analysis by RT-PCR to confirm successful transfection of VHH in 
BHK cells 
 
In order to assess the presence or absence of VHH mRNA in BHK cells, mRNA 
analysis was carried out using the beta-actin housekeeping gene as a positive control. 
All cells were transfected using Lipofectamine® LTX (Invitrogen) as described in 
methods section 2.3.2.2. RNA was extracted from the cells as described in methods 
2.3.5, and untransfected cells were used as a negative control for VHH expression. 
RNA was converted to cDNA and amplified using PCR. The PCR products were 
then run on an agarose gel to check for VHH or Beta-actin expression. 
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In each of the samples from cells transfected with the VHH plasmids, as well as the 
untransfected BHK cell line, the beta-actin housekeeping gene was detected as seen 
in figure 4.4 where bands can be seen at approximately 100 bp as expected. 
 
 
Figure 4.4. PCR products using primers for beta-actin gene after 48 hours cell 
growth. 
RNA extracted from BHK-FVIII cells. A:  Lane 1 DNA ladder, lane 2 untransfected 
BHK cells, lanes 3 to 8 cells transfected with L2C1, L2C2, L2C3, L6C1, L6C2 and 
L6C3 respectively. B:  Lane 1 DNA ladder, lane 2 to 4 cells transfected with L7C1, 
L7C2 and L7C3. 
 
Cells that were transfected with VHH plasmids were assessed for presence of VHH 
mRNA 48 hours after transfection. The 48 hour time point was chosen because this is 


































































































































































































assay. This is relevant because it was planned to co-express VHH and FVIII in the 
BHK cell line so it was imperative to check that VHH was still being expressed at 
this time point. For 6 of the VHH constructs (L2C2, L6C1, L6C2, L6C3, L7C2, 
L7C3) PCR products indicated the presence of VHH mRNA at 48 hours post 
transfection (see figure 4.5). However, for the remaining 3 VHH constructs (L2C1, 
L2C3 and L7C1), mRNA was not detected at 48 hours. For these 3 constructs RNA 
was extracted at an earlier time point of 24 hours after transfection instead of 48 
hours and the PCR products were then successfully amplified (figure 4.6). It was 
thought that perhaps at 48 hours, the mRNA for these 3 constructs may have 
degraded and therefore could not be detected (see discussion 4.9). 
 
Figure 4.5. VHH PCR products, mRNA analysis 48 hours after transfection 
A: Lane 1 DNA ladder, lane 2 untransfected BHK cells (negative control), lane 3 
cells transfected with L2C1 (not detected), lane 4 cells transfected with L2C2 (band 
at approximately 450 bp), lane 5 cells transfected with L2C3 (not detected), lane 6 
cells transfected with L6C1 (band at approximately 500 bp), lane 7 cells transfected 

















































































































































































































at approximately 500 bp). B: Lane 1 DNA ladder, lane 2 untransfected BHK cells 
(negative control), lane 3 cells transfected with L7C1 (not detected), lane 4 cells 
transfected with L7C2 (band at approximately 450 bp), lane 5 cells transfected with 
L7C3 (band at approximately 500 bp). 
 
 
Figure 4.6 VHH PCR products, mRNA analysis 24 hours after transfection 
A: Lane 1 DNA ladder, lane 2 cells transfected with L2C1 (band detected at 
approximately 500 bp). B: Lane 1 DNA ladder, lane 2 cells transfected with L2C3 
(band detected at approximately 500 bp), lane 3 cells transfected with L7C1 (band 
detected at approximately 500 bp). 
 
All nine VHH constructs were successfully transfected into the BHK cell line and 
subsequently expression of mRNA was detected by RT-PCR experiments either 24 
or 48 hours after transfection. In all of the transfected cell samples, as well as the 









































































4.5 Expression and detection of VHH ligands in CHO-K1 cell line 
 
4.5.1 Western blotting to detect VHH (using anti-VHH and anti-His antibodies) 
 
VHH plasmids were transfected into CHO-K1 cells using Lipofectamine® as 
described in 2.3.2.2. In order to detect if the VHH were being expressed at the 
protein level, several dot blots and western blotting experiments were carried out as 
described in sections 2.3.6. All nine VHH constructs were expressed in CHO-K1 
cells, with variable results. An example of a western blot showing possible L2C1 
protein expression can be seen in figure 4.7. There are 4 bands seen at approximately 
12 KDa, which is the size expected for the VHH protein (12-15 KDa). 2 VHH 
standard solutions were also run on the same agarose gel (lane 5 and 6, both supplied 
by BAC) and gave bands at the expected sizes. There are also some other bands on 
the top half of the blot which are unidentified and could potentially be aggregated 
VHH protein. 
This experiment also compared the effect of linearising the plasmid (see 2.2.10) prior 
to transfection. When comparing media samples from cells transfected with a 
linearised plasmid to those that were transfected with a whole plasmid, the highest 




Figure 4.7. Anti –VHH western blot to detect VHH expression in CHO-K1 cells 
Western blotted PVDF membrane using rabbit anti-VHH antibody as the primary 
antibody and goat anti-rabbit antibody as the secondary antibody. Lane 1; Lysed cells 
transfected with whole L2C1 plasmid, 2; Media from cells transfected with whole 
L2C1 plasmid, 3; Lysed cells transfected with linearised L2C1 plasmid, 4; Media 
from cells transfected with  linearised L2C1 plasmid, 5; 5 x VHH mixture (positive 
control), 6; R2 VHH (positive control). Lanes 1 to 4 show bands at approximately 12 
KDa which is close to the approximate size expected for the L2C1 VHH (12-15 
KDa). The media sample from cells transfected with linearised plasmid (lane 4) 
shows the highest expression of L2C1. A negative control was not included in this 
blot. 
In addition to western blots using anti-VHH antibodies as a detection method, anti-
His antibodies were also used to detect those six VHH ligands that had a Histidine 
tag encoded in their gene sequence (constructs 1 and 2). An example of an anti-His 
























































































































from cells transfected with linearised L2C1 plasmid, lane 4) gave a faint band 
indicating very low protein expression. It may be that the histidine tag had been 
cleaved by the cell during protein production and therefore could not be detected by 
western blot. Cleavage of histidine tag was not investigated further in this study. This 
experiment was repeated on several occasions and at no point was the anti-His signal 
improved, for any of the histidine tagged VHH proteins. 
 
Figure 4.8. Anti-His western blot to detect L2C1 expression in CHO-K1 cells  
Western blotted PVDF membrane using Anti-His antibody (conjugated to HRP). 
Lane 1; Lysed cells transfected with whole L2C1 plasmid, 2; Media from cells 
transfected with  whole L2C1 plasmid, 3; Lysed cells transfected with linearised 
L2C1 plasmid, 4; Media from cells transfected with  linearised L2C1 plasmid, 5; 























































































































Faint band in lane 4 at 
approximately 12 KDa
(possibly L2C1)




the size expected for L2C1 protein (12-15 KDa). No negative control was included in 
this experiment. 
 
4.5.2 Nickel column purification of His-tagged proteins  
 
Since the histidine-tagged constructs could barely be detected in an anti-His western 
blot, cell culture media from cells transfected with plasmids encoding for histidine-
tagged VHH was purified on a nickel column (see methods 2.5.6). Samples were 
collected from the column over a range of imidazole eluting buffer concentrations. 
Each of these samples were analysed in a dot blot using an anti-His antibody as 
described in methods 2.3.8.  
For cell culture media from cells transfected with L2C2 plasmid (construct encodes 
for histidine tag at 3’ end), a signal was seen in samples eluted at 150mM imidazole. 
These samples were tested in two western blots under both denaturing and non-
denaturing conditions using either anti-VHH or anti-His antibodies. The anti-VHH 
western blot showed no bands at the expected VHH protein size in both the 
denaturing and non-denaturing conditions. The non-denaturing anti-His western blot 
did show one band at approximately 12KDa which is likely to be a histidine tagged 




Figure 4.9 Anti-His western blot (nickel column eluted samples) 
Lane 1: BHK cell media (untransfected cells); lane 2: L2C2 transfected cell media, 
elution sample 1; lane 3: L2C2 transfected cell media, elution sample 2; lane 4: L2C2 
transfected cell media, elution sample 3; lane 5: L2C2 transfected cell media, elution 
sample 4; lane 6: L2C2 transfected cell media, elution sample 5; lane 7: L2C2 
transfected cell media, elution sample 6; lane 8: positive control (his-tagged ScFv, 30 
KDa).   
 
4.6 Development of stable CHO-K1 cell lines expressing VHH  
 
Multiple attempts were made at developing stable CHO-K1 cell lines expressing 
each of the nine VHH proteins as described in 2.3.3. Both electroporation and 
chemical methods of transfection were tested (as described in 2.3.2) in order to try 
and produce a stable cell line. During the course of developing a stable cell line, 




























































































































































electroporation and chemical transfection methods. Various buffers were tested, a 
range of VHH plasmid DNA concentrations, as well as trying both linearised and 
whole versions of the VHH plasmids. It is regretful and disappointing that despite all 
of the resources and attempts employed, none of the approaches were successful in 
producing a stable VHH cell line, however, the steps taken and the limited results 
will be outlined here.   
Once the cells had been transfected with VHH plasmid, the cell media and lysed cells 
were tested at regular intervals in a dot blot using anti-VHH antibodies to detect 
expression of VHH protein. Although VHH protein expression could be detected 24 
hours after transfecting the cells (by dot blot analysis using an anti-VHH antibody), 
subsequent VHH protein expression was lost (see 3 examples in figure 4.10). The 
loss of VHH protein expression was evident just 10 days after transfection, as the 
VHH could not be detected in cell culture media or lysed cells, in neither a dot blot 









Figure 4.10. Dot blot using anti-VHH antibodies to detect VHH expression in 
CHO-K1 cell media (in the presence of G418).  
VHH expression can clearly be seen 24 hours after addition of genetecin to the media 
(dots 1 and 2), but cannot be seen after 10 days (dots 3 and 4). 100 µl of cell media in 
each well.  
 
No VHH protein expression was seen after 10 days for any of the VHH plasmids 
tested, and this could have been due to a very low percentage of cells incorporating 
the VHH gene into their genome. Consequently the single cell cloning method was 
used to try and grow any cells which may have incorporated the VHH gene.  
Transfected cells were grown in the presence of genetecin and consequently any cells 
that had not taken up the VHH gene would eventually die. As expected, the majority 
of the cells died in the presence of 400 µg / ml genetecin after a couple of weeks. 
Those few cells that survived the presence of genetecin were taken through to single 
cell cloning. None of the clones that were picked and bulked up showed any sign of 
VHH expression in dot blots or western blots, despite the fact they were growing in 






Due to project time constraints, it was decided that a stable CHO-K1 cell line 
expressing VHH, although interesting to study, was not an essential element to 
fulfilling the aims of this project, and therefore transient transfections became the 
method of choice for all future investigations into VHH expression. 
 
4.7 Co-expression of VHH and FVIII in BHK cells 
 
The ultimate aim of this project was to co-express VHH and FVIII together in 
mammalian cells in order to assess the effect of VHH on FVIII expression levels. 
Two approaches were investigated; one being the development of a stable CHO-K1 
cell line expressing VHH which could then be transfected with a plasmid encoding 
the FVIII protein; the second approach was to take a stable BHK cell line that 
expresses FVIII (available in-house) and transiently transfect these cells with 
plasmids encoding the VHH ligands.  
The first approach was unsuccessful as a stable CHO-K1 cell line expressing VHH 
could not be developed as previously described.  
The second approach was more promising as VHH mRNA expression was detected 
between 24 and 48 hours after transfection into the BHK – FVIII cell line as 
described previously in section 4.4. Lysed cells and cell media were tested for VHH 
protein expression after a 48 hour incubation period using western blotting as 
described in 2.3.6.2. The VHH proteins could not be detected in a western blot 
(under reducing and non-reducing conditions) in any of the transfected cell lines, and 
this was thought to be due to low expression levels. VHH detection in a western blot 
was also limited by the availability and specificity of anti-VHH antibodies (see 
communication 2 from Professor Serge Muyldermans).   
FVIII protein expression was also investigated in the BHK cell line. FVIII protein 
could not be detected in a western blot despite several optimisation attempts. 
Although the BHK cell line had been developed to express B domain deleted FVIII 
by Pete Lollar et al, the levels were so low that they could not be detected in a 
western blot. In the many publications where FVIII is detected, it is widely 
acknowledged that a functional coagulation assay is the preferable method of FVIII 
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detection as it is more sensitive than traditional protein detection methods such as 
western blot. This is described in detail in chapter 5. 
4.7.1 Immunoprecipitation of VHH  
 
An alternative approach was sought in order to detect the VHH and FVIII proteins 
using immunoprecipitation (2.3.7), followed by western blotting and SYPRO® 
protein staining (2.3.9). Immunoprecipitation was carried out using an anti-VHH 
antibody in order to purify VHH proteins from the cell media of transfected cells 
(plus untransfected cell samples for a negative control). These samples were then 
analysed in both an anti-VHH western blot (Figure 4.11) and an anti-FVIII western 
blot (Figure 4.12). The anti-VHH western blot showed some faint bands between 6 
KDa and 15 KDA for each of the media samples collected from the cell lines 
transfected with ligand 2, ligand 6 and ligand 7 VHH constructs. This could indicate 
VHH expression, albeit at a very low level, as the expected size of these proteins is 
between 12-15KDa. No bands at the VHH protein size were seen in the untransfected 
cell line. A darker band can be seen in the samples from the cells transfected with 
L7C3 compared to samples from the cell lines transfected with the other 8 VHH 
constructs, which could simply be carrying over from the other lanes or be an 
indication of a greater amount of protein expression versus the other VHH. But, since 
this was not a quantitative assay conclusive comparisons could not be made on 
protein expression levels between the different VHH.  
It was not expected that construct 2 for each of the ligands would be found in the cell 
culture media as they did not have a leader sequence encoded in their plasmid and 
therefore should not have been secreted into the cell culture media via the ER/Golgi 
pathway. However it may be that a small amount of cells had lysed, thereby releasing 
the contents of their cytosol into the surrounding media, potentially explaining the 
presence of construct 2 in the cell culture samples. 
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Figure 4.11 Anti-VHH western blot after immunoprecipitation of BHK-FVIII 
cell media samples. 
Lane 1 and 15 protein size ladder, lane 2, untransfected cells (negative control). lane 
3, L2C1 transfected cells, lane 4, L2C2 transfected cells, lane 5, L2C3 transfected 
cells, lane 6, L6C1 transfected cells, lane 7, L6C2 transfected cells, lane 8, L6C3 
transfected cells, lane 9, L7C1 transfected cells, lane 10, L7C2 transfected cells, lane 
11 L7C3 transfected cells, lane 12 and lane 13 positive controls (VHH), lane 14 is 
empty. Faint bands can be seen between 6 - 15 KDa for some of the VHH transfected 
cell lines. The band for L7C3 is darker than for the other VHHs, which could 
indicate a higher amount of VHH protein expression in this sample, or carryover 
from another lane.  
 
The anti-FVIII western blot (Figure 4.12) was carried out as it was known that some 
of the VHH ligands have anti-FVIII activity (ligand 2 and ligand 7) and therefore 
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clearly be seen at 80 KDa, the size of the FVIII light chain for cell samples 
transfected with ligand 2 and ligand 7 constructs. No bands for the FVIII light chain 
could be seen for any of the cell samples transfected with ligand 6, which was 
expected since ligand 6 does not bind FVIII. 
For those cells transfected with L2C2, L7C1, and L7C3, darker bands could be seen 
compared to the L2C1, L2C3 and L7C2 transfected samples. Given that the 
immunoprecipitation was carried out on cell media, it was surprising to see that the 
sample from L2C2 transfected cells gave a strong signal. This is because the plasmid 
encoding construct 2 does not contain a leader sequence, and should not be secreted 
from the cell. Therefore the presence of L2C2/FVIII in the cell media suggests some 
degree of cell lysis. It is also interesting to see that the cell media from L7C3 
transfected cells gave a strong signal since the plasmid encoding L7C3 contains 
KDEL, and could have resulted in the L7C3/FVIII complex being retained inside the 
cell. There are two possible reasons why L7C3 may be secreted into the media even 
in the presence of KDEL; the KDEL receptor may have been saturated with VHH 
causing the excess to be secreted, although this seems unlikely given the low 
expression levels previously demonstrated. Alternatively, the binding of VHH to the 
FVIII protein may be interfering with the way the VHH interacts with the KDEL 





Figure 4.12. Anti-FVIII western blot after immunoprecipitation of cell media 
samples. 
Lane 1 and 15 protein size ladder, lane 2, untransfected cells (negative control). lane 
3, L2C1 transfected cells, lane 4, L2C2 transfected cells, lane 5, L2C3 transfected 
cells, lane 6, L6C1 transfected cells, lane 7, L6C2 transfected cells, lane 8, L6C3 
transfected cells, lane 9, L7C1 transfected cells, lane 10, L7C2 transfected cells, lane 
11 L7C3 transfected cells, lane 12, 13 and 14 empty wells. Several bands can clearly 
be seen at approximately 80 KDa (the size of the FVIII light chain) for cell samples 
transfected with L2C2, L7C1, and L7C3. Faint bands can be seen at 80 KDa for 
L2C1 and L7C2 transfected samples. No bands for the FVIII light chain can be seen 
for any of the cell samples transfected with ligand 6 (as expected).  
 
A protein staining technique, SYPRO® Ruby stain was used to detect proteins in all 
of the samples resulting from the immunoprecipitation experiment (2.5.5). Since 
SYPRO® is a fluorescent stain that is sensitive to light it was important to analyse 
the stained gel as quickly as possible once the incubation time was reached as any 
exposure to light would reduce the signal. Figure 4.13 shows the best image that was 
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captured using a fluorescent imager. This was the third image to be captured after the 
SYPRO® incubation time, since some of the parameters of the imager had to be 
changed in order to capture the best image. The corner of the gel had to be covered 
up as the signal from the positive controls was so strong that it was impacting the 
quality of the image. Due to exposing the gel three times to capture the best image, 
some of the fluorescent signal was lost, however it was still possible to see some 
bands between 6 - 15 KDa in the media samples from transfected cell lines, which is 
the approximate size of the VHH proteins (between 12-15 KDa). It is difficult to 
pinpoint which bands on the gel could be the FVIII light chain due to multiple bands 
in the size region expected (approximately 80 KDa). Also it looks as though there 
may have been a loading error with carryover from lane 3 into lane 2 as there are 
some unexpected bands in the negative control.  
 
 
Figure 4.13. SYPRO® stained SDS-PAGE agarose gel of immunoprecipitated 
proteins. 
Lane 1 and 15 protein size ladder, lane 2, untransfected cells (negative control). lane 
3, L2C1 transfected cells, lane 4, L2C2 transfected cells, lane 5, L2C3 transfected 
cells, lane 6, L6C1 transfected cells, lane 7, L6C2 transfected cells, lane 8, L6C3 
Cell media sample 
from untransfected 
cell line (negative 
control)
Bands between 
6 – 15 KDa




transfected cells, lane 9, L7C1 transfected cells, lane 10, L7C2 transfected cells, lane 
11 L7C3 transfected cells, lane 12 and lane 13 positive controls (VHH), lane 14 is 
empty. Very faint bands can be seen at approximately 15 KDa for samples 
transfected with L2C2 and L7C3.  
4.8 Enzyme Linked Immuno‐Sorbent Assay (ELISA) 
 
4.8.1 CaptureSelect™ VIII Leakage ELISA 
 
At the time of the project there was a commercially available anti-VHH ELISA, the 
CaptureSelect™ VIII Leakage ELISA (ThermoFisher). This was originally designed 
for the detection of less than 1 ng/mL Factor VIII ligand (BAC’s VHH ligand 7) that 
may be present in FVIII product purified with GE‐Healthcare’s VIII Select product. 
This is a sandwich assay where anti-ligand 7 is bound to a microtiter plate, to which 
samples containing ligand 7 bind, followed by a biotinylated affinity ligand, which is 
then detected by a streptavidin horseradish peroxidase substrate reaction.    
This ELISA kit was used to test cell media and lysed cell samples from cells 
transfected with VHH plasmid (these experiments were conducted in the BAC 
laboratory in the Netherlands). 
The CaptureSelect™ VIII leakage assay enabled detection of the VHH in solutions 
with and without the presence of the target protein i.e. VHH alone or VHH bound to 




Figure 4.14. ELISA format, Capture Select Leakage ELISA 
Assay 1: Original manufacturer specified assay format to detect VHH in the cell 
media or cell lysate of cells transfected with VHH plasmid;  
Assay 2: Modified manufacturer specified assay format to detect VHH:FVIII 
complex in cell media or cell lysate of BHK cells transfected with VHH plasmids 
using a mouse anti-FVIII antibody as a secondary antibody;  
Assay 3: Modified manufacturer specified assay format to detect VHH:FVIII 
complex in cell media or cell lysate of BHK cells transfected with VHH plasmids 
using a sheep anti-FVIII antibody as a secondary antibody. 
 
Standard curves were generated as advised by the manufacturer. An example 
standard curve can be seen in Figure 4.15. 
Purpose: To detect ‘VHH :FVIII complex’ in VHH 
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Figure 4.15. Example Standard Curve, CaptureSelect VIII Leakage ELISA  
In this experiment, it was expected that the cell media samples from BHK cells 
transfected with ligand 7 would be detected in the ELISA. 
Under the conditions specified by the manufacturer, none of the samples (tested both 
undiluted cell media and cell lysate) taken from BHK cells transfected with ligand 7 
showed an absorbance reading above 0.06 nm. Therefore none of the data could 
show conclusive evidence that ligand 7 VHH was being expressed and alternative 
assay formats were investigated. Given that the ELISA kit was designed by the 
manufacturer to detect 1 ng/mL VHH ligand 7, it would indicate that if VHH ligand 
7 was present in these samples, the concentration is less than 1ng/mL. 
Assays 2 and 3 were developed to use the same coating antibody from the 
CaptureSelect FVIII leakage ELISA; however the secondary antibodies were anti-
FVIII not anti-VHH. The aim of these experiments was to detect any VHH ligand 7 
that may have formed a complex with FVIII in the cell media of BHK cells 
transfected with ligand 7. The anti-FVIII secondary antibodies tested were either 
from a mouse (monoclonal), or sheep (polyclonal). It was known from personal 
communication with the manufacturer (see Communication) that the polyclonal anti-
FVIII antibody recognises variable epitopes between lots of product.  The 
immunogen used to prepare these antibodies is full-length Factor VIII, and therefore 
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varying degrees by different lots. This is why it was decided to test the mouse 
monoclonal antibody first and then the sheep polyclonal antibody. 
In this experiment, it was not possible to generate a standard curve and use it 
measure protein concentration since a solution containing VHH: FVIII complex was 
not available. However, it may have been possible to detect a difference between the 
control sample (cell media from untransfected BHK cells that contained FVIII) and 
the samples from BHK cells transfected with ligand 7. 
Assay format 2 using mouse monoclonal anti-FVIII as the secondary antibody: 
It was hypothesised that the cell media samples taken from BHK cells transfected 
with ligand 7 may generate a positive result in the ELISA (a higher absorbance 
reading than the untransfected sample). However none of the samples gave 
absorbance readings above 0.06 nm and therefore were not able to discern any 
difference between the untransfected and transfected samples. 
Assay format 3 using sheep polyclonal anti-FVIII as the secondary antibody: 
Although this assay was able to produce substantial absorbance readings (OD above 
0.8 for test samples), there was variability in the data even with a small sample size 
(n=6), and no significant difference in the absorbance readings between the 
untransfected and transfected cell media samples (see figure 4.16). Therefore it was 
concluded that this assay format would not be suitable for confirming the presence or 
absence of a ligand 7: FVIII complex in cell media samples. 






Figure 4.16. Assay format 3 to detect ligand 7:FVIII complex (n=6 per sample 
type) 
4.8.2  ELISA 
Due to the limited selection and prohibitive cost of the commercial ELISA kits, 
several ELISA formats were also designed and optimised in-house. Multiple formats 
were tested for both VHH and FVIII proteins and these are summarised in figure 
4.17. 
 
Figure 4.17. ELISA formats to test for VHH or FVIII protein expression 
Assay 1: Detection of VHH in cell media or cell lysate of cells transfected with VHH 
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Assay 1: Detection of VHH in cell media or cell lysate of cells transfected with VHH 
plasmid: 
The microtiter plate was coated directly with cell culture media from either 
untransfected BHK cells, or cells transfected with VHH plasmid. The untransfected 
cell culture media samples were treated as the baseline (no VHH expression = 1) and 
data from transfected cells normalised to this. Out of the 54 transfected cell samples 
tested only 2 of those showed a positive fold change compared to the untransfected 
cells and these were one L7C1 sample and one L7C3 sample. However these data 
were not reproducible for any other samples tested and therefore this assay format 
was not developed any further.  
Assay 2: For the detection of FVIII in BHK cell media or cell lysate: 
The first step was to generate a standard curve. This was done using dilutions of 
Kogenate® which is a human full length FVIII product currently registered for 
treatment of haemophilia. The plates were coated at a range of pH including 7.2, 8, 9 
and 10. The best ‘standard curve’ (that which gave the greatest difference between 
the lowest and highest data points) was generated at pH 10 (see Figure 4.18). 
However when cell culture supernatants from transfected and untransfected BHK 
cells were tested, no signal was seen, probably due to levels of FVIII expression 
below the limit of detection in this assay. 
 
Figure 4.18. The effect of coating at different pH on the standard curve for 
Kogenate in FVIII ELISA. 
100 50 25 12.5 6.25 3.125
pH7.2 0.106 0.110 0.104 0.108 0.113 0.104
pH8 0.131 0.105 0.107 0.102 0.091 0.084
pH9 0.214 0.201 0.178 0.169 0.151 0.136





























On the advice of the manufacturer of the anti-FVIII antibody (Affinity Biologicals 
Inc. – see communication 1), it was advised to develop the assay using the same type 
of FVIII contained within test samples i.e. B-domain deleted FVIII. Therefore a 
standard curve was generated using Advate® (see figure 4.19) which is a human B-
domain deleted FVIII also approved for the treatment of haemophilia. A standard 
curve was generated using this reagent; however, when testing samples from 
transfected and untransfected BHK cells, no difference in absorbance values between 
the negative control (AIM-V media) and the samples were seen. This indicated that 




Figure 4.19. Example of Advate® standard curve, FVIII ELISA. 
Advate® (BDD FVIII) was used to generate a standard curve in the FVIII ELISA.   
 
Assay 3: For the detection of FVIII in BHK cell media or cell lysate 
Standard curves were generated for the assay using Advate®. Cell culture media 
samples were tested for each of the transfected (with VHH ligand) and untransfected 
BHK cell lines. The absorbance at 450 nm was calculated for each sample and the 
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this assay had high variability across the plate as was observed in previous FVIII 
ELISA experiments. Samples from L2C1 transfected cells gave an absorbance value 
lower than the untransfected cell samples, which could indicate a reduction in FVIII 
concentration, however this was not statistically significant. Samples from L7C1 
transfected cells gave an absorbance value higher than the untransfected cell 
samples, which could indicate an increase in FVIII concentration; however this was 
not statistically significant. Only n=6 of each sample (6 x untransfected, 6 x L2C1, 
etc.) were tested in this experiment, so if it had been repeated with a larger number of 
samples, the results may have had more statistical power.  
 
Figure 4.20. FVIII ELISA 
BHK = untransfected cells (positive control). Mean absorbance plotted for n=6 
samples. L2C1 samples have a lower mean absorbance when compared to the 
untransfected BHK cell line (not significant).  L7C1 samples had an increased mean 
absorbance versus the untransfected BHK cell line (not significant). Error bars 






























4.9 Discussion  
 
This chapter explains in detail the expression studies carried out for both VHH 
expression and VHH and FVIII co-expression in mammalian cells. Nine VHH 
plasmids were investigated in total, six of which encoded an anti-FVIII VHH ligand 
and various design elements.  
Transfection conditions were tested using a plasmid encoding the reporter gene, 
Green Fluorescent Protein (GFP). This was important to ensure that the transfection 
method of choice was not excessively toxic to the cells, and also that the transfection 
efficiency was of a reasonable level to perform protein expression studies. In CHO-
K1 cells both electroporation and chemical methods were tested and it was clear after 
testing both methods that the chemical method using Lipofectamine® gave the 
greatest GFP expression levels. This was therefore the method chosen for all future 
transfection experiments in CHO-K1 cells. Lipofectamine® was also the most 
successful transfection reagent in BHK cells for GFP expression. Of course there are 
many more potential methods of transfection available commercially that were not 
tested as it was concluded that Lipofectamine® was sufficient to fulfil the 
experimental aims. These preparation experiments could have been significantly 
improved by using flow cytometry to measure the number of fluorescing cells, 
instead of judging by eye through a microscope which is highly subjective and 
variable. 
Reverse Transcriptase-PCR (RT-PCR) remains the most commonly used tool in the 
confirmation of gene expression by comparing mRNA levels in different samples 
(Bustin 2002). This method was used to determine if the VHH genes were being 
transcribed in BHK cells upon transfection with Lipofectamine®. In all nine 
transfected cell lines and in an untransfected (negative control) cell sample, beta-
actin mRNA was detected. Although mRNA from 6 of the VHH constructs was 
positively identified in cell samples that were assessed 48 hours after transfection, 
mRNA from the remaining 3 VHH transfected cells was not found at this timepoint. 
These 3 VHH constructs were however detected in cell samples assessed 24 hours 
after transfection. There could be a number of reasons why these constructs were 
found after 24 hours but not 48 hours. These include operator error in one of the 
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steps from transfection to RNA extraction and the production of a PCR product. It is 
also possible that a loss in cell viability in response to transfection and expression of 
VHH may have resulted in mRNA degradation at the later time point. Low 
transfection efficiency could also have been an issue in some of these samples as 
mammalian cells are variable by their biological nature and hence the mRNA 
expression levels may have been too low to detect on these occasions. However since 
the expression of the beta actin housekeeping gene was also assessed in the 48 hour 
samples (untransfected and transfected cells) and appears to be expressed at a similar 
level in all samples, it is thought that cell viability was not the main issue. Several 
steps could have been taken to investigate VHH mRNA levels further. Firstly this 
experiment was conducted to an n=1, so it should have been repeated to confirm the 
results. Secondly, it would have been prudent to test for presence of mRNA at 
various time points after transfection, not just at 24 or 48 hours. This may have 
helped to inform protein expression studies, since a lack of mRNA at a certain time 
point ultimately equals no VHH protein expression and may have helped to explain 
some of the results from the protein studies discussed later. Lastly, it would have 
been useful to conduct quantitative real time RT-PCR (qRT-PCR) studies to compare 
mRNA expression levels at different time points and between the different VHH 
transfected cell samples. 
A protein expression experiment was carried out to compare the effect of transfecting 
cells with a linearised plasmid encoding VHH rather than a whole plasmid. The 
reason this was tried was because of a publication that showed tranfecting with a 
linearised plasmid rather than an intact plasmid may incur a positive effect on protein 
expression levels, even in transient transfections (Stuchbury and Münch 2010). In a 
western blot of lysed cell samples, a stronger band appeared for those cells 
transfected with a linearised plasmid rather than an intact plasmid which may 
indicate a positive effect on protein expression levels as has been reported previously 
in the literature. The reason for this is that when transfecting with whole plasmids, it 
has to be linearised before the cell can process the DNA. Since this is a random 
process, some of the plasmids may not be linearised and this may have an adverse 
effect on protein production. Also when transfecting with a whole plasmid, there is 
no control over where in the sequence the plasmid is linearised by the cell, and could 
therefore result in the gene of interest being interrupted and a lack of protein 
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produced. Transfecting with a linearised plasmid increases the likelihood of the DNA 
being transcribed, as well as allowing control over where in the plasmid the sequence 
is digested. Although this is commonly only carried during the creation of a stable 
cell lines, where the gene of interest has to integrate with the genome and therefore it 
is desirable to control where the plasmid is digested, it was thought that it could have 
a positive on transient transfections in the present study due to the published paper 
mentioned earlier. Also the protein expression studies were not proving successful at 
that time so it seemed a sensible strategy to try and increase expression levels. 
It is known from personal communication with Serge Muyldermans who discovered 
VHH (see communication 2), that VHH don't perform very well in Western blot 
experiments, as anti-VHH antibodies recognise conformational epitopes that are 
disrupted upon SDS treatment. Therefore both denaturing and non-denaturing 
conditions were tested to try to optimise the binding conditions. Western blotting 
experiments showed very low or negligible expression of VHH proteins in CHO-K1 
cells. Although some of the constructs were designed in a manner that would render 
them secretion incompetent and therefore retained inside the cell (construct 2 does 
not have a leader sequence, construct 3 encodes KDEL), these VHH were detected in 
cell media. This could have been due to apoptosis and cell lysis, with the cell 
contents being released into the cell culture media. A study to detect apoptosis in 
these cells could have confirmed this, perhaps using flow cytometry (Wlodkowic et 
al, 2009). The presence of construct 3 in the cell media are somewhat more difficult 
to interpret since the plasmid encodes for both a leader sequence and KDEL. The 
presence of a leader sequence normally results in the extracellular secretion of a 
protein, whereas the presence of KDEL should cause a protein to bind to the KDEL 
receptor in the ER-Golgi secretory pathway and be retained intracellularly and 
subsequently degraded. Construct 3 was found in the cell media and this could be 
due to the VHH protein folding in a manner that KDEL receptor binding is somehow 
inhibited. The binding of the VHH to FVIII could also be blocking KDEL 
interaction. An alternative hypothesis is that the KDEL receptor was saturated, 
causing excess protein to bypass KDEL and be secreted, but this is unlikely given the 
low expression levels demonstrated.  
In the immunoprecipitation experiments, the cell media from cells transfected with 
L7C3 gave the strongest band. This could either be spillover from one of the other 
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lanes or it could indicate a higher level of protein expression than for the other VHH 
investigated. When harvesting cell media from the transfected cells, it was not 
obvious to the eye that a large amount of cell lysis had occurred and therefore it is 
suggested that in this situation KDEL is in fact being bypassed in some way and the 
leader sequence is causing construct 3 to be actively secreted. It is more than likely 
that the cause is spill over from another lane since the ELISA experiments conducted 
do not confirm any ligand 7 expression as discussed later.     
Some of the VHH ligand constructs (1 and 2) were designed to encode a His-tag at 
their 3’ end. It was anticipated that the VHH proteins expressing a His-tag could then 
be detected in western blotting experiments using an anti-His antibody. Despite 
repeated attempts at detecting His-tagged VHH ligands in cell culture media of 
transfected cells, only one sample (L2C1) gave a very faint band on a western blot. 
For the other VHH ligands that should have contained a His-tag it may be that the tag 
was cleaved by the cell during protein production and therefore could not be detected 
by western blot. It may also have been the low expression levels of the protein meant 
that the His-tag was below the levels of detection, and beyond the sensitivity level of 
a western blot. Another reason could be that the conformation of the VHH was such 
that the His tag was ‘hidden’ in a protein fold, and therefore could not be detected.  
A further step was carried out in an attempt to purify His-tagged proteins from the 
cell culture media using a column containing immobilised nickel ions, which bind to 
the histidine tag. All untagged proteins should pass straight through the column 
allowing the bound His-tagged proteins to be eluted separately. Eluted samples were 
analysed for His-tag expression and a positive signal was seen on an anti-His dot blot 
for cell culture media from cells transfected with L2C2 plasmid. However, further 
analysis of these samples on an anti-VHH western blot revealed that the positive 
signal on the dot blot was not a VHH ligand, but possibly just other cellular proteins 
that contained histidine-like residues. Following this result, no further work was 
carried out on the basis of the HIS-tag. Potential further work could be carried out to 
investigate what is happening to the HIS-tag in the VHH proteins. 
One of the strategies for co-expressing VHH and FVIII was to attempt to make a 
stable cell line expressing VHH which could then be transfected with a plasmid 
encoding full length FVIII. Since VHHs are easily produced in bacteria and yeasts, 
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mammalian cell lines have not been routinely been evaluated for this purpose (De 
Mayer et al 2014). However there are examples noted in the literature showing that it 
is possible to produce VHH-fusion proteins in mammalian cell lines. A 6xVHH-Fc 
fusion protein has been expressed transiently in a HEK293 cell line (Zhang, Liu et al. 
2009). The Zhang et al study used expression vectors bearing the Epstein–Barr virus 
origin of replication (oriP), and a pTT plasmid expression vector with protein yield 
ranging from 20 to 136 mg per liter of culture. An example of a stable CHO cell line 
expressing another fusion protein (single domain VHH and a green fluorescent 
protein as a reporter gene) was demonstrated by Bazl et al (Bazl, Rasaee et al. 2007). 
Similarly another stable cell line was developed expressing VHH-GFP fusion protein 
in Human neuroblastoma cells using a pEGFP-N1 vector and a Fugene 6 transfection 
reagent (Gueorguieva et al, 2006). Therefore the current study results were 
somewhat surprising in that attempts to express VHH either transiently or stably in 
CHO-K1 or BHK-FVIII cell lines produced very little or no VHH protein. This could 
be due to a number of reasons. In the stable cell line attempts, it may be that the 
relatively few cells that were stably expressing VHH were simply not selected and 
cultivated effectively using the methods employed in this project. Another reason 
may be that the plasmid and the promoter contained within was not the most ideal for 
stable insertion of the VHH gene into the genome of the cell, but this seems unlikely 
given the frequent use of pcDNA3.1 in mammalian expression systems. Perhaps a 
specialised expression system which is optimised for the generation of constitutive 
expression cell lines such as FlpIn™ (Invitrogen) would be better for this aim. The 
majority of the literature surrounding VHH expression explores the use of 
microorganisms such as E.coli (Rahbarizadeh, Rasaee et al. 2005) or Pichia pastoris 
(Rahbarizadeh, Rasaee et al. 2006), and even in plants (Teh and Kavanagh 2010) 
rather than mammalian cells and therefore it is difficult to make a recommendation. 
The use of microorganisms was not suitable for this study since FVIII is a large 
complicated protein that requires extensive post-translational modification which is 
not supported in microorganisms such as E.coli. One more possibility is that the 
VHH investigated were toxic to the mammalian host and therefore integration into 
the cell genome resulted in cell death. However, several reports in the literature state 
that VHH are non-toxic to mammalian cells, therefore this an unlikely concept (Li, 
Bourgeois et al. 2012). The VHH gene sequences that were supplied by BAC were 
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optimised for expression in yeast. It may be that adapting the codons for expression 
in hamster cell lines would have resulted in more successful expression. 
Studies investigating the expression of FVIII protein upon co-expression with VHH 
ligands in BHK cells included western blotting and ELISA. It was known that this 
cell line does produce functional FVIII protein, as the cell media was tested in a gold 
standard functional coagulation assay at the start of this study. However, the exact 
amount of FVIII being expressed was not able to be confirmed in this study (see 
chapter 5). The western blotting experiments initially proved unsuccessful due to 
very low levels of FVIII protein expressed by the BHK cell line. However following 
immunoprecipitation of VHH protein from cells co-expressing VHH and FVIII, and 
anti-FVIII western blot showed bands at the expected size of the FVIII light chain for 
the cell samples transfected with VHH ligand 2 and VHH ligand 7. This was 
reassuring as it is known that these two ligands bind FVIII (BAC BV, Netherlands). 
However the results of this experiment are limited by the fact that no positive FVIII 
control was included in the western blot. The purpose of the ELISA was to determine 
if co-expressing VHH and FVIII together had any effect on FVIII protein expression 
levels. Unfortunately it was not possible to determine this using an ELISA due to the 
low protein levels, sensitivity limits of the assay and restricted availability of 
monoclonal anti-FVIII antibodies specifically for the detection of B-domain deleted 
FVIII (see communication 1). 
In conclusion, expression studies in mammalian cells have produced highly variable 
results. VHH ligands were expressed at the RNA level as confirmed by RT-PCR; 
however the evidence for VHH protein expression is weak with many results 
showing little or no VHH expression. Future work could address this by codon 
optimisation, and alternative transfection systems. The immunoprecipitation and the 
western blot of the precipitated samples indicated that the ligand 2 and ligand 7 VHH 
bind FVIII; however it was not possible to show if these ligands cause an increase in 
the amount of total FVIII protein using proteomic methods due to consistently low 
levels of protein.  
It was deemed that the best way forward from this point was to investigate the 
functional activity of FVIII produced in BHK cells since the proteomic studies did 
not yield any conclusive results. Functional FVIII activity could be tested using a 
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coagulation assay (clotting assay, see chapter 5), with or without transfecting those 





Chapter 5: Co-expressing FVIII and VHH: the effect on the 
functional activity of FVIII in a coagulation assay 
 
5.1 Introduction  
 
The aim of this study was to assess the effect of anti-FVIII VHH ligands on FVIII 
expression when the two proteins are co-expressed in a mammalian cell line. 
Plasmids encoding different VHH ligands were transfected into BHK-BDD FVIII 
expressing cell line, and the effect on FVIII expression investigated using a 
coagulation assay. Previously, VHH expression was confirmed at the messenger 
RNA level, however there was little or inconclusive evidence of expression at the 
protein level (see chapter 4). In addition, the level of total FVIII protein was also 
investigated by both western blot and ELISA, without success. However, any change 
in total FVIII protein would not have directly translated into a change in the amount 
of functional (active) FVIII protein, which is necessary for coagulation. Therefore it 
was deemed an essential part of this study to investigate a functional coagulation 
assay as a way of determining if the transfection of plasmids encoding VHH into the 
BHK-FVIII cell line would have any impact on the functional activity of FVIII.  
In a clinical setting, the amount of active FVIII available for blood clotting can be 
assessed using an array of different coagulation assays, one of which is the aPTT 
assay (activated partial thromboplastin time – see section 2.4). The aPTT measures 
the efficacy of both the intrinsic and extrinsic pathways of the coagulation cascade, 
and is one of the assays used in diagnosing haemophilia. The ‘partial’ part of the 
aPTT is described as such due to the absence of tissue factor that would be needed 
for the in vivo cascade reaction. Clinically a prolonged aPTT time may indicate a 
coagulation factor deficiency. In this project, the aPTT assay was employed in order 
to determine the amount of active FVIII protein expressed in a BHK cell line.   
As part of fulfilling the study aims, statistical analysis on any data produced was 
carried out to see if any change in active FVIII levels as demonstrated by a change in 
the coagulation time in the aPTT assay was statistically significant. 
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5.2 Coagulation assay  
 
The Ceveron® alpha analyser, a machine manufactured by Technoclone, is a fully 
automated coagulation measuring instrument used for clotting, chromogenic and 
turbidimeric assays. For clotting assays with an endpoint of fibrin clot formation, it 
measures the time taken to form a ‘blood clot’ in vitro via a change in turbidity 
caused by the formation of fibrin fibres. In a clinical setting FVIII deficiency in 
humans can be tested using a clotting assay called aPTT (activated partial 
thromboplastin time). An aPTT assay was used in this project to detect changes in 
active FVIII protein expression; where the faster the ‘clot’ was formed (in seconds) 
the more active FVIII is present in the sample (serum-free cell media in this project).  
According to the manufacturer’s instructions, a calibration curve was carried out for 
each new set of reagents to be used in the aPTT assay. An example of a valid 
calibration curve can be seen in figure 5.1. In addition to this, Technoclone supplied 
a sample of normal and abnormal plasma samples (containing levels of active FVIII 
which were considered normal or deficient for a human) which were used as internal 
controls for each experiment, as well as a calibration reagent. If these plasma 
samples gave clotting times outside of the specified times for the normal or abnormal 
samples (different for every batch, specified by manufacturer on batch documents), 
all data from that experiment was to be disregarded. Fortunately, of the many 
experiments carried out on the Ceveron machine, this only happened once due to a 





Figure 5.1. An example calibration curve for the aPTT assay. 
A calibration curve was carried out using predefined dilution steps (automated) for 
each new batch of reagents for the aPTT assay and validated according to 
Technoclone instructions. 
 
AIM-V media was taken from B-domain deleted FVIII expressing cells and tested in 
the aPTT assay. The cells were either untransfected or transfected with plasmids 
encoding nine different VHH ligands. To allow enough time for FVIII to accumulate 
into the cell media, all samples were taken 48 hours after addition of AIM-V media 
(media changed from full media to AIM-V at time of transfection). Cells were 
seeded at the same density at the start of each experiment and monitored under the 
microscope to detect any major differences at transfection and at the time of 
sampling the cell media. Under a light microscope, the cell density did not appear to 
be any different between those cells that were untransfected versus transfected at the 
time of sampling the cell media. The cells were not counted at the time of media 
sampling; however in retrospect this should have been done in order to see if there 



























AIM-V media taken from untransfected BHK cells was tested in the aPTT assay and 
treated as the standard (baseline) to which all transfected cell samples were 
compared to. Data analysis of the standard samples gave a mean clotting time of 35 
seconds (n=48 samples) as can be seen in table 33.  
AIM-V media samples taken from BHK cells transfected with either ligand 2, 6 or 7 
constructs, and tested in the aPTT assay at least 20 times per construct. In order for 
the experiments to be statistically significant, the minimum number of times each 
ligand should have been tested was 16, in order to produce enough data that 
comparisons could be accurately drawn between transfected and untransfected cell 
lines. This number was calculated in conjunction with the advice of Jian Zhang, 
Professor of Statistics in the School of Mathematics, Statistics and Actuarial 
Sciences at the University of Kent. This advice was based on a power analysis and 
long established principles of experimental design (Cochran and G.M.Cox 1957). A 
power analysis is where a research question is phrased as two different statistical 
hypotheses and gives you an estimation of the sample size you should be testing in 
order to detect statistical significance. The null hypothesis (H0) would be the 
negative result and the alternative hypothesis (Ha) would be the positive result (or the 
finding that is of interest to the researcher) (Steidl and Thomas 2001). In this study 
the null hypothesis was that there would be no difference between untransfected cell 
lines and transfected cell lines in terms of the amount of FVIII secreted. The 
alternative hypothesis was that there would be a difference between the untransfected 
and transfected cell lines i.e. the amount of FVIII secreted would increase or 
decrease when co-transfected with Camelid antibody ligands. Initial data sets that 
were generated were analysed for the standard deviation, and were assumed to have a 
normal distribution. The significance level of the test (the P-value) was assigned 
‘0.05’ (5%) which is the probability of rejecting the null hypothesis even if it is true. 
Degrees of freedom were also calculated which is the number of values in a 
distribution that are free to vary (Healey 1990). Based on these calculations the 
minimum sample size to be tested for statistical significance was 16.  
All data generated in the aPTT assay was vigorously statistically analysed. The 
recommended statistical test was the student (unpaired) t-test, which was used to 
directly compare clotting times of media taken from transfected with that of 
untransfected cells. An unpaired student t-test is used to compare the mean of two 
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independent data sets (you would only use paired if you were looking at the same 
sample before and after treatment, or at two time points for example). The student t-
test was selected as no assumptions are placed on the data (non-parametric), so it 
does not introduce any bias or restriction of data points into any parameters. 
5.2.1 Marketed FVIII products 
 
Fahndi®, Replenate®, and Advate® FVIII samples were kindly donated by the Kent 
Haemophilia centre in Canterbury, Kent.  These were samples that had expired and 
therefore were no longer able to be used in humans. These samples were tested in the 
coagulation assay alongside cell media samples from the BHK-FVIII cell line. The 
aim of this experiment was to try to correlate clotting time (seconds) with either 
protein concentration (ng) or international units (IU), so that the FVIII concentration 
of BHK-FVIII cell media samples could be calculated using their clotting times.   
FVIII samples were tested at a range of concentrations (%), in triplicate (3 lots of 
materials tested) in the coagulation assay. Table 31 shows the differences in 
international units, protein concentration and the mean clotting times between the 
products tested.   
Table 31. Characteristics of marketed FVIII products (all full length FVIII) 
 Fandhi® Replenate® Advate® 
IU FVIII in 100 
µL of  100% 
solution 
10 5 2.5 
ng protein in 100 
µL of 100% 
solution 




19.3 (18.7 – 20.3) 18.1 (17.6 -19.0) 14.3 (13.7 – 15.4) 
 
Each product varied in terms of their FVIII protein concentration (ranging from 5 
ng/100 µL to 355 ng / 100 µL) and international units, and their mean clotting times 
ranged from 14.3 seconds to 19.3 seconds (see figure 5.2). Considering that the 
clotting time is indicative of functional FVIII content, it was expected that the 
product with the highest concentration of international units (Fandhi) would perform 
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the fastest in the coagulation assay; however this product gave the slowest clotting 
time of the three products. It may be some level of degradation had occurred with 
these products since they were all past their expiry date. When comparing the profile 
of the marketed FVIII products to that of the BHK cell media (containing BDD-
FVIII), the BHK cell media gave the slowest clotting time, at least 15 seconds slower 
versus any of the marketed FVIII product solutions.  
 
 
Figure 5.2. Performance of marketed FVIII products and BHK cell media in the 
coagulation assay. 
For every log reduction in FVIII solution concentration (e.g. 100% to 10%), the 
clotting time slowed by approximately 10-15 seconds. Given that the BHK media 
clotting time was 15 to 20 seconds slower than any of the marketed FVIII products; it 
could be concluded that the FVIII concentration of the BHK media was at least a log 
factor less than any of the marketed FVIII products. However, due to the large 
variance of the FVIII protein concentration of the marketed FVIII products, it was 
not possible to estimate the FVIII protein concentration of the cell media. 
 
5.2.2 FVIII co-expression with VHH ligands 
 
BHK-FVIII cells (untransfected) gave a mean clotting time of 35.0 seconds (n=48) 




i.e. transfected without any DNA plasmid present, to see if the transfection reagents 
had any effect on clotting time (35.3 seconds, n=30). The two datasets were analysed 
and compared using the student t-test, and the clotting times were not statistically 
significantly different from one another (p value = 0.74), confirming that the 
transfection reagents used in this study did not impact FVIII activity. 
BHK-FVIII cells were transfected with plasmids encoding one of the nine VHH 
ligands. Cell media samples were taken 48 hours after transfection and tested in the 
coagulation assay. Media samples from those cells transfected with plasmids 
encoding L2C1, L2C2, L7C1, or L7C3 VHH ligands showed a statistically 
significant change in FVIII clotting time when compared to untransfected BHK-
FVIII cell media samples (see figure 5.3). 
 
 
Figure 5.3. A summary of the FVIII clotting times for each VHH transfected cell 
line (48 hours after transfection). 
A bar chart showing the results of co-expressing each of nine VHH ligands with 
FVIII in a BHK cell line and the resulting cell culture media tested in a coagulation 
































clotting time compared to cell culture media from untransfected cells (BHK) 
(indicated by *). Error bars indicate one standard deviation. Minimum n=20 per test 
construct. Untransfected sample n=48. 
 
Analysis of Variance (ANOVA) (Cochran and G.M.Cox 1957) was carried out on 
the entire dataset of clotting times. The null hypothesis was that all media samples 
tested had the same amount of functional FVIII (clotting times used as an indirect 
measure). The ‘F ratio’ was equal to 7.22, and the critical value for F at the 0.05 
significance level was equal to 1.87. Because the calculated value (F ratio) is greater 
than or equal to the critical value, the null hypothesis can be rejected, which means 
that at least 2 groups of samples are different from each other. 
Student t-test analysis was then carried out to see which of the clotting times for each 
of the VHH ligands tested were significantly different from one another (see table 
32). When comparing the VHH transfected cells against each other, both L2C1 and 
L2C2 were statistically significantly different from L2C3 but not from each other. 
L2C1 was also statistically significantly different to all of the other VHH tested. In 
addition to the above, L2C2 was statistically significantly different to all other VHH 
with the exception of L6C1 and L6C2. L7C1 is statistically significantly different to 
all other VHH with the exception of L6C3, L7C2 and L7C3. L7C3 is statistically 
significantly different to all VHH with the exception of L7C1 and L7C2. 
Table 32. Comparison of VHH ligands to show if they statistically significantly 
different to one another 
 
Yes = statistically significantly different from one another; No = not statistically 
significantly different from one another 
BHK 





L2C3 No Yes Yes
L6C1 No Yes No No
L6C2 No Yes No No No
L6C3 No Yes Yes No No No
L7C1 Yes Yes Yes Yes Yes Yes No
L7C2 No Yes Yes No No No No No
L7C3 Yes Yes Yes Yes Yes Yes Yes No No
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5.2.2.1 FVIII co-expressed with VHH ligand 2 
 
BHK-FVIII cells were transfected with a plasmid encoding an anti-FVIII VHH 
ligand 2. Three different constructs of ligand 2 were tested; constructs 1, 2 and 3 (see 
2.2). The cell media from each of these three transfected cell lines was tested along 
with media taken from mock transfected (minus VHH DNA) BHK-FVIII cells in an 
aPTT coagulation assay. 
The transfection of plasmid encoding ligand L2C1, into the BHK-FVIII cell line, had 
a negative effect on the clotting time of cell media samples in the aPTT coagulation 
assay when compared with cell media samples from the untransfected BHK-FVIII 
cell line. This prolonged clotting time indicated a reduction in the amount of active 
FVIII being expressed when compared to the untransfected cell line. Cell media from 
the transfected cells gave a clotting time of 41 seconds compared to a clotting time of 
35 seconds for the untransfected cells, a difference of 6 seconds. Statistical analysis 
of the data using an unpaired student t-test indicated that this difference in clotting 
time was statistically significant, with a P-value of 0.0001 (summarised in table 33).  
The transfection of plasmid encoding ligand L2C2 into the BHK-FVIII cell line, had 
a similar effect as the L2C1 transfection, in that this construct also had a negative 
effect on the clotting time of BHK-FVIII cell media samples, when compared to 
untransfected cell media samples. Again, the prolongation of the clotting time of 3.4 
seconds indicated a reduction in the in the amount of functional FVIII. Although this 
difference in clotting time was not as large of an effect as that of the L2C1 
transfection, this difference was also statistically significant, giving a P-value of 
0.0072 (see table 33).  
Cell media samples from that of BHK-FVIII cells transfected with L2C3 resulted in a 
clotting time very similar to that of cell media from untransfected cells, with a 
difference of 0.3 seconds. Statistical analysis of the data showed that this change in 





Table 33. Coagulation assay results from BHK-FVIII cells +/- ligand 2 
constructs 
 Media from BDD-
FVIII cell line 
(control - no 
transfection) 
Media from BDD-




FVIII cell line 
transfected with  
L2C2 
Media from BDD-







35.0 41.0 38.4 35.3 
Standard 
deviation 
4.6 5.5 5.5 5.1 
Sample 
Size (n) 








n/a Yes Yes No 





33.7-36.3 38.5-43.5 36.5-40.3 33.2-37.4 
 
5.2.2.2 FVIII co-expressed with VHH ligand 6 
 
FVIII was co-expressed with an anti-FII VHH called ligand 6 in BHK cells. Three 
different constructs of ligand 6 were tested; constructs 1, 2 and 3 (see 2.2). The cell 
media from each of these three transfected cell lines was tested alongside media from 
untransfected cells in an aPTT coagulation assay. Since ligand 6 does not bind to 
FVIII it was expected that these ligands would have no effect of FVIII expression. 
L6C1 and L6C2 caused a prolongation of the clotting time (plus 1.2 seconds and 2.9 
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seconds respectively) whereas L6C3 caused a shortening in the clotting time (minus 
1.2 seconds) when comparing transfected and untransfected cells. None of these 
clotting times was statistically significantly different to cell media from 
untransfected cells (summary in table 34). 




FVIII cell line 
(control - no 
transfection) 
Media from BDD-















35.0 36.2 37.9 33.8 
Standard 
deviation 
4.6 6.1 8.5 5.7 
Sample 
size (n) 








n/a No No No 





33.7-36.3 33.5-38.9 34.2-41.6 31.3-36.3 
 
5.2.2.3 FVIII co-expressed with VHH ligand 7 
 
FVIII was co-expressed with an anti-FVIII VHH called ligand 7 in BHK cells. Three 
different constructs of ligand 7 were tested; constructs 1, 2 and 3 (see 2.2). The cell 
media from each of these three transfected cell lines was tested alongside media from 
untransfected cells in an aPTT coagulation assay. 
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Transfection of BHK-FVIII cells with L7C1, had a positive effect on the clotting 
time media samples when compared with untransfected cells. Cell media from the 
transfected cells gave a clotting time of 31.9 seconds compared to a clotting time of 
35 seconds for the untransfected cells, a difference of 3.1 seconds. Statistical analysis 
of the data using an unpaired student t-test indicated that this difference in clotting 
time is statistically significant, with a P-value of 0.0057 (summarised in table 35), 
and indicates an increase in functional FVIII. 
Transfection of BHK-FVIII cells with L7C2, had a very small effect on the clotting 
time of media samples when compared with untransfected cells giving a difference in 
the clotting time of minus 0.2 seconds. The data was analysed using an unpaired 
student t-test which indicated that this difference in clotting time is not statistically 
significant (see table 35).  
Transfection of BHK-FVIII cells with L7C3 had a positive effect on the clotting time 
of media samples when compared with untransfected cells. Cell media from the 
transfected cells gave a clotting time of 31 seconds compared to a clotting time of 35 
seconds for the untransfected cells, a difference of 4 seconds faster in the transfected 
cells. Statistical analysis of the data using an unpaired student t-test indicated that 
this difference in clotting time is statistically significant, with a P-value of 0.0002 
(summarised in table 35).  
The shortened clotting time using cell media from transfected cells may indicate an 
increase in the amount of functional FVIII being expressed when compared to the 
untransfected cell line.  
Table 35. Coagulation assay results from BHK-FVIII cells +/- ligand 7 
constructs 
 Media from BDD-
FVIII cell line 
(control - no 
transfection) 
Media from BDD-




















4.6 3.2 7.8 4.3 
Sample 
size (n) 








n/a Yes No Yes 









Plasmids encoding nine unique VHH constructs were transfected into BHK-FVIII 
cells. The media taken from those cells was tested in an aPTT coagulation assay and 
the clotting times compared to cell media taken from untransfected BHK cells (see 
figure 5.2). The clotting assay used in this study is currently considered the gold 
standard method for detection of FVIII and the diagnosis of haemophilia A and 
screening for thrombophilia (Gouws, Botha et al. 2014). Of the nine BHK cell lines 
that were transfected with VHH constructs, four of those VHH resulted in a 
statistically significant effect on the clotting times of FVIII; L2C1, L2C2, L7C1 and 
L7C3 respectively. All four of these VHH constructs are anti-FVIII Camelid 
antibody ligands (ligand 2 and ligand 7) as confirmed by BAC BV (Netherlands).  
Co-expression of FVIII with the ligand 2 constructs L2C1 and L2C2 gave a 
prolonged clotting time, potentially indicating a reduction in the amount of 
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functional FVIII expressed into the cell media when compared to that of 
untransfected cells. However, this was not able to be supported by proteomic studies 
due to the inability to detect total FVIII protein (chapter 4). Hypothetically speaking, 
if there was a decrease in functional FVIII levels, this could be due to a number of 
potential reasons, for example, a reduction in total FVIII protein, increased FVIII 
degradation, or a masking of binding sites required for FVIII clotting activity.  
Co-expression of FVIII with the ligand 7 constructs L7C1 and L7C3, gave a 
shortened clotting time, potentially indicating an increase in the amount of functional 
FVIII in the cell media when compared to that of untransfected cells. Again, this was 
not supported by proteomic studies in chapter 4. If an increase in functional FVIII 
had been confirmed, it could have been due to a number of potential reasons, for 
example, an increase in total FVIII protein, or a decrease in FVIII degradation 
(prolonged half-life). 
The difference between the negative effect of transfecting with the ligand 2 
constructs and the positive effect of ligand 7 on clotting times may be explained by 
their anti-FVIII activity. Firstly it is known that ligand 7 and ligand 2 bind to 
different regions of the FVIII light chain consisting of A3, C1 and C2 domains as 
well as having different binding affinities. Ligand 7 competes with vWF for the same 
binding site whereas ligand 2 binds to a region other than the vWF binding site (data 
not shown, confidential to BAC). Since FVIII is known to circulate in blood plasma 
bound to vWF which has been shown to stabilize FVIII, it could be that ligand 7 is 
behaving in a similar protective fashion thereby preventing degradation of FVIII and 
preserving the amount of FVIII available for clotting activity. Two regions on the 
FVIII light chain have been implicated in binding VWF: the N-terminal acidic a3 
domain and the C-terminal C2 domain (Shiltagh, Kirkpatrick et al. 2014). It would 
be interesting to conduct epitope mapping to find out exactly where the ligand 7 
VHH binds to FVIII in comparison with vWF. There are several methods available 
for epitope mapping ranging from the gold standard of x-ray co-crystallography to 
site-directed mutagenesis, and the chosen method depends on whether you are 
analysing a linear or conformational epitope. Since it is known that both ligand 7 and 
ligand 2 bind to the light chain, deletions could be introduced in the FVIII light chain 
to examine the binding profile of these ligands. Similar experiments have been noted 
in the literature looking at the impact of anti-FVIII antibodies on the clotting time of 
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FVIII, albeit with the use of monoclonal antibodies rather than VHH. One particular 
study demonstrated that an anti-FVIII monoclonal antibody bound to FVIII heavy 
chain enhanced FVIII coagulant activity, demonstrated by a shortened coagulation 
time in the aPTT assay, by approximately 1.5-fold. The monoclonal antibody in that 
study bound to the A2 domain of the heavy chain and was shown to enhance 
thrombin-induced activation of the FVIII protein, as well as improve the interaction 
of thrombin with the A2 domain (Takeyama, Nogami et al. 2010). Another study 
demonstrated that an anti-FVIII monoclonal antibody that bound to FVIII light chain 
blocked vWF binding in a dose dependent manner as well as acting as an inhibitor in 
FVIII coagulation assays (both aPTT and chromogenic), thought to be due to the 
prevention of thrombin activation of FVIII light chain (Precup, Kline et al. 1991)  
When comparing the three L7 VHH constructs, the effect of L7C1 and L7C3 on the 
clotting time was statistically significant, whereas the effect of L7C2 was not. L7C3 
had a more significant effect on the clotting time than L7C1. L7C1 reduced the 
clotting time by 3.1 seconds and L7C3 reduced the clotting time by 4 seconds. Both 
L7C1 and L7C3 contained a leader sequence which meant they should have been 
secreted into the cell media along with FVIII. The only difference between these two 
constructs is that L7C3 has a KDEL sequence encoded within the construct. It is 
possible that the interaction of L7C3 at the KDEL receptor, if bound to FVIII could 
slow down the processing and secretion of FVIII through the ER/Golgi secretory 
pathway. It is known that the folding/misfolding of the FVIII protein is a rate 
limiting step in FVIII protein expression, so it is possible that this could result in a 
net increase of protein. You could test this by comparing the rate of FVIII production 
in the presence and absence of this construct. Although exact amounts of total 
protein could not be calculated in this study, the clotting assay is the gold standard 
for FVIII detection.    
Co-expression of L7C2 with FVIII had no significant effect on the FVIII clotting 
time when compared to the untransfected BHK cells. The difference between L7C2 
and the other two L7 constructs (L7C1 and L7C3) is that the plasmid does not 
encode a leader sequence and thereby should be not be secreted via the ER/golgi 
pathway in the same way as the L7C1 and L7C3. If L7C2 was retained 
intracellularly, it would not be co-secreted with FVIII and would not be able to 
provide the same protective effect to the FVIII protein in the cell media. However it 
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was seen in the immunoprecipitation/anti-FVIII western blot experiment (figure 
4.13) that FVIII was co-purified with L7C2 from cell media indicating that at least a 
small amount of L7C2 was present in the cell culture media, but perhaps not enough 
to elicit a protective effect on FVIII. The presence of L7C2 in the cell media may be 
due to an accumulation inside the cell, resulting in cell lysis and causing a release of 
the contents of the cytosol into the surrounding cell culture media.    
It is hypothesised that the negative effect that the ligand 2 constructs had on the 
clotting time of functional FVIII in the cell media may be due to the binding region 
on the FVIII protein. This may be a region that affects its activity in the coagulation 
assay, similar to that demonstrated in the Precup et al study (Precup et al, 1991). 
When comparing the effect of the different ligand 2 constructs, whereby construct 1 
and 2 had a statistically significant negative effect on the clotting time of FVIII in the 
cell culture media, and construct 3 (L2C3) which had no significant effect on the 
clotting time of FVIII in the cell culture media it is important to consider the design 
of each of these constructs VHH. Despite only 2 of these constructs containing a 
leader sequence (construct 1 and 3), it appears from the immunoprecipitation 
experiments that all 3 constructs were present in the cell culture media of transfected 
cells (as shown in immunoprecipitation/western blotting experiments, see 4.7.1). 
Also that FVIII was co-purified with each of these ligands in the same experiment 
suggests that they were bound together in the cell culture media. The similar feature 
of construct 1 and 2 (that construct 3 does not contain) is a HIS tag. It could be 
hypothesised that the HIS tag of the bound ligand 2 VHH is somehow affecting the 
functional activity of the FVIII protein, perhaps by masking an important coagulation 
assay co-factor epitope. 
The differences in the binding sites of these two anti-FVIII VHH (ligand 2 and 
ligand 7) may impact the way the cell processes the FVIII protein (if they were 
bound intracellular), including the way FVIII interacts with other chaperones. This in 
turn could lead to many differences including the way the protein is folded (affecting 
its activity), how much protein is sent for degradation and how much is secreted from 




Co-expression of FVIII with the ligand 6 constructs had no significant effect on the 
amount of FVIII expressed in BHK cells.  This result was expected as ligand 6 has 
no anti-FVIII activity and was used as negative control in this study.  
In conclusion, although statistically significant differences in cell media clotting 
times have been demonstrated in BHK-FVIII cells transfected with plasmids 
encoding anti-FVIII VHH, it is not clear as to the reasons why. Especially as the 
proteomic studies did not give convincing evidence of VHH or FVIII protein 
expression in the BHK cells. If it had been possible to categorically confirm VHH 
and FVIII protein expression, the evidence generated in the coagulation studies 
would have shown much more promise than they currently do.   
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Chapter 6: General discussion  
 
The field of research on the FVIII protein is vast and continues to remain a hot topic 
of research due to the enduring problem of low levels of expression and poor 
stability. Indeed prior to this study, many attempts have been made to improve the 
expression of FVIII include tweaking the intracellular trafficking of the protein, 
removing sections of the B domain which are not required for coagulant activity, 
improving the stability of the protein, improving the manufacturing/purification 
conditions and also extending the half-life of the protein with more modern fusion 
proteins. Attempts have also been made at optimising the gene sequence encoding 
the protein, and making porcine/human hybrids that confer higher expression levels. 
The present study aimed to build on what has previously been done in this area by 
testing a novel approach with regard to influencing FVIII expression levels by co-
expression with camelid derived heavy chain antibodies. Had this study been 
successful, the principles could have been applied to the expression of other 
recombinant proteins. 
The present study aimed to improve the production and yield of biologically active 
FVIII from mammalian cell lines, via co-expression with camelid derived anti-FVIII 
antibody ligands (VHH). VHH ligands are 12 – 15 KDa heavy chain only antibody 
fragments that are highly specific for their antigen, very stable and can be easily 
separated from their antigen at neutral pH. Antibody fragments, such as the VHH 
ligands used in this study are relatively new to research when compared to the body 
of work that has been done with conventional antibodies, and they are currently 
being tested in human clinical trials as treatments in their own right. Because of their 
desirable properties, the potential of VHH ligands to be used as molecular tools is 
vast and there are many approaches currently being investigated to harness this 
potential (De Meyer, Muyldermans et al. 2014). Co-expression of VHH with a 
protein of interest has previously been successful in bacterial cells (de Marco 2014). 
There is also an example of VHH being directed to intracellular compartments of 
mammalian cells using KDEL-specific VHH that bind to ER resident proteins in 
human umbilical vein endothelial cells (HUVECS) (Klooster, Eman et al. 2009). 
However, co-expression of antibodies, antibody fragments or VHH with the FVIII 
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protein in mammalian cells has not previously been explored as a mechanism for 
increasing the levels of functional FVIII produced in mammalian cells. 
3 VHH gene sequences were provided for use in this study by BAC BV (The 
Netherlands). From these, nine unique plasmids encoding VHH were designed and 
produced using a variety of molecular biology techniques. These VHH plasmids 
were transiently expressed in mammalian cells including a BHK-FVIII expressing 
cell line. However there were significant hurdles along the way, not least that both 
VHH and FVIII proteins were expressed at very low levels, as seen in proteomic 
studies (chapter 4). This was to be not a surprise for the FVIII protein, despite the use 
of a BHK cell line that was previously optimised for FVIII expression by Lollar et al, 
since FVIII is renowned for expressing at low levels and that is the foundation for the 
purpose of this study. However, it was expected that the VHH would be simple to 
express, given their small size, supposed high solubility and non-toxic properties that 
has been reported several times in the literature. It is likely that this particular study 
did not employ optimal methods for VHH protein expression. Aternative expression 
systems such as FlpIn could be explored, and also gene sequences with optimised 
codons could be tested in future studies. 
Significant problems were encountered in this study with low or no VHH protein 
expression, meaning that is was not possible to confirm VHH expression using 
proteomic methods. However, since the function of FVIII can be tested in gold 
standard coagulation assays, these were carried out to investigate clotting times of 
the cell media samples from cells transfected with plasmids encoding VHH. An 
automated coagulometer was used to test the time taken to form a ‘plasma clot’ using 
the cell culture media containing FVIII, either in the presence or absence of VHH. 
The coagulation assay employed in this study is the gold standard method which is 
currently used clinically to diagnose coagulation disorders. Four out of the nine VHH 
ligand constructs tested had a statistically significant effect on FVIII clotting times. 
These four VHH were all anti-FVIII ligands (ligand 2 and ligand 7 provided by BAC 
BV). Two ligand 2 constructs had a negative effect (slowing down) on FVIII clotting 
times and two of the ligand 7 constructs had a positive effect (speeding up) on FVIII 
clotting times. The other five VHH ligands tested had no significant effect on FVIII 
clotting times. It was already known prior to this study that ligand 2 and 7 had a high 
binding affinity for the FVIII light chain due to these ligands being available 
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commercially for the purification of FVIII. However these ligands had not previously 
been co-expressed with FVIII. Ligand 2 and ligand 7 VHHs bind to different areas of 
the FVIII light chain, with ligand 7 binding to one of the vWF binding sites and 
ligand 2 binding to a site dissimilar to the vWF binding site. It is proposed that the 
effect these two ligands have on FVIII expression is opposing due to their different 
binding sites on the FVIII protein. vWF is well known to have a protective effect on 
FVIII (Takeyama, Nogami et al. 2009) so it is possible that ligand 7 demonstrates 
similar protective properties due to its binding location.  
It is possible that the four VHH ligands that had a statistically significant effect on 
FVIII clotting times, if bound to the protein intracellularly, could be molecular 
chaperones to the FVIII protein. Immunoprecipitation studies demonstrated that all 
the VHH tested were secreted into the cell media along with FVIII and therefore it is 
reasonable to assume that the two proteins could have been bound when secreted into 
cell media. It is well known that one of the reasons that FVIII is expressed at low 
levels is due to the way it is trafficked through the cell, and is limited by its 
interactions with molecular chaperones such as BiP. It would be worth further 
investigation to decipher why the ligand are having the effect on clotting times. 
In conclusion, this study has shown: 
1. The selected methods for mammalian expression of these VHH ligands are 
suboptimal in this instance and require significant optimisation. 
2. In order to informed make conclusions about FVIII clotting times in co-
expression studies it is useful to have some proteomic data to back up the 
findings. 
3. FVIII protein is notoriously difficult to detect in conventional proteomic 
assays due to low expression levels and the lack of availability of specific and 






It is clear that there is the potential for many more studies to be done to confirm the 
findings of this study as well as enhance it. 
It was very difficult to detect FVIII protein in standard proteomic assays such as 
western blotting and ELISA due to low expression levels, as well as the large 
multimeric nature of the protein. The only way to reliably confirm its presence was 
to test the cell media in a functional assay, which has limitations in itself since the 
functional activity of FVIII is not directly related to protein concentration but correct 
folding/post-translational modification of the protein. The study was also limited by 
the lack of availability of specific tools for detection of VHH and FVIII. Those that 
were available commercially such as the VisuLize™ FVIII Antigen Kit (Affinity 
Biologicals) for the quantitative determination of Factor VIII antigen in human 
plasma samples and Factor VIII concentrates were prohibitively expensive for an 
academic research project.  
The BHK-FVIII cell line used in this study was not generating enough protein to 
detect in traditional proteomic studies such as western blot or ELISA. Therefore 
additional profiling studies should be carried out on this cell line to confirm if it is 
still expressing FVIII protein. RT-PCR could be used to test for presence of FVIII 
mRNA. You could also concentrate the cell media to increase the concentration of 
any FVIII present – this could be done very simply using centrifugation and a sample 
concentrator such as Vivaspin (GE Healthcare). The concentrated samples could then 
be used in traditional proteomic studies, perhaps using a validated commercial 
ELISA. It would also be possible to try and purify the FVIII protein from cell media 
using an affinity chromatography column designed for the purification of 
recombinant b domain deleted factor VIII, for example VIIISelect (GE Healthcare). 
The VHH protein did not express in sufficient concentrations in any of the cell lines 
tested so that they could be consistently detected in proteomic assays like western 
blotting and ELISA. It would be interesting to take the VHH gene sequences and see 
if the protein would express in yeast cells, in the same way that BAC produced these 
ligands originally. There are many reports in the literature of VHH expression in 
yeast for industry usage, much less so in mammalian cells. 
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The leader sequence selected for this study was optimised for production of a 
monoclonal antibody (Herceptin) in CHO cells. It would be useful to consider the 
use of a VHH optimised leader sequence for future expression studies since the 
leader sequence can have a major impact on protein synthesis and secretion (review, 
see Stern et al, 2007).  
It would be useful to try purifying the VHH protein from cell media by methods 
other than those tried already (nickel column purification of his-tagged VHH, and 
also immunoprecipitation) in order to increase the concentration of expressed 
protein. Crude methods such as centrifugal filter concentration was an option 
explored in this project however, due to the small size of the VHH protein (12-15 
KDa), and the manufacturer recommendation of choosing a filter one-half to one-
third smaller than the protein to be concentrated (the molecular weight cut-off being 
5 KDa), this was not considered as a reliable method. Zhong et al was able to purify 
a 45 KDa VHH protein produced in E.Coli via gel filtration on a Sephadex G-200 
column (Amersham Biosciences, United Kingdom) so that is an option that could be 
explored (Zhong, Zhang et al. 2006). 
It could be perceived that another limitation to this study was the fact that the cells 
were not counted post-transfection in the experiments where FVIII was co-expressed 
with VHH. Instead of counting, all the cells were harvested and lysed to test for 
intracellular VHH and FVIII expression. However, if this study was to be repeated 
then of course the cells could be counted using a cell counting machine or a simple 
haemocytometer to confirm that the results seen in the clotting assay were not 
attributed to differences in cell numbers, but in fact the presence or absence of VHH. 
There is also room for optimisation of the expression of VHH ligands in order to 
achieve higher protein levels. It would be interesting to investigate a variety of VHH 
expression levels in a stable cell line to see if this has any effect on FVIII expression 
i.e. a high VHH expressing cell line versus a low VHH expressing cell line co-
expressed with FVIII.  
In the present study, all clotting experiments were carried out using B-domain 
deleted FVIII. It would be desirable to repeat the experiments with full length FVIII 
to see if ligand 7 and ligand 2 co-expression has the same effect on FVIII clotting 
times, since many of the FVIII products on the market are derived from the full 
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length protein. It would also be good to study the full-length FVIII protein since it is 
viewed as the gold standard treatment for haemophilia versus B-domain deleted 
FVIII, and therefore would be preferable to work on from a clinical perspective. 
It would also be interesting to consider the interaction of VHH with chaperones in 
the secretory pathway when co-expressed with FVIII, and indeed whether the 
interaction of FVIII with classical chaperones such as BiP is affected. 
Competition binding studies could be conducted, for example ligand 7 VHH vs. vWF 
binding site on FVIII. In order to do this you would need either a labelled form of 
vWF or VHH to this. Potential labels could be fluorescent or radiolabeled to allow 
dose-dependent detection.  
Epitope mapping could be carried out to find out exactly where the ligand 7 and 
ligand 2 VHH bind to FVIII. A much larger question is how the difference in binding 
location of ligand 2 and ligand 7 could affect FVIII coagulant activity. 
The coagulation experiments could be repeated without co-expressing FVIII and 
VHH proteins together. VHH could be produced in another system such as yeast, 
purified and then added to the BHK cell media and measure any subsequent effect on 
clotting times to see if the effect is the same i.e. no transfection necessary. 
Microscopy studies could be conducted to investigate VHH trafficking in the BHK 
cell line, to see where in the secretory pathway VHH binds to FVIII if at all. 
Fluorescent tagging could be used for this as demonstrated in the literature (Bazl, 
Rasaee et al. 2007). 
1. FVIII proteolytic activity – could be used to investigate FVIII activity +/- 
VHH (does L2 block FVIII activity?). Peptide cleavage = fluorescence 







Antonarakis, S. E., et al. (1995). "Molecular etiology of factor VIII deficiency in hemophilia 
A." Human mutation 5(1): 1-22. 
Aridor, M. (2007). "Visiting the ER: The endoplasmic reticulum as a target for therapeutics 
in traffic related diseases." Advanced drug delivery reviews 59: 759-781. 
Bagg, A. (2007). Molecular Pathology in Clinical Practice, Springer. 
Barlowe, C. (2003). "Signals for COP-II dependent export from the ER: what's the ticket 
out?" Trends in Cell Biology 13: 295-300. 
Bates, S. M. and J. I. Weitz (2005). "Coagulation Assays." Circulation: Journal of the 
American Heart Association 112(4): e53-e60. 
Baxter (2013) Baxter International Inc. : Baxter Submits Application for FDA Approval of 
OBI-1 for Patients with Acquired Hemophilia A.   
Bazl, M. R., et al. (2007). "Production of chimeric recombinant single domain antibody-
green fluorescent fusion protein in Chinese hamster ovary cells." Hybridoma (Larchmt) 
26(1): 1-9. 
Bolton-Maggs, P. H. B. (2013). "The rare inherited coagulation disorders." Pediatric Blood & 
Cancer 60(Supplement 1): S37-S40. 
Bolton-Maggs, P. H. B. and K. J. Pasi (2003). "Haemophilias A and B." The Lancet 361(9371): 
1801-1809. 
Braakman, I. and N. J. Bulleid (2011). Protein Folding and Modification in the Mammalian 
Endoplasmic Reticulum. Annual Review of Biochemistry, Vol 80. R. D. Kornberg, C. R. H. 
Raetz, J. E. Rothman and J. W. Thorner. 80: 71-99. 
Brandizzi, F, and Barlowe, C. (2013). Organization of the ER–Golgi interface for membrane 
traffic control. Nature Reviews Molecular Cell Biology 14, 382-392. 
Burnouf, T. and M. Radosevich (2001). "Affinity chromatography in the industrial 
purification of plasma proteins for therapeutic use." Journal of Biochemical and Biophysical 
Methods 49(1-3): 575-586. 
Bustin, S. (2002). "Quantification of mRNA using real-time reverse transcription PCR (RT-
PCR): trends and problems." Journal of Molecular Endocrinology 29(1): 23-39. 
Butash, K. A., et al. (2000). "Reexamination of the effect of endotoxin on cell proliferation 
and transfection efficiency." Biotechniques 29(3): 610-614, 616, 618-619. 
Cao, W., et al. (2008). "Factor VIII accelerates proteolytic cleavage of von Willebrand factor 
by ADAMTS13." Proc Natl Acad Sci U S A 105(21): 7416-7421. 
Carr, M.E. et al (2015). Emerging and future therapies for hemophilia. Journal of Blood 
Medicine. Volume 6. Pages 245-255. 
 
Castaman, G., et al. (2010). "F8 mRNA studies in haemophilia A patients with different 
splice site mutations." Haemophilia 16(5): 786-790. 
182 
 
Cerecedo, D. (2013). "Platelet cytoskeleton and its hemostatic role." Blood Coagul 
Fibrinolysis 24(8): 798-808. 
Chandler, W. L., et al. (2003). "Comparison of three methods for measuring factor VIII levels 
in plasma." Am J Clin Pathol 120(1): 34-39. 
Chudy, M., et al. (1999). "A new cluster of hepatitis A infection in hemophiliacs traced to a 
contaminated plasma pool." Medical Virology 57(2): 91-99. 
Cochran, W. G. and G.M.Cox (1957). Experimental Designs. New York, Wiley. 
Cool, D.E. et al (1985). Characterization of human blood coagulation factor XII cDNA. 
Prediction of the primary structure of factor XII and the tertiary structure of beta-factor 
XIIa. J. Biol. Chem; 260(25): 13666-13676. 
Cottam, N. P. and D. Ungar (2012). "Retrograde vesicle transport in the Golgi." Protoplasma 
249: 943-955. 
Dahlbäck, B. (2005). "Blood coagulation and its regulation by anticoagulant pathways: 
genetic pathogenesis of bleeding and thrombotic diseases." Journal of internal medicine 
257(3): 209-223. 
Dancourt, J. and C. Barlowe (2010). "Protein sorting receptors in the early secretory 
pathway." Annual Review of Biochemistry 79: 777-802. 
Darby, S. C., et al. (1997). "Mortality from liver cancer and liver disease in haemophilic men 
and boys in UK given blood products contaminated with hepatitis C." The Lancet 350(9089): 
1425-1431. 
Darby, S. C., et al. (2007). "Mortality rates, life expectancy, and causes of death in people 
with hemophilia A or B in the United Kingdom who were not infected with HIV." Blood 
110(3): 815-825. 
De Caterina, R., et al. (2013). "General mechanisms of coagulation and targets of 
anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task 
Force on Anticoagulants in Heart Disease." Thromb Haemost 109(4): 569-579. 
De Marco, A. (2014). "Co-expression and co-purification of antigen-antibody complexes in 
bacterial cytoplasm and periplasm." Methods Mol Biol 1129: 125-135. 
De Meyer, T., et al. (2014). "Nanobody-based products as research and diagnostic tools." 
Trends Biotechnol 32(5): 263-270. 
Doering, C. B., et al. (2002). "High Level Expression of Recombinant Porcine Coagulation 
Factor VIII." Journal of Biological Chemistry 277(41): 38345-38349. 
Doering, C. B., et al. (2004). "Identification of Porcine Coagulation Factor VIII Domains 
Responsible for High Level Expression via Enhanced Secretion." Journal of Biological 
Chemistry 279(8): 6546-6552. 
Dooriss, K. L., et al. (2009). "Comparison of factor VIII transgenes bioengineered for 
improved expression in gene therapy of hemophilia A." Human gene therapy 20(5): 465-
478. 
Dorner, A., et al. (1987). "The relationship of N-linked glycosylation and heavy chain-binding 
protein association with the secretion of glycoproteins." J. Cell Biol. 105(6): 2665-2674. 
183 
 
Dorner, A., et al. (1992). ''Overexpression of GRP78 mitigates stress induction of glucose 
regulated proteins and blocks secretion of selective proteins in chinese hamster ovary 
cells.'' Embo Journal, 11(4), 1563-1571.  
Eaton D, et al (1986). ''Proteolytic processing of human factor VIII. Correlation of specific 
cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of 
factor VIII coagulant activity.'' Biochemistry. 25(2):505-12. 
Ehrenforth, S., et al. (1992). "Incidence of development of factor VIII and factor IX inhibitors 
in haemophiliacs." The Lancet 339(8793): 594-598. 
Ellgaard, L. and A. Helenius (2003). "Quality control in the endoplasmic reticulum." Nature 
Reviews 4: 181-191. 
EMEA (2000). Core SPC for human plasma derived and recombinant coagulation factor VIII 
products. EMEA. London. 
EMEA (2005) EMEA Public Statement: Review of recombinant Factor VIII (FVIII) products* 
and inhibitor development. *Advate, Kogenate Bayer/Helixate NexGen, Kogenate/Helixate, 
Recombinate, ReFacto.   
EMEA (2007). Report of expert meeting on factor VIII products and inhibitor development. 
London. 
Evatt, B. L., et al. (2002). "Haemophilia 2002: emerging risks of treatment." Haemophilia 
8(3): 221. 
Fang, H., et al. (2007). "The protein structure and effect of factor VIII." Thrombosis Research 
119(1): 1-13. 
Farr, A. D. (1981). "Treatment of haemophilia by transfusion: The first recorded case." 
Journal of the Royal Society of Medicine 74: 301-305. 
Fox, J.E. (1993). The platelet cytoskeleton. Thrombosis and Haemostasis  70(6): 884-893 
Franchini, M., et al. (2005). "Acquired hemophilia A: a concise review." Am J Hematol 80(1): 
55-63. 
Franchini, M., et al. (2008). "Laboratory, clinical and therapeutic aspects of acquired 
hemophilia A." Clinica Chimica Acta 395(1-2): 14-18. 
Franchini, M. (2013). The modern treatment of haemophilia: a narrative review. Blood 
Transfus. 11(2): 178–182. 
Ghosh, K. (2007). "Coagulation disorders seen through the window of molecular biology." 
Indian Jounal of Human Genetics 13(3): 81-87. 
Giangrande, P. L. F. (2011). "Management of haemophilia." Paediatrics and Child Health 
21(8): 344-347. 
Gillon, A. D., et al. (2012). "Vesicle-mediated ER export of proteins and lipids." Biochimica et 
Biophysica Acta 1821: 1040-1049. 
Glockshuber, R., et al (1990). Biochemistry 29, 1362. 
Gomez, K. and P. Bolton-Maggs (2008). "Factor XI deficiency." Haemophilia 14: 1183-1189. 
184 
 
Gordon, F. H., et al. (1998). "Outcome of orthotopic liver transplantation in patients with 
haemophilia." Gut 42: 744-749. 
Gouws, W., et al. (2014). "Method validation and clinical utility of chromogenic factor VIII 
assay compared to one-stage assay." J Thromb Thrombolysis 37(2): 210-215. 
Grzegorski, S. J., et al (2014). Natural Variability of Kozak Sequences Correlates with 
Function in a Zebrafish Model. PLoS One. 9(9). e108475 pages 1-6. 
Gribble, J. and M. B. Garvey (2000). "Porcine factor VIII provides clinical benefit to patients 
with high levels of inhibitors to human and porcine factor VIII." Haemophilia 6: 482-486. 
Gruppo, R. A., et al. (2003). "Comparative effectiveness of full-length and B-domain deleted 
factor VIII for prophylaxis--a meta-analysis." Haemophilia 9(3): 251-260. 
Gueorguieva, D., et al. (2006). "Identification of single-domain, Bax-specific intrabodies that 
confer resistance to mammalian cells against oxidative-stress-induced apoptosis." FASEB J 
20(14): 2636-2638. 
Haas, I. G. and M. Wable (1983). "Immunoglobulin heavy chain binding protein." Nature 
306: 387-389. 
Hashimoto, T., et al (2011). Acquired haemophilia A with massive haemorrhage after 
caesarean section. Case Report. Jikeikai Med J; 58; 17-21. 
Hay, C. R. M. (1998). "1 Acquired haemophilia." Baillière's Clinical Haematology 11(2): 287-
303. 
Healey, J. F. (1990) Statistics: A tool for social research.   
Healey, J. F., et al. (2009). "The comparative immunogenicity of human and porcine factor 
VIII in haemophilia A mice." Thromb Haemost 102(1): 35-41. 
Helenius, A. and M. Aebi (2004). "Roles of N-linked glycans in the endoplasmic reticulum." 
Annual Review of Biochemistry 73: 1019-1049. 
Hill-Eubanks, D. C. and P. Lollar (1990). "von Willebrand factor is a cofactor for thrombin-
catalyzed cleavage of the factor VIII light chain." Journal of Biological Chemistry 265(29): 
17854-17858. 
Hoffbrand, A. V., et al., Eds. (2006). Essential Haematology, Blackwell Publishing. 
Hollestelle, M. J., et al. (2001). "Tissue distribution of factor VIII gene expression in vivo - A 
closer look." Thrombosis and Haemostasis 86(3): 855-861. 
Hulstein, J., et al. (2005). "A novel nanobody that detects the gain-of-function phenotype of 
von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B." Blood 
106(9): 3035-3042. 
Izawa, T., et al. (2012). "Yos9p and Hrd1p mediate ER retention of misfolded proteins for 
ER-associated degradation." Molecular Biology of the Cell 23: 1283-1293. 
Jackson, E. C., et al. (2013). "The effects of an inhibitor of diglyceride lipase on collagen-
induced platelet activation." J Pharmacol Exp Ther 347(3): 582-588. 
Janeway, C. A., et al., Eds. (2005). Immunobiology, Garland Science Publishing. 
185 
 
Jankowski, M. A., et al. (2007). "Defining 'full-length' recombinant factor VIII: a comparative 
structural analysis." Haemophilia 13(1): 30-37. 
Jenkins, N., et al. (2008). "Post-translational modifications of recombinant 
proteins:significance for biopharmaceuticals." Molecular Biotechnology 39: 113-118. 
Kanaji, S., et al. (2012). "Contribution of platelet vs. endothelial VWF to platelet adhesion 
and hemostasis." Journal of Thrombosis & Haemostasis 10(8): 1646-1652. 
Kaufman, R. J. and S. W. Pipe (1999). "Regulation of factor VIII expression and activity by 
von Willebrand factor." Thrombosis and Haemostasis 82(2): 201-208. 
Kaufman, R. J., et al. (1989). "Effect of von Willebrand Factor Coexpression on the Synthesis 
and Secretion of Factor VIII in Chinese Hamster Ovary Cells." Molecular and Cellular Biology 
9(3): 1233-1242. 
Kernoff, P. B. A. (1991). "Rationale and evolution of therapy with porcine factor VIII:C." The 
American Journal of Medicine 91(5, Supplement 1): S20-S22. 
Kim, P. S., et al. (1992). "Transient Aggregation of Nascent Thyroglobulin in the Endoplasmic 
Reticulum: Relationship to the Molecular Chaperone, BiP." The Journal of cell biology 18: 
541-549. 
Klooster, R., et al. (2009). "Selection and characterization of KDEL-specific VHH antibody 
fragments and their application in the study of ER resident protein expression." J Immunol 
Methods 342(1-2): 1-12. 
Knör, S., et al. (2008). "Efficient factor VIII affinity purification using a small synthetic 
ligand." Journal of Thrombosis & Haemostasis 6(3): 470-477. 
Kolind, M. P., et al. (2010). "The B-domain of Factor VIII reduces cell membrane attachment 
to host cells under serum free conditions." Journal of Biotechnology 147: 198-204. 
Kondylis, V., et al. (2009). "The early secretory pathway in development: A tale of proteins 
and mRNAs." Seminars in Cell & Developmental Biology 20: 817-827. 
Kozak, M. (1987). "At least six nucleotides preceding the AUG initiator codon enhance 
translation in mammalian cells." J Mol Biol 196(4): 947-950. 
Kruse-Jarres, R. (2015). Efficacy and safety of OBI-1, an antihaemophilic factor VIII 
(recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia. 
21(2):162-70. 
Kuether, E. L., et al. (2012). "Lentivirus-mediated platelet gene therpay of murine 
hemophilia A with pre-existing anti-factor VIII immunity." Journal of Thrombosis & 
Haemostasis 10(8): 1570-1580. 
Lacroix-Desmazes, S., et al (2002). The prevalence of proteolytic antibodies against factor 
VIII in hemophilia A. N Engl J Med, 346 (9). 662-7. 
Leandro, P. and C. M. Gomes (2008). "Protein misfolding in conformational disorders: 
rescue of folding defects and chemical chaperoning." Mini Reviews in Medicinal Chemistry 
8(9): 901-911. 
Lee, C. A., et al. (2010). Textbook of hemophilia. Oxford, Wiley-Blackwell. 
186 
 
Lenting, P.J. et al (1998). The Life Cycle of Coagulation Factor VIII in View of Its Structure 
and Function. Blood: 92 (11). 
Lenting, P. J., et al. (2010). "The disappearing act of factor VIII." Haemophilia 16: 6-15. 
Ley, R., et al. (2003). "Activation of the ERK1/2 Signaling Pathway Promotes 
Phosphorylation and Proteasome-dependent Degradation of the BH3-only Protein, Bim." 
Journal of Biological Chemistry 278(21): 18811-18816. 
Li, T. F., et al. (2012). "Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion 
protein VHH-GFP spontaneously cross the blood-brain barrier and specifically recognize 
astrocytes:application to brain imaging." The FASEB Journal 26(10): 3969-3979. 
Lippincott-Schwartz, J., et al. (2000). "Secretory protein trafficking and organelle dynamics 
in living cells." Annual Review of Cell Developmental Biology 16: 557-589. 
Ljung, R. (2009). "Prophylactic therapy in haemophilia." Blood Reviews 23(6): 267-274. 
Lodish, H., et al. (2000). Golgi and Post-Golgi Protein Sorting and Proteolytic Processing. 
Molecular Cell Biology New York, W.H. Freeman. 
Lollar, P., et al. (1992). "Coagulant properties of hybrid human/porcine factor VIII 
molecules." J Biol Chem 267(33): 23652-23657. 
Lopez, M. F., et al. (2000). "A comparison of silver stain and SYPRO Ruby Protein Gel Stain 
with respect to protein detection in two-dimensional gels and identification by peptide 
mass profiling." ELECTROPHORESIS 21(17): 3673-3683. 
Lubin, I. M., et al. (1994). "Elimination of a major inhibitor epitope in factor VIII." Journal of 
Biological Chemistry 269(12): 8639-8641. 
Lusher, J. M. and I. Scharrer (2009). "Evolution of recombinant factor VIII safety: 
KOGENATE(A (R)) and Kogenate(A (R)) FS/Bayer." International Journal of Hematology 
90(4): 446-454. 
Maass, D. R., et al. (2007). "Alpaca (Lama pacos) as a convenient source of recombinant 
camelid heavy chain antibodies (VHHs)." Journal of Immunological Methods 324(1-2): 13-
25. 
MACFARLANE, R. G. (1964). "AN ENZYME CASCADE IN THE BLOOD CLOTTING MECHANISM, 
AND ITS FUNCTION AS A BIOCHEMICAL AMPLIFIER." Nature 202: 498-499. 
Mannucci, P. (2012). "The role of natural VWF/FVIII complex concentrates in contemporary 
haemophilia care: a guideline for the next decade." Haemophilia 18 (Suppl 2): 2-7. 
Marder, V., et al. (2013). Hemostasis and Thrombosis: Basic Principles and Clinical Practice 
Sixth Edition.  
Marquardt, T, and Helenius, A., (1992). Misfolding and Aggregation of Newly Synthesized 
Proteins in the Endoplasmic Reticulum. The Journal of Cell Biology, 117 (3). 505-513. 
Mayne, E. E., et al. (1981). "Highly purified porcine FVIII in haemophilia A with inhibitors to 
factor VIII." British Medical Journal 282(6260): 318. 
McCue, J. T., et al. (2009). "Application of a novel affinity adsorbent for the capture and 
purification of recombinant factor VIII compounds." J Chromatogr A 1216(45): 7824-7830. 
187 
 
Metcalf, D. J., et al (2007). Formation and function of Weibel-Palade bodies. Journal of Cell 
Science. 121 (1), 19-27. 
Miao, H. Z., et al. (2004). "Bioengineering of coagulation factor VIII for improved secretion." 
Blood 103(9): 3412-3419. 
Miners, A. H., et al. (1998). "Assessing the effectiveness and cost effectiveness of 
prophylaxis against bleeding in patients with severe haemophilia and severe von 
Willebrand's disease." Journal of internal medicine 244(6): 515-522. 
Miners, A. H., et al. (2004). "Assessing the effectiveness and cost effectiveness of 
prophyaxis against bleeding in patients with severe haemophilia and severe von 
Willebrand's disease." Journal of internal medicine 244(6): 515-522. 
Morris, J. A., et al. (1997). "Immunoglobulin binding protein (BiP) function is required to 
protect cells from endoplasmic reticulum stress but is not required for the secretion of 
selective proteins." Journal of Biological Chemistry 272(7): 4327-4334. 
Mulder, K. and A. Llinás (2004). "The target joint." Haemophilia 10(s4): 152-156. 
Murphy, S. and K. A. High (2008). "Gene therapy for haemophilia." British Journal of 
Haematology 140(5) 479–487. 
Muyldermans, S. (2001). "Single domain camel antibodies: current status." Reviews in 
Molecular Biotechnology 74(4): 277-302. 
Muyldermans, S., et al. (2001). "Recognition of antigens by single-domain antibody 
fragments: the superfluous luxury of paired domains." Trends in Biochemical Sciences 
26(4): 230-235. 
Muyldermans, S., et al. (2009). Camelid immunoglobulins and nanobody technology. 
Veterinary Immunology and Immunopathology. 128 (issues 1–3): 178–183 
Naylor, J., et al. (1993). "Characteristic mRNA abnormality found in half the patients with 
severe haemophilia A is due to large DNA inversions." Hum. Mol. Genet. 2(11): 1773-1778. 
Nichols, W. C., et al. (1998). "Mutations in the ER-Golgi intermediate compartment protein 
ERGIC-53 cause combined deficiency of." Cell 93(1): 61. 
Nilsson, I., et al. (2014). "The code for directing proteins for translocation across ER 
membrane: SRP cotranslationally recognizes specific features of a signal sequence." J Mol 
Biol. 
Nilsson, I. M. and G. v. Heijne (1993). "Determination of the distance between the 
oligosaccharyltransferase active site  and the endoplasmic reticulum membrane." Journal of 
Biological Chemistry 268: 5798-5801. 
Nogami, K., et al. (2000). "Factor VIII C2 Domain Contains the Thrombin-binding Site 
Responsible for Thrombin-catalyzed Cleavage at Arg1689." Journal of Biological Chemistry 
275(33): 25774-25780. 
Nord, K., et al. (2001). "Recombinant human factor VIII-specific affinity ligands selected 
from phage-displayed combinatorial libraries of protein A." European Journal of 
Biochemistry 268(15): 4269-4277. 
188 
 
Norja, P., et al. (2012). "Parvovirus transmission by blood products - a cause for concern?" 
Br J Haematol 159(4): 385-393. 
Oldenburg, J. and T. Albert (2014). "Novel products for haemostasis - current status." 
Haemophilia 20 Suppl 4: 23-28. 
Omidfar, K., et al. (2007). "Studies of thermostability in Camelus bactrianus (Bactrian camel) 
single-domain antibody specific for the mutant epidermal-growth-factor receptor 
expressed by Pichia."  46(Pt 1): 41-49. 
Orlova, N.A. et al. (2013). Blood Clotting Factor VIII: From Evolution to Therapy. Acta 
Naturae. 5 (2): 19–39. 
Pagant, S., et al. (2007). "Inhibiting Endoplasmic Reticulum (ER)-associated Degradation of 
Misfolded Yor1p Does Not Permit ER Export Despite the Presence of a Diacidic Sorting 
Signal." Molecular Biology of the Cell 18: 3398-3413. 
Palade, G. (1975). "Intracellular aspects of the processof protein synthesis." Science 
189(4200): 347-358. 
Pallister, C. and M. Watson (2010). Haemotology, Scion Publishing. 
Park, E. and T. A. Rapoport (2012). "Mechanisms of Sec61/SecY-Mediated Protein 
Translocation Across Membranes." Annual Review of Biophysics 41: 21-40. 
Peake, I. R. (1995). "The molecular biology of haemophilia." Developments in Hematology 
and Immunology 30: 3-9. 
Pelham, H. (1996). "The Dynamic Organisation of the Secretory Pathway." Cell structure 
and function 21: 413-419. 
Peyvandi, F., et al. (2006). "Genetic diagnosis of haemophilia and other inherited bleeding 
disorders." Haemophilia 12: 82-89. 
Pfeffer, S. R. and J. E. Rothman (1987). "Biosynthetic protein transport and sorting by the 
endoplasmic reticulum and Golgi." Annual Review of Biochemistry 56: 829-852. 
Pipe, S. W. (2008). "Recombinant clotting factors." Thrombosis and Haemostasis 99(5): 840-
850. 
Pipe, S. W. (2009). "Functional roles of the factor VIII B domain." Haemophilia 15(6): 1187-
1196. 
Pipe, S. W. and R. J. Kaufman (1997). "Characterization of a genetically engineered 
inactivation-resistant coagulation factor VIIIa." PNAS 94(22): 11851-11856. 
Pipe, S. W., et al. (1998). "Differential interaction of coagulation factor VIII and factor V with 
protein chaperones calnexin and calreticulin." J Biol Chem 273(14): 8537-8544. 
Plantier, J. L., et al. (2005). "B-domain deleted factor VIII is aggregated and degraded 
through proteasomal and lysosomal pathways." Thrombosis and Haemostasis 93: 824-832. 
Plantier, J. L., et al. (2001). "A factor VIII minigene comprising the truncated intron I of 
factor IX highly improves the in vitro production of factor VIII." Journal of Thrombosis & 
Haemostasis 86: 596-603. 
189 
 
Porath J. (1992). Immobilized metal ion affinity chromatography. Protein Expr Purif. 
3(4):263-81. 
Precup, J. W., et al. (1991). "A monoclonal antibody to factor VIII inhibits von Willebrand 
factor binding and thrombin cleavage." Blood 77(9): 1929-1936. 
Pérez-Gómez, F. and R. Bover (2007). "[The new coagulation cascade and its possible 
influence on the delicate balance between thrombosis and hemorrhage]." Rev Esp Cardiol 
60(12): 1217-1219. 
Radtke, K.-P., et al. (2007). "Disulfide bond-stabilized factor VIII has prolonged factor VIIIa 
activity and improved potency in whole blood clotting assays." Journal of Thrombosis and 
Haemostasis 5(1): 102-108. 
Raffini, L. and C. Manno (2007). "Modern management of haemophilic arthropathy." British 
Journal of Haematology 136(6): 777-787. 
Rahbarizadeh, F., et al. (2006). "Over expression of anti-MUC1 single-domain antibody 
fragments in the yeast Pichia pastoris." Molecular Immunology 43(5): 426-435. 
Rahbarizadeh, F., et al. (2005). "High expression and purification of the recombinant 
camelid anti-MUC1 single domain antibodies in Escherichia coli." Protein Expression and 
Purification 44(1): 32-38. 
Raut, S., et al. (2012). "Value assigment of the WHO 8th International Standard for factor 
VIII, concentrate (07/350)." Journal of Thrombosis & Haemostasis 10: 1175-1176. 
Rawle, F. E., et al. (2006). Induction of partial immune tolerance to factor VIII through prior 
mucosal exposure to the factor VIII C2 domain. Journal of Thrombosis & Haemostasis, 
Blackwell Publishing Limited. 4: 2172-2179. 
Raykhel, I., et al. (2007). "A molecular specificity code for the three mammalian KDEL 
receptors." Journal of Cell Biology 179(6): 1193-1204. 
Reynders, E., et al. (2011). "How Golgi glycosylation meets and needs trafficking: the case of 
the COG complex." Glycobiology 21(7): 853-863. 
Rodriguez-Merchan, E. C. (1996). "Effects of Hemophilia on Articulations of Children and 
Adults." Clinical Orthpaedics & Related Research 328: 7-13. 
Rosenthal, R. L., et al. (1953). "New haemophilia-like disease caused by deficiency of a third 
plasma thromboplastin factor." Proc Soc Exp Biol Med 82: 171-174. 
Roth, J., et al. (2010). "Protein N-Glycosylation, Protein Folding, and Protein Quality 
Control." Molecules and Cells 30: 497-506. 
Roth, S. D., et al. (2012). "Chemical Chaperones Improve Protein Secretion and Rescue 
Mutant Factor VIII in Mice with Hemophilia A." Plos One 7(9): 1-13. 
Saenko, E. L., et al. (2003). "The future of recombinant coagulation factors." Journal of 
Thrombosis & Haemostasis 1(5): 922-930. 
Saenko, E. L. and D. Scandella (1997). "The acidic region of the Factor VIII light chain and the 
C2 domain together form the high affinity binding site for von Willebrand factor." Journal of 
Biological Chemistry 272: 18007-18014. 
190 
 
Sakurai, Y et al (2014). Acquired Hemophilia A: A Frequently Overlooked Autoimmune 
Hemorrhagic Disorder. Journal of Immunology Research. Volume 2014, Article ID 320674. 
 
Schattner, M. and G. A. Rabinovich (2013). "Galectins: new agonists of platelet activation." 
Biol Chem 394(7): 857-863. 
Schouten, A., et al. (1996). "The C-terminal KDEL sequence increases the expression level of 
a single-chain antibody designed to be targeted to both the cytosol and the secretory 
pathway in transgenic tobacco." Plant Molecular Biology 30: 781-793. 
Schroeder, M. and R. J. Kaufman (2005). "The mammalian unfolded protein response." 
Annual Review of Biochemistry 74: 739-789. 
Serruys, B., et al. (2009). "Llama-derived single-domain intrabodies inhibit secretion of 
hepatitis B virions in mice." Hepatology 49(1): 39-49. 
Shahani, T. et al. (2014). Human liver sinusoidal endothelial cells but not hepatocytes 
contain factor VIII. J Thromb Haemost. 12(1):36-42.  
Shiltagh, N., et al. (2014). "Solution structure of the major factor VIII binding region on von 
Willebrand factor." Blood 123(26): 4143-4151. 
Siediecki, C., et al. (1996). "Shear-dependent changes in the three-dimensional structure of 
human von Willebrand factor." Blood 88(8): 2939-2950. 
Soukharev, S., et al. (2002). "Expression of Factor VIII in Recombinant and Transgenic 
Systems." Blood Cells, Molecules, and Diseases 28: 234-248. 
Spiller, N. (2013). Hemophilia Pipeline. DataMonitor Healthcare. DataMonitor. 
DataMonitor, DataMonitor. 
Steidl, R. J. and L. Thomas (2001). Power analysis and experimental design. Design and 
Analysis of Ecological Experiments. S. M. Scheiner and J. Gurevitch. New York, Oxford 
University Press: 14-36. 
Stern, B., et al. (2007). Improving mammalian cell factories: The selection of signal peptide 
has a major impact on recombinant protein synthesis and secretion in mammalian cells. 
Trends in Cell & Molecular Biology. 2: 1-17. 
Stuchbury, G. and G. Münch (2010). "Optimizing the generation of stable neuronal cell lines 
via pre-transfection restriction enzyme digestion of plasmid DNA." Cytotechnology 62(3): 
189-194. 
Tagliavacca, L., et al. (2000). "ATP-dependent dissociation of non-disulphide-linked 
aggregates of coagulation factor VIII is a rate-limiting step for secretion." Biochemistry 39: 
1973-1981. 
Takeyama, M., et al. (2010). "Characterisation of an antibody specific for coagulation factor 
VIII that enhances factor VIII activity." Thromb Haemost 103(1): 94-102. 
Takeyama, M., et al. (2009). "Von Willebrand factor protects the Ca2+-dependent structure 
of the factor VIII light chain." British Journal of Haematology 146(5): 531-537. 
Tanaka, K. A., et al. (2009). "Blood coagulation: hemostasis and thrombin regulation." 
Anesthesia & Analgesia 108(5): 1433-1446. 
191 
 
Teh, Y. H. and T. A. Kavanagh (2010). "High-level expression of Camelid nanobodies in 
Nicotiana benthamiana." Transgenic Res 19(4): 575-586. 
Terraube, V., et al. (2010). "Factor VIII and von Willebrand factor interaction: biological, 
clinical and therapeutic importance." Haemophilia 16(1): 3-13. 
Tiede, A. (2015). Half-life extended factor VIII for the treatment of hemophilia A. J Thromb 
Haemost. Suppl 1:S176-9.  
Thim, L., et al (2010). Purification and characterization of a new recombinant factor VIII 
(N8). Haemophilia, 16, pp. 349–359. 
Thomassen, Y. E., et al. (2002). "Large-scale production of VHH antibody fragments by 
Saccharomyces cerevisiae." Enzyme and Microbial Technology 30(3): 273-278. 
Toole, J. J., et al. (1984). "Molecular cloning of a cDNA encoding human antihaemophilic 
factor." Nature 312: 342-347. 
Toole, J. J., et al. (1986). "A large region (95 KDa) of human factor VIII is dispensible for in 
vitro procoagulant activity." Proc. Natl. Acad. Sci. 83: 5939-5942. 
Tortora, G. J. and B. Derrickson (2006). Principles of anatomy and physiology, John Wiley & 
Sons, Inc. 
Toschi, V. (2010). "OBI-1, porcine recombinant Factor VIII for the potential treatment of 
patients with congenital hemophilia A and alloantibodies against human Factor VIII." Curr 
Opin Mol Ther 12(5): 617-625. 
Valentijn, K.M., et al (2011). Functional architecture of Weibel-Palade bodies. Blood: 117 
(19): 5033 - 5043. 
Van Den Biggelaar, M., et al. (2007). "Requirements for cellular co-trafficking of factor VIII 
and von Willebrand factor to Weibel–Palade bodies." Journal of Thrombosis and 
Haemostasis 5(11): 2235-2243. 
van den Biggelaar, M., et al. (2009). "Intracellular cotrafficking of factor VIII and von 
Willebrand factor type 2N variants to storage organelles." Blood 113(13): 3102-3109. 
Vasquez-Martinez, R., et al. (2012). "Revisiting the regulated secretory pathway: From frogs 
to human." General and comparative endocrinology 175: 1-9. 
Vehar, G. A., et al. (1984). "Structure of human factor VIII." Nature 312: 337-342. 
Vu, K.B. et al. (1997) Comparison of llama VH sequences from conventional and heavy chain 
antibodies. Mol. Immunol. 34, 1121–1131. 
Wagner, D. D. (1990). "Cell biology of von Willebran factor." Annu Rev Cell Biol 6: 217-246. 
Walter, P., et al. (1981). "Translocation of proteins across the endoplasmic reticulum. I. 
Signal recognition protein (SRP) binds to in-vitro-assembled polysomes synthesizing 
secretory protein." J Cell Biol 91(2 Pt 1): 545-550. 
Wang, W., et al. (2003). "Coagulation factor VIII: structure and stability." International 
Journal of Pharmaceutics 259(1-2): 1-15. 
192 
 
Ward, E. S. and D. Gussow (1989). "Binding activities of a repertoire of single 
immunoglobulin variable domains secreted from E.coli." Nature 341(6242): 544. 
Weibel, E. R. and Palade, G. E. (1964). New cytoplasmic components in arterial endothelia. 
J. Cell Biol. 23, 101-112.  
Wesolowski, J., et al. (2009). "Single domain antibodies: promising experimental and 
therapeutic tools in infection and immunity." Medical Microbiology and Immunology 198: 
157-174. 
Winge, S. (2015). Development, upscaling and validation of the purification process for 
human-cl rhFVIII (Nuwiq®), a new generation recombinant factor VIII produced in a human 
cell-line. Protein Expression and Purification. Volume 115, 165–175. 
Wlodkowic, D., et al (2009). Flow cytometry-based apoptosis detection. Methods Mol Biol. 
559, 19-32. 
Xu, Y. and F. C. Szoka (1996). "Mechanism of DNA Release from Cationic Liposome/DNA 
Complexes Used in Cell Transfection†,‡." Biochemistry 35(18): 5616-5623. 
Yonemura, H., et al. (1993). "Efficient production of recombinant human factor VIII by co-
expression of the heavy and light chains." Protein Eng. 6(6): 669-674. 
Zhang, B., et al. (2005). LMAN1 and MCFD2 Form a Cargo Receptor Complex and Interact 
with Coagulation Factor VIII in the Early Secretory Pathway. The Journal of Biological 
Chemistry. 280, 25881-25886. 
Zhang, J., et al. (2009). "Transient expression and purification of chimeric heavy chain 
antibodies." Protein Expr Purif 65(1): 77-82. 
Zhong, Y., et al. (2006). "Overexpression, purification, characterization, and pathogenicity of 
Vibrio harveyi hemolysin VHH." Infect Immun 74(10): 6001-6005. 







1. Amino acid codes 
Table 36. Amino acid codes 
A    Ala Alanine 
C  Cys  Cysteine 
D  Asp  Aspartic Acid 
E  Glu  Glutamic Acid 
F  Phe  Phenylalanine 
G  Gly  Glycine 
H  His  Histidine 
I  Ile  Isoleucine 
K Lys Lysine 
L Leu Leucine 
M Met Methionine 
N Asn Asparagine 
P Pro Proline 
Q Gln Glutamine 
R Arg Arginine 
S Ser Serine 
T Thr Threonine 
V Val Valine 
W Trp Tryptophan 




2. VHH ligand gene sequences 
 
The gene sequences for the VHH ligands utilised in this project are of a 
commercially sensitive nature (owned by BAC BV, The Netherlands) and therefore 
have been omitted from this thesis. 
 
3. pcDNA3.1 sequence 
 
Comments for pcDNA3.1 (+) 
5428 nucleotides 
CMV promoter: bases 232-819 
T7 promoter/priming site: bases 863-882 
Multiple cloning site: bases 895-1010 
pcDNA3.1/BGH reverse priming site: bases 1022-1039 
BGH polyadenylation sequence: bases 1028-1252 
f1 origin: bases 1298-1726 
SV40 early promoter and origin: bases 1731-2074 
Neomycin resistance gene (ORF): bases 2136-2930 
195 
 
SV40 early polyadenylation signal: bases 3104-3234 
pUC origin: bases 3617-4287 (complementary strand) 
Ampicillin resistance gene (bla): bases 4432-5428 (complementary strand) 
ORF: bases 4432-5292 (complementary strand) 
Ribosome binding site: bases 5300-5304 (complementary strand) 
bla promoter (P3): bases 5327-5333 (complementary strand) 
 
  
4. Electroporation buffers 
Salts buffer (20 mM Hepes, 135 mM KCl, 2 mM MgCl
2
, 0.5 % FiColl 400, pH 7.6 
with NaOH, filter sterilised) 
DMEM/F12 with serum 
Phosphate Buffered Saline, autoclaved 
Hepes buffered saline (10 mM Hepes, 140 mM NaCl at pH 7.3, autoclaved). 
Phosphate buffered sucrose (272 mM sucrose, 10 mM sodium phosphate, pH 7.3, 
filter sterilised). 
Hepes buffered sucrose (272 mM sucrose, 10 mM Hepes, pH 7.3, filter sterilised). 
5. Media and buffer formulations 
 
1. LB media composition: 
5 g NaCl 
5 g tryptone 
2.5 g yeast extract 
Make up to 500 ml with Milli Q H2O 
pH 7 with 5 M NaOH 
Autoclave 
After autoclaving cool to 55 °C before adding antibiotics 
 
 
2. LB agar plates composition 
5 g NaCl 
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5 g tryptone 
2.5 g yeast extract 
10 g agar 
Make up to 500 ml with Milli Q H2O 
pH 7 with 5 M NaOH 
Autoclave 
After autoclaving cool to 55 °C before adding antibiotics 
Pour out into sterile petri dishes (20 ml media per plate)  
Leave to set for 30 minutes and store at 4 °C 
 
3. SOB medium 
10 g tryptone 
2.5 g yeast extract 
0.25 g NaCl 




Add 5 ml of filter-sterilized 1 M MgCl
2
  




4. Restriction enzyme buffer  
Buffer E: 6 mM Tris-HCl, 6 mM MgCl
2, 
100 mM NaCl, pH 7.5. 
Buffer H: 90 mM Tris-HCl, 10 mM MgCl
2, 




Cell culture regents: 
197 
 
1. BHK cell media: 
500 ml DMEM/F-12  
15 mM Hepes (50 ml of 150 mM stock)  
2 mM L-Glutamine (5 ml of 200 mM stock) 
10 % heat inactivated Fetal Bovine Serum (50 ml of stock) 
5 ml 100 x Penn/Strep into 500 ml media 
For FVIII expression studies in BHK cells, media is switched to AIM-V (no serum). 
 
2. CHO-K1 cell media: 
415 ml DMEM/F12 
5 ml L-Glutamic acid/Asparagine stock 
10 ml Nucleoside stock 
15ml L-Glutamine stock 
50ml dialysed Foetal Calf Serum (10%) 
5ml Non-essential amino acids (Gibco x100) 
Vacuum cap filter media into 1 L sterile bottle.  
  
3. HEK cell media:  
500 ml DMEM 
50 ml Foetal Calf Serum (10%) 
5 ml L-Glutamine stock 
5 ml Penicillin/streptomycin stock 
 
4. Phosphate Buffered Saline: 
1 PBS tablet dissolved in 100ml distilled water. PBS was sterilised by autoclaving. 
 
5. Hepes buffer: 
150mM made using autoclaved water and then sterile filtered using a vacuum pump 
and a 0.22 uM Millipore express 500 ml funnel/receiver bottle. 
 
6. Nucleoside stock: 
175 mg Adenosine 
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175 mg Guanosine 
175 mg Cytidine 
175 mg Uridine 
60 mg Thymidine 
In 500 ml ddH2O 
Store -20 °C 
 
7. L-Glutamine stock: 
4.383 g in 150 ml ddH20 
Store -20°C 
 
8. L-Glutamic acid/L-Asparagine stock: 
1.5g L-Glutamic acid 
1.5g L-Asparagine 
In 250ml ddH2O 
Store -20oC 
  
9.  Heat-inactivation of foetal bovine serum/foetal calf serum:  
Defrost dialysed Foetal Bovine Serum (dFBS) or Foetal Calf Serum (dFCS), heat to 
56°C for 30 minutes. Aliquot in sterile cabinet into 50 ml sterile containers and store 
at -20°C  until use. 
 
6. Western blotting buffers 
Table 37. Western blotting buffers 
Reagent Blocking buffer Wash buffer 
PBS 1x 1x 
Marvel milk powder 5% none 
Tween 0.2% 0.2% 
 
7. Purification of his-tagged proteins on a nickel column 
199 
 
Binding buffer (equilibration): 20mM sodium phosphate, 0.5M NaCl, 20mM 
imidazole, pH 7.4 
Elution buffer: 20mM sodium phosphate, 0.5M NaCl, imidazole varying from 50mM 
to 500mM on 50mM increments, pH 7.4. 
 
8. ELISA buffers 
Blocking buffer: 2% BSA (or protifar or marvel) in PBS pH 7.4 
Sample buffer: 1% blocking agent in PBS pH 7.4 with 0.05% Tween 20 






Communication 1. Regarding the use of anti-FVIII antibodies 
 
Hi Caroline, 
Sorry for the delay in responding. The antibodies you are using are polyclonal 
therefore there may be variable recognition of epitopes between  lots of product.  The 
immunogen used to prepare these antibodies is full-length Factor VIII therefore 
epitopes throughout the protein including the B-domain will likely be recognized to 
varying degrees by different lots.  If you are using as your sample a recombinant 
FVIII-deleted protein, such as a B-domain deleted FVIII, it is recommended that the 
calibration curve be prepared using the same type of protein in order to minimize the 
observed variability from lot-to-lot.  We do not perform epitope mapping on these 
polyclonal antibodies therefore cannot guarantee that each lot recognizes the exact 
same epitopes on the Factor VIII. 
  




 Ada Blythe 
Operations Manager 


















The best thing to do is to clone a tag at the C end of the VHH and to detect the VHH 
via this tag. You can use His6 tag or heamaglutinin tag or c-myc tag or whatever. 
You can also biotinylate the VHH and then detect with HRP or AP conjugated 
streptavidin.  
 
Rabbit antibodies against VHH do not work that well. The outcome for ELISA 
detection is rather unpredictable.  
In addition, please remember that VHH don't perform very well in Western blot, 
normally as they recognize conformational epitopes that are disrupted upon SDS 
treatment. 
 
 
Kind regards, 
Serge Muyldermans 
svmuylde@vub.ac.be  
23.03.12 
